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Abstract
Risk Reduction Regarding Stigmatized and Marginalized Communities
M. Navinkumar
2021
While there are several perspectives on marginalization, there are multiple marginalized
individuals, social groups, and communities globally. This process of marginalization produces
individuals, groups and communities which are refused complete privileges, rights, and power
within the broader political and social framework. Social, cultural, biological, and economic
factors can thus be used as yardsticks to marginalize individuals and communities.
Marginalization can be based on gender, race and ethnicity, social class, and sexuality, among
others.
Clearly, marginalized communities face poorer health outcomes and these outcomes are
sometimes linked to risky behaviors more prevalent in such demographics. Marginalization is
associated with reduced health outcomes and can limit the agency of marginalized
communities. However, even within sites of marginalization, affected communities make
significant attempts to mitigate health risks and retain agency. For example, marginalized men
who have sex with men in China face severe discrimination which affects their health
outcomes. Even within such contexts, these men still encourage peers to receive sexually
transmitted infection testing. I explore how marginalized communities reduce health risks
likely produced by marginalization and retain agency through doing so. I explore sexually
transmitted infection testing and related issues in Chinese men who have sex with men, the
United States legal cannabis industry, and medication for those with opioid use disorder. In
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doing so, I will provide understanding on risk reduction of health behaviors in marginalized
communities, building a knowledge base to aid overall health outcomes.
In the first chapter, I detailed a range of cannabis-centric studies. First, I detailed cannabis
usage preferences among United States cannabis users. I put forth that frequent cannabis use
may increase risk of health harms and highlighted the need to minimize problematic use. I also
explored sociodemographic indicators and their association with likelihood for cannabisrelated emergency department admissions in New York City. Results suggested that cannabis
use may further burden marginalized groups. I investigated large cannabis firms’ motivations
for participating in the cannabis space. I put forth that policymakers be aware that non-profits
and for-profits both seek to expand cannabis access and consider the groups as a unified
whole.
In the second chapter I explored concerns regarding sexually transmitted infection testing in
the Chinese men who have sex with men environment. I first detailed factors associated with
sexually transmitted infection testing. Results detailed the role of altruism in a sexually
transmitted infection testing intervention. Expressions of altruism may promote contributions
toward public health initiatives in marginalized communities. In the same vein, I detailed the
association between men who have sex with men community-centric behaviors and
contributions toward others’ sexually transmitted infection testing. I proposed that
community-oriented behaviors may be related with a reduction in testing service costs. Then,
I evaluated whether men who have sex with men selected a sexually transmitted infection test
appropriate for their sexual behavior. I suggested that disclosing sexual identity to treatment
providers can improve men who have sex with men sexually transmitted infection prevalence
estimates. I also detailed the correlates of antisocial behavior on the world's largest gay dating
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app among Chinese men who have sex with men. I suggested that age, condom use, and
number of social ties may be associated with antisocial behavior, with implications for the
design of online sexual health interventions. Finally, I assessed if same-sex sexual behavior
disclosure of Chinese men who have sex with men was related to number of HIV self-testing
kits requested, and number of test results successfully uploaded by alters in a network-based
HIV self-testing intervention. Findings had implications for the development of networkbased interventions for key populations.
In the final chapter I detailed that various forms of social support may influence medication
for opioid use disorder treatment outcomes. Failure to implement successful social support
programs within medication for opioid use disorder treatment settings may represent an
important missed opportunity to engage patients at risk of treatment failure.
While the topics here are broad, they all share similar thematic arcs. Low sexually transmitted
infection testing uptake, opioid use disorder and cannabis use are issues often
disproportionately faced by marginalized communities. Establishing marginalization as the
causal factor behind these concerns is often complex, but there is significant work indicating
that problematic patterns of drug use and poor sexual health outcomes are engendered by
marginalization. Marginalization is associated with conditions inimical to health and wellbeing, creating a host of health risks. Such marginalization limits the agency of affected
communities. However, even within these sites of marginalization, men who have sex with
men seek testing and opioid use disorder patients seek medication, mitigating health risks
borne from marginalization. I advance that marginalized communities are not completely
helpless considering reduced health outcomes, indicating how agency is reclaimed. Finally, I
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indicated other cases where fostering agency in marginalized communities needs to be
carefully considered.
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Introduction
While there are several perspectives on marginalization,1,2 it is clear that there are multiple
marginalized individuals, social groups and communities globally. I define marginalization as
the complex process through which certain people and ideas are privileged over others at a
specific time, and the process by which given groups can be ignored, and made
inconsequential.3 This process of marginalization produces individuals, groups and
communities which are refused privileges, rights and power within the broader political and
social framework.2 Social, cultural, and economic factors are thus used as yardsticks to
marginalize individuals and communities.4 Marginalized communities can face a lack of
support and resources for pursuing higher education5 and are often less likely to complete high
school.6 In the job market, marginalized communities often experience discrimination and
obstacles to workplace success.7 Marginalization can be based on gender,8 race and ethnicity,9
social class,10 and sexuality,11 among other factors. While these factors marginalize people in
different ways, everyone can be affected in some form, where an unfortunate circumstance
can cause someone to be marginalized.2
The unequal distribution of wealth, health and life outcomes is associated with the interaction
of biological, social, cultural, economic and political factors.11 One’s social, cultural, and
economic context affects one’s daily experiences and their relationship to the broader social
system influencing health outcomes. Broadly, social, cultural, and economic context of
marginalized individuals and communities can, but not always, create conditions inimical to
good health. I note that marginalization may not always lead to reduced health outcomes.
Within various marginalized communities, behaviors associated with poor health outcomes
are commonplace. Marginalization can cause and magnify such behaviors. Examples of these
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types of behaviors are smoking, drinking alcohol, drug use, unprotected sexual intercourse,
diet and gun violence.12
Marginalized communities can thus sometimes face poorer health outcomes and these
outcomes are sometimes linked to health-related behaviors more prevalent in such
demographics. For example, men who have sex with men suffer from stigma and
discrimination globally.13 Men who have sex with men are male-identified persons who engage
in sexual activity with members of the same sex, regardless of how they identify themselves.14
They may identify as gay, homosexual, bisexual, pansexual, or heterosexual; or dispense with
sexual identification altogether. Men who are have sex with men are considered part of the
broader lesbian, gay, bisexual, and transgender community. In China, majority of people
believe that homosexual behaviors were a psychological disorder.15,16 In such contexts, men
who have sex with men may be more likely to get married to women, and hide their sexual
orientation and put their wives and children at risk of sexually transmitted infections and
HIV/AIDS.17
Similarly, substance users are often marginalized, facing stigma from health providers who see
a patient’s drug or alcohol use as their own fault. Such views may lead to substandard care or
even the rejection of individuals from seeking treatment.18 Those who show signs of acute
intoxication or withdrawal symptoms are sometimes expelled from emergency rooms by staff
fearful of such behavior.19 Some health professionals may not see substance use as a medical
condition and refuse to provide treatment.18 People who use drugs may internalize this stigma,
incurring further marginalization, and perhaps refuse to seek treatment. For example,
substance users with other medical issues may refuse to seek treatment, fearing dismissal as a
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drug addict.18 Marginalization and stigma may also worsen isolation and encourage further drug
use, worsening the condition.18
However, even within sites of marginalization, affected communities make significant
attempts to mitigate health risks and retain agency. While some communities face great
marginalization, it is not uncommon to see these same communities marshal the sense of
shared identity formed around marginalization, to improve overall community well-being. This
concept of marginalized communities reclaiming agency is central to this thesis. For example,
men who have sex with men in China, a marginalized group, often face severe discrimination
which affects their health outcomes. Despite facing discrimination, these men still encourage
peers to receive sexually transmitted infection testing.20 I explore how marginalized
communities reduce health risks likely produced by marginalization and retain agency through
doing so. I explore sexually transmitted infection testing and related issues in Chinese men
who have sex with men, the United States legal cannabis industry, and medication for those
with opioid use disorder. In doing so, I will provide understanding on risk reduction of health
behaviors in marginalized communities, building a knowledge base to aid overall health
outcomes.
Underlying the themes here, is the idea that agency and solidarity within marginalized
communities needs to be fostered and encouraged. I suggest that when marginalized
individuals support each other, reduced health outcomes from marginalization can be
mitigated. However, the cases selected here do not indicate that solidarity and agency within
marginalized communities should always be promoted. I then extend the argument central to
this thesis around fostering agency in marginalized communities and explore other cases where
increased agency and solidarity may not always augur positive outcomes.
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Dissertation Structure
I first detail research around marginalization and health outcomes within the men who have
sex with men population, with a focus on men who have sex with men in China, and
marginalization and problematic drug use, centering on cannabis use and medication for
opioid use disorder. Finally, I detail empirical chapters as follows: Sexually transmitted
infection testing and related issues in Chinese men who have sex with men; the United States
legal cannabis industry; medication for opioid use disorder.
Marginalization versus stigma
Building on the earlier provided definition, I note that marginalization can refer to a personal
or paradigmatic perspective, a personal or group experience, a condition, a socio-politically
influenced process, and the outcomes of such a process.21 Marginalization is further defined
as a process by which persons or groups are socio-politically peripheralized from dominant,
central experiences, they are deprived of mobility, control over self-will or critical resources;
indignified and humiliated, exposed to toxic environments, or exploited physically or mentally,
such that they face increased safety, health, social, and political risk.21 The outcomes of
marginalization include distress and health disparities, but also survival and empowerment.
The pattern of disparate risks parallel to modes of social categorization make marginalization
a major health concern.21 Marginalizing ideologies such as vilifying religious beliefs,
colonialism, heteronormativity, racism, classism, sexism, commodification of personhood,
globalization, and white supremacy22,23 support marginalizing dynamics. Marginalizing
dynamics include scapegoating, stigmatization, bullying, exclusion, incarceration, deprivation
of basic resources, control, symbolic violence, intersectionality of several sources of
oppression, microaggressions, implicit biases, and toxic environmental exposure.24–28

18

Stigma is here defined as the co-occurrence of labeling, stereotyping, separation, status loss,
and discrimination in a context in which power is exercised.29 Stigma has a negative effect in
the health and well-being of individuals and can contribute to psychosocial stress, coercion,
violence, job loss, and social exclusion.30 The communities in this dissertation, such as men
who have sex with men, and people who use drugs, are at the intersection of stigma and
prejudice against their identities, occupations or behaviors, often worsening their experiences
of stigma and discrimination.31
Marginalization and stigma are related and often intersect. Stigma is often associated with or
attached to marginalized individuals (e.g. Men who have sex with men or people who use
drugs).21 Stigma in such scenarios can often affect marginalized communities’ relationship with
the broader community.32 Stigma may also result in feelings of helplessness or homelessness,
which may cause distress for marginalized individuals or communities.33
Marginalization and Health Outcomes in the men who have sex with men
Population
Men who have sex with men are more vulnerable to conditions of poverty as compared to the
heterosexual population.34 Men who have sex with men are more likely to receive cash
assistance and food stamps compared to their heterosexual counterparts, among other
indicators.35 Men who have sex with men’s socio-economic position may relate to experiences
of discrimination. Higher earning men who have sex with men were less likely to report
discrimination compared to those of a lower socioeconomic status, with discrimination linked
to higher depressive symptoms and anxiety.36 This effect is further compounded as workplace
discrimination against men who have sex with men can exacerbate socioeconomic
differences.37 Young men who have sex with men also face various deleterious outcomes due
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to marginalization. Young men who have sex with men experience homelessness at a
disproportionate rate, and also experience mental health issues at a far higher rate compared
to the heterosexual population.38 Homelessness in this demographic tends to arise from
parents not accepting the child’s sexual identity or possible violence towards men who have
sex with men in foster care.38 Men who have sex with men experience various health issues,
such as depression and suicidality, at greater rates than the heterosexual population.39,40 Men
who have sex with men also are one of the populations most affected by HIV infection.41
HIV/AIDS, stigma, and marginalization
The first AIDS cases were identified in the United States in 1981 and almost immediately
people with AIDS were faced with marginalization and stigma.42 People with AIDS were
evicted from their homes, fired from jobs and shunned by family and friends. Public opinion
surveys at the time indicated widespread fears around HIV/AIDS, lack of accurate
information and willingness to support policies that would restrict civil liberties to combat
AIDS.43,44 HIV/AIDS stigma globally is represented through social ostracism and rejection of
people with HIV.45
AIDS manifests several characteristics that relate to stigma and marginalization. 46,47 Firstly,
stigma is more often related to a condition whose cause is perceived to be the bearer’s
responsibility.42 If a medical condition is perceived as having been contracted through
voluntary and avoidable behaviors, especially if such behaviors evoke social disapproval, it is
likely to be stigmatized and associated with anger and marginalization.48 As the primary
transmission routes for HIV are often regarded as voluntary and immoral, those with HIV are
often viewed as responsible for their condition and stigmatized.49 Secondly, more stigma is
related with conditions that are incurable or degenerative. In the earliest days of the epidemic,
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HIV/AIDS was regarded as fatal.50 Diagnosis with such a condition is often equivalent to
dying, as those with the condition may be a reminder or personification of death.51 Thirdly,
greater stigma is associated with conditions believed to be contagious or harm others.
Perceptions of danger and fears of contagion have enveloped AIDS since the epidemic
began.52 Fourth, a condition is more stigmatized when it is readily apparent to others, when it
disrupts a social interaction or viewed as off-putting or upsetting.42 The advanced stages of
untreated AIDS often affect one’s physical appearance and stamina, evoking distress, stigma
and marginalization.53 AIDS stigma may result from the communicability and possible lethality
of HIV. HIV/AIDS reflects the fear and apprehension likely associated with any transmissible
and deadly illness. HIV/AIDS stigma is best indicated by the experiences of people who
acquired HIV through blood transfusion. Compared to men who have sex with men and
people who use drugs, such individuals did not previously face societal stigma. After
HIV/AIDS, such individuals faced rejection and isolation due to fears about the spread of
HIV.54 Symbolic stigma around HIV/AIDS is related to the social meanings attached to AIDS.
This stigma represents the use of the condition as a mode for expressing a range of attitudes.
Historically, AIDS stigma has centered on men who have sex with men communities and
AIDS is often related to men who have sex with men.42,52
The Lesbian, Gay, Bisexual, And Transgender Community in China
China has the world’s largest lesbian, gay, bisexual, and transgender population. There are
about 30 million LGBT individuals in China.55 Until 10 years ago, lesbian, gay, bisexual, and
transgender individuals were an invisible and hidden community in China. 56 While legal
persecution against lesbian, gay, bisexual, and transgender communities was repealed in 1997,
discrimination is still rampant.57 Chinese culture prizes filial piety for raising children and
continuing the family line. Not doing so is often considered a social transgression. While
21

rescinded in 2015, China’s one-child policy created great pressure on lesbian, gay, bisexual,
and transgender individuals to continue the family line. Marriage pressures resulted in Tongqi
(wives of gay men) and Tongfu (husbands of lesbians). While the Chinese government does not
directly prohibit lesbian, gay, bisexual, and transgender content, most lesbian, gay, bisexual,
and transgender-centric media is censored as unsuitable for the general population.
Discrimination against the lesbian, gay, bisexual, and transgender community has broader
implications for Chinese society. Social stigmatization of lesbian, gay, bisexual, and
transgender communities can manifest as barriers to sexually transmitted infection
prevention.58
In 2000, the Chinese Classification of Mental Disorders 3 removed homosexuality and
bisexuality from the mental disorders categories.59 However, a significant number of Chinese
mental health professionals still consider homosexuality a disorder treatable by sexual
orientation conversion efforts. Sexual orientation conversion efforts is provided by several
hospitals across China and several leading medical centers in major Chinese cities.60 In Chinese
Classification of Mental Disorders 3, transgender presentations are still categorized as mental
disorders.59 While the recent International Classification of Diseases has removed gender
incongruence from its mental disorders section,61 it is not clear whether Chinese Classification
of Mental Disorders 3 will follow similarly. Such reclassification may be key in reducing
stigma.62 It is difficult for transgender individuals to access hormone treatment or gender
affirming surgery and there is limited availability of transgender healthcare.63 Moreover, despite
changes in international standards, transgender individuals in China require at least a year of
psychotherapy before gaining approval for gender-affirming surgery.64
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A recent survey by the United Nations Development Program and Beijing lesbian, gay,
bisexual, and transgender Center indicates that 11.1% of heterosexual participants reported
being unable to accept lesbian, gay, bisexual, and transgender family members.56 The rejection
rare was far greater when heterosexual participants were asked about the acceptance of their
own children being bisexual (25.1%), homosexual (17.5%), or transgender (66.8%). In
addition, more than 10% of heterosexual participants rejected the idea of being close,
relationship-wise, to lesbian, gay, bisexual, and transgender individuals. They did not believe
that bisexual (6.0%), homosexual (8.2%), or transgender (21.9%) people should be allowed to
raise children.56
Marginalization and Problematic Drug Use
Recent research has indicated that social exclusion and marginalization foreshadow may be
related to problematic illicit drug use.65,66 In general, those experiencing problematic drug use
tend to be those in the most deprived and socially excluded communities.67 While it may appear
that deprivation is an inevitable outcome for drug users, for a significant proportion of users,
exclusion and disadvantage are major issues prior to drug use.68 Various studies have indicated
that, compared to the wider population, those with problematic drug usage patterns are much
more likely to have suffered difficult childhoods, encountered issues in formal education, been
unemployed more frequently, and committed crime.69–71 Clearly, many of those who engage in
problematic drug use have encountered marginalization prior to drug use. For this group, drug
use may lead to further marginalization when users become stigmatized e.g. they are refused
medical treatment. Often, this stigmatizing of drug users is reinforced by governments trying
to protect the public from the supposed dangers posed by drug users.72 Thus, the war against
drugs can easily evolve in to a war against drug users, worsening marginalization.70 The
increased exclusion faced by drug users can worsen their familial relationships and broader
23

connections to their community, possibly resulting in increased stigma and lack of treatment
for problematic drug use.73
Within marginalized communities in the United States, problematic drug use in low-income
Black and Hispanic communities can sometimes result in far worse outcomes when compared
to drug use in white middle class youth.74 For example, white middle class adolescents may
have economic and social resources not available to Black and Hispanic low income youth,
such as insurance to cover drug treatment, and money for legal counsel.75 While low-income
Black and Hispanic youths experience many of the developmental transitions as their white
middle class counterparts, they also experience inadequate education, family stressors and poor
job opportunities.76 While marginalization can worsen outcomes for drug users, it can be
particularly damaging for health, with the health of drug users bound to their social
environment.77 As indicated, possibly problematic drug use behaviors can be affected by social
processes, and the health of drug users is a product of both drug use behaviors and social
determinants. For example, homeless drug users are more likely to engage in high-risk sexual
activity.78 Social factors can establish the living condition and resources that indirectly worsen
the consequences of drug use. Inadequate housing can increase the likelihood of infectious
disease transmission and conversely, social relationships can offer protective financial and
emotional resources.77 As with broader outcomes, the role of marginalization is highly relevant
to the health of minority drug users. While minorities report levels of drug use similar to or
lower than nonminorities, minorities, especially marginalized minority drug users experience a
disproportionate number of health consequences from drug use.79,80 Fatal drug overdoses are
more common in minorities, and high rates of homicide for Black and Hispanic Americans
are associated with drug use and sale.81,82 Thus, marginalization can contribute to and worsen
possibly problematic illicit drug use.
24

Cannabis and drug policy
Around 1853, recreational cannabis use was considered fashionable in the United States.83
Cannabis was used in home remedies and patented medicines, and hemp as a commercial
product. Despite the ubiquity of cannabis, its use began to be equated with Mexican
immigrants and their recreational cannabis use. Anti-drug campaigners in the early 20th century
warned against the encroaching Marijuana Menace and a range of crimes were attributed to
cannabis and the Mexican and Black individuals who were perceived as using it.84 Cannabis
restrictions in the United States began when it was labelled as a poison in 1906 at the statelevel, with outright prohibition in the 1920s.85 By the mid-1930s, cannabis was regulated as a
drug in every United States state, along with 35 states that adopted the Uniform State Narcotic
Drug Act.83 A federal excise tax on hemp sales made possession or transfer of cannabis illegal
throughout the United States.86 In the early 20th century, cannabis became criminalized in
several countries,87 with multiple nations having international agreements to control drugs.88
The United States became a signatory to international drug treaties that restricted the trade,
production and supply of cannabis.89,90
As cannabis use grew beyond marginalized ethnic enclaves and was taken up by white college
students, United States drug policy became increasingly conservative.83 Beginning in late 1969
and continuing to date, the United States has made a concentrated effort to stem the tide of
illegal drugs, including cannabis.91 Several statutes such as the Racketeer-Influenced and
Corrupt Organizations and Continuing Criminal Enterprise (CCE) laws of 1970 served as
harsh anti-drug platform to allow for forfeiture of property and assets associated with criminal
operations.91 Air and sea blockades of illicit drug producing nations’ have served as reminders
of United States drug policy. Operation Intercept in 1969 and a series of similar efforts further
buttressed drug policy efforts.92 President Richard Nixon formed the Drug Enforcement
25

Administration as a single federal agency to enforce federal drug laws.93 During Reagan’s
Presidency, mandatory sentencing guidelines were established and mandatory prison sentences
were re-established for large-scale cannabis distribution.94
However, in the late 1970s, the Carter Administration considered decriminalizing cannabis
and indicated it was not interested in prosecuting individuals possessing small amounts of
cannabis.95 Despite the Administration’s stance and efforts by various non-profits,
decriminalization was unsuccessful, possibly due to a lack of public opinion consensus and
concern to precipitate legislative action. In the 1980s and more recently, harsh drug policies
have continued with cannabis as a key theme. Under the Reagan and Bush administrations,
interdiction became a priority.96,97 The Posse Comitatus Act was amended in 1982, allowing
the United States military to engage in drug supply reduction activities like intelligence
gathering and detection.98 These interdiction efforts were somewhat successful in reducing the
amounts of cannabis smuggled into the United States. The reduction in supply created a
shortage of cannabis but was swiftly filled by increased domestic cultivation. Cannabis policy
parallels were also observed in the military. The United States military had previously
emphasized drug use prevention and treatment,99 but in the 1980s adopted a zero tolerance
policy.100 Urine screening regimens were introduced in the military to locate and discharge drug
users, with this policy spreading to the workplace. In 1995, the Senate introduced the Violent
Crime Control and Law Enforcement Act of 1995 (S-3).101 This act specifically targeted, with
mandatory minimum sentences, drugs sales to minors and near schools, among other
activities. Although cannabis was not specifically mentioned, the act was used to criminalize
cannabis and its users.91
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In the United States, Federal, State, and local law enforcement agencies share responsibility
for enforcing drug laws, although most arrests are made by State and local authorities. The
Drug Enforcement Administration and the Federal Bureau of Investigation make arrests at
the Federal level. There were less than 30000 arrests for drug offenses in 1960.102 In the same
year, 169 federal cannabis violations were recorded.103 In 1965, there were about 20000 arrests
for all cannabis offences in the United States. By 1970, this figure had risen significantly to
190000 and then at an even greater rate to 421000 in 1973. Overall, drug arrests began their
rapid escalation after 1983.104 The increase in arrests since 1983 is likely attributable to the
increase in arrests for opium and cocaine, not cannabis. Between 1945 and 1968, the numbers
of federal defendants charged in United States District Courts was relatively stable. The
number of drug offenders gradually increased from 1968, stabilized and may be decreasing.
About three-quarters of defendants charged in United States District Court in 1985 with a
cannabis violation were convicted. The percentage convicted has been growing steadily. 104,105
Of those convicted in 1985, 67% received prison time, with this number rising steadily. 104,105
However, the average length of prison sentence among those convicted for cannabis violation
in United States District Courts has remained relatively unchanged till recently.
When considering all drug offenses, the number of Americans incarcerated has risen from
40900 in 1980 to 452900 in 2017.106 In 1986, people were released after serving an average of
22 months in prison. By 2004 however, people convicted on federal drug offenses were
expected to serve 62 months in prison.107 At the federal level, people incarcerated for drug
offenses are about half the prison population. At the state level, those in prison for drug
offenses has been increasing since 1980 but is currently on the decline. Most of those
incarcerated are low in the drug sale hierarchy and have no prior criminal record for a violent
offense.106
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There are significant ethnic disparities in drug-related sentencing. Black individuals in the
United States are four times more likely to be arrested for cannabis charges compared to their
white peers.108 Black individuals in the United States are about 30 percent of all drug-related
arrests, despite only being 12.5 percent of substance users.109 Almost 80 percent of people in
prison for a federal drug offense are Black or Latinx individuals.110 In the federal system, the
average Black defendant convicted of a drug offense will serve about the same amount of time
(58.7 months) as a white defendant would for a violent crime (61.7 months). People of color
account for 70% of all defendants convicted of charges with a mandatory minimum sentence.
Prosecutors are twice as likely to pursue a mandatory minimum for a Black defendant than a
white defendant charged with the same offense.110 However, despite the sometimes
exaggerated public health messages around cannabis, many have stopped believing in and
mock anti-cannabis programming.111 Such messages often contradict the lived experiences of
many people who use cannabis.100
The earliest survey data on cannabis use in the United States was obtained in 1967.112 The
nationally-based telephone poll of college students indicated a 5% lifetime prevalence of
cannabis use. Two years after, this proportion had increased to 22%, with similar trends in the
years after.113 It is possible cannabis use first rose among college students and then spread to
those of younger ages. Data from these surveys and other similar data indicate that there was
almost no cannabis use in the United States prior to the 1960s.114
According to the National Survey on Drug Use and Health in 2014, past year use of cannabis
in the United States was 13.3%.115 Many prominent individuals, celebrities and politicians
admitted to cannabis use, without any significant impact on their careers.116 However, not
everyone who uses cannabis is treated the same. In the United States, about 663367 people
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were arrested in 2018 for cannabis-related offenses.117 Of those, about 608775 were arrested
for possession only.118 The penalties for an ordinary person with a cannabis felony can
continue for the rest of the individual’s life. They become legally distanced from their civil
rights,119 cannot vote, serve on a jury, hold office, own a firearm or possess an occupational
licence.120,121
In line with the move toward stringent penalties for cannabis use, several organizations have
worked for reducing penalties, easing access to, and decriminalizing cannabis.122 Due to the
efforts of these organizations and other factors, sanctions against cannabis use have eased in
several jurisdictions.123 Persons with certain medical conditions were allowed to obtain
cannabis from the Federal Government since 1978.124 In 1996, California became the first
state to legalize medical cannabis125 and several other jurisdictions continue to do so.
Medication for opioid use disorder
In the 19th century, substance use was not generally associated with crime. However, opium
smoking was an exception.126 Opium eating was common among the upper classes but not
among criminals.127 Opioid use disorder was generally not as maligned as alcoholism and
opioids were a treatment for treatment-resistant alcoholism.126 The Harrison Act in 1914
marked a change in the American drug landscape. It seemed to be an effort to increase
revenue, but it did not seek to punish drug users. The Act did not seek to penalize medical
practitioners either.127 However, by 1938, about 25000 physicians were arraigned on narcotics
charges.126 In light of the decreased role of physicians in the treatment of opioid use disorder,
more than 40 clinics were started. Many of these sites were under governmental oversight but
were eventually closed.128 After these clinics were closed, many individuals were incarcerated.129
Thus, the government set up several prison-hospital complexes to treat substance abuse
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disorder. In 1922, it became a crime for a physician to prescribe narcotics to an individual a
substance use disorder.127 By World War II, opioid use disorder rates had dropped, not because
of governmental or medical efforts, but more to do with reduced opioid supplies from Asia.
Methadone was mistakenly believed to be developed during World War II but was developed
during research on spasmolytic compounds. Methadone was synthesized in Germany by Bayer
and then brought to the United States, primarily researched at Harvard for use in pain
management.130 Methadone had little resemblance to any known compounds so its analgesic
properties were surprising.126 Despite the morphine shortage, methadone was not used as an
analgesic till the postwar period.131 Oral methadone was established as treatment for opioid
use disorder in the United States Public Health Service hospitals in 1950.126
A heroin epidemic hit New York City in the 1950s and early 1960s, with a rise in heroin-related
deaths. Several groups such as the American Medical Association and the New York Academy
of Medicine called for reestablishment of methadone clinics.132 In 1963, Vincent Dole received
a research grant and the next year methadone maintenance treatment was discovered. The first
methadone maintenance treatment program had two patients and by 1968 there were 1139
individuals in the program. A report on the first 17500 patients in treatment indicated that
those in treatment experienced a 35% increase in productive behavior and a decrease in
arrests.132
The early rapid expansion of methadone maintenance treatment was tolerated by the public
because of its possible link with reduction in crime.126 Public and governmental concerns
shifted toward the economy in the 1970s and publicly funded programs faced reduced budgets.
Private enterprise entered the methadone maintenance treatment environment in response to
government cutbacks. Methadone experienced a slight resurgence in public acceptability when
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methadone maintenance was linked to the reduced spread of AIDS.133 Over the next few
decades, multiple studies documented the safety, efficacy and effectiveness of methadone.130
While there are over a millions individuals in the United States with opioid use disorder, only
a minority are enrolled in some form of medication for opioid use disorder treatment.134 While
data indicates that methadone doses above 80mg significantly improve treatment outcomes,
doses provided are generally below this threshold.135 Several factors explain this trend. Firstly,
there are philosophical objections to the treatment of addiction through a medication.
Secondly, there are numerous social and societal objections to medication for opioid use
disorder. Thirdly, polysubstance use can affect treatment outcomes. Finally, there are several
restrictions around clinical practice and medication for opioid use disorder regulations.
Philosophical objections are related to a misunderstanding of methadone. The therapeutic
community movement, 12-Step Fellowship groups and a range of drug-free treatment providers
have opposed medication for opioid use disorder. These groups believe that medication for
opioid use disorder is essentially substituting one drug for another. As a result, medication for
opioid use disorder patients are often stigmatized. Societal and social objections to medication
for opioid use disorder generally take two forms. Firstly, family and friends pressure patients
to end their medication for opioid use disorder treatment. Some patients may thus discontinue
treatment prematurely. Secondly, some communities do not allow medication for opioid use
disorder treatment centers to be built in a particular jurisdiction.136,137 Similarly, mass media
outlets in such environments often portray medication for opioid use disorder in a poor light.
Societal objections to medication for opioid use disorder can operate even within medication
for opioid use disorder treatment programs. Lower doses of methadone are often administered
in clinics which prefer an abstinence model of treatment.138 Clinics that treat primarily more
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Black patients also tend to prescribe lower doses, possibly due to decreased funding and less
well-trained staff.138 It is unclear to what extent negative attitudes toward methadone have
extended to buprenorphine treatment.139 Urine test results are called clean or dirty instead of
positive, negative, expected or unexpected. Medically indicated situation in which patients receive
medication for opioid use disorder are reducing their doses are often described as
detoxification, as if medications are toxins harmful to the body.136
In the early days of medication for opioid use disorder, polysubstance use was common with
patients. However, usage patterns evolved such that heroin became the main drug of choice
for most patients.132 More recently, patients present with comorbid dependence on alcohol,
cocaine and benzodiazepines.140 The final issue facing medication for opioid use disorder is
the nature of the clinics and their regulations. The economic dependency and poly-drug use
of medication for opioid use disorder patients is often ascribed to treatment rather than
broader systemic factors, often leading to further restrictions in funding. Patients often must
pick up medication during limited clinic hours which can impact patient ability to attend school
or work. Treatment providers are often low paid and have large caseloads, thus unable to meet
therapeutic goals.134
Three strategies have been highlighted to address stigma associated with opioid use disorder
and medication for opioid use disorder: 1) personal or mass protest; 2) public and professional
education; and 3) strategies that enhance contact between stigmatized and non-stigmatized
groups.141 The recovery status of medication for opioid use disorder patients is unlikely to be
fully embraced by policymakers, the public, addiction professionals and recovery communities
till a vanguard of current and former patients and their communities declare their positive
treatment outcomes.142 Changes in attitudes and treatment outcomes around medication for
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opioid use disorder are most likely to occur not from acceptance of addiction as a medical
condition, but through identification with an admired figures in one’s medication for opioid
use disorder social support network.143,144
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Chapter 1: The United States Legal Cannabis Industry
This chapter details concerns in the United States legal cannabis industry. I first look at
cannabis use patterns at the dawn of United States cannabis reform. I then explore correlates
of cannabis-related emergency department visits and present a qualitative study that explores
motivations for large United States cannabis firms’ participation in the space. Through these,
I hope to provide more insight on the rapidly developing United States cannabis space,
charting trajectories of cannabis usage and the consequent policy outcomes. On a broader arc,
I will demonstrate risk reduction around cannabis use and the intersections with individual
agency within a marginalized community.
Cannabis Use Patterns at the Dawn of United States Cannabis Reform
This section has been published as: Kumar N, Puljević C, Ferris J, Winstock A, Barratt MJ.
Cannabis Use Patterns at the Dawn of United States Cannabis Reform. J Cannabis Res.
2019;1(1):5. Doi:10.1186/s42238-019-0003-z
In the United States, three in 10 cannabis users develop cannabis use disorder under
Diagnostic and Statistical Manual of Mental Disorders-IV guidelines.145 When using
Diagnostic and Statistical Manual of Mental Disorders-5 guidelines, 19.5% of lifetime cannabis
users met the criteria for cannabis use disorder.146 I define cannabis use disorder as a
problematic pattern of cannabis use leading to clinically significant impairment or distress as
manifested by at least two of the markers of cannabis use disorder, as defined by the
Diagnostic and Statistical Manual of Mental Disorders 5.147 Usage patterns in line with
cannabis use disorder may be associated with socio-economic disadvantage, including
unemployment or decreased financial stability.148 Research on cannabis use disorder is
paramount, to guide policy and interventions, especially with the rapid growth of United States
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legal cannabis markets, given that states with legalized cannabis have greater rates of cannabis
use and cannabis use disorder.149 Cannabis may also provide some therapeutic benefits, for
conditions such as multiple sclerosis and nausea.150,151 There are also recommendations for
lower risk use, such as avoiding early initiation of use, and using low-potency products.152 In
this vein, some of the risk from cannabis use may be mitigated through informed behavioral
choices by users.152
Thus, to provide understanding around cannabis use disorder, it is necessary to detail cannabis
usage preferences. However, there is a paucity of research exploring preferences around
United States cannabis use. Past work has explored demographic characteristics and cannabis
use preferences, but these generally use data prior to rapid legalization in recent years.123,153–155
More recent data is key as additional jurisdictions rapidly legalize medical and recreational
cannabis use, and the possibly associated changes in cannabis use disorder. Moreover, while
these studies report cannabis prevalence, primarily utilizing the National Survey on Drug Use
and Health, National Epidemiologic Survey on Alcohol and Related Conditions, and
Monitoring the Future, they do not indicate nuanced data on usage preferences, such as time
of use and preferred cannabis variants (edibles, resin etc.). For example, given the sheer range
of cannabis products,156 charting prevalence of cannabis is not sufficient if users have
preferences for different products and some are more likely to contribute to cannabis use
disorder compared to others.157 With the shifting United States cannabis landscape, granular
data on cannabis usage practices are key to pioneering policy and crafting future research.
Using a United States-subset of a large cross-sectional online global survey, this paper
describes a range of cannabis usage preferences, including time of first and last joint, quantities
of use, and preferred forms of cannabis preparations. The survey questions I highlight are not
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in themselves the strongest markers of cannabis use disorder but understanding prevalence of
cannabis use from a large sample may shed light on patterns of cannabis use disorder.
Methods
The Global Drug Survey annually conducts anonymous, online surveys to investigate
international trends in drug use, both legal and illicit. Data from Global Drug Survey 2017,
collected from November 15, 2016 to January 18, 2017, is utilized in this paper. The age and
sex distributions of cannabis users who completed the Global Drug Survey in Australia, the
United States, and Switzerland were similar to their respective countries’ demographic
distributions in a household survey across the three countries.158 When the Global Drug Survey
(2014) is compared to the similar National Survey on Drug Use and Health (2013) data, there
are several key similarities. For example, regardless of age, men were more likely to report
cannabis use compared to women. Both men and women typically demonstrate similar trends
of a decreasing probability of lifetime and previous-year cannabis use with age. While the
probability of ever using cannabis is greater in the Global Drug Survey (2014) sample, the
probability of using cannabis in the past year among lifetime users, and using within the past
month among past-year users is comparable across Global Drug Survey (2014) and National
Survey on Drug Use and Health (2013) data. While non-response bias and volunteer bias may
influence Global Drug Survey samples, unmeasured confounders may affect data in household
surveys.159 Household surveys may underestimate the prevalence of illicit drug use due to
stigma and other factors.160,161 In addition, Global Drug Survey is far cheaper given its higher
response rate, compared to household surveys.158 For example, in Global Drug Survey (2014),
6419 users were surveyed to recruit 3879 past-month cannabis users. In comparison, the
National Survey on Drug Use and Health (2013) surveyed 43465 to recruit 5664. Thus, the
Global Drug Survey is an effective way of gaining a nuanced understanding of stigmatized
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behaviors, if it is not used to estimate drug prevalence of the general population.158 Sample
representativeness may only be necessary when exploring research questions about population
prevalence estimates,158 and the Global Drug Survey is thus appropriate to provide insight
about United States cannabis usage preferences within specific samples such as young males.
The survey was actively promoted on social media platforms, such as Twitter, Facebook, and
through media partners, such as, Mixmag and The Guardian (United States). All respondents
confirmed they were 16+ years and provided informed consent. The study received
institutional review board approval from The Psychiatry, Nursing and Midwives Ethics
subcommittee at Kings College, London (141/02), The University of Queensland (No:
2017001452) and The University of New South Wales (HREC HC17769). Analyses were first
restricted to United States-based respondents. Responses were included only if individuals
indicated use of cannabis in the last 12 months, through all forms of administration, such as
smoking, eating or vaporizing. The measures described in this paper (see Appendix) included
demographic characteristics, whether cannabis was mixed with tobacco in the last year, time
of first joint, amount of cannabis used per session, number of hours of day spent stoned in a
session, time of last joint, number of days cannabis was used in the last year, preferred form
of cannabis in the last year, and most common method of administration.
Results
TABLE 1. Descriptive Variables (Number of Participants Reporting Cannabis Use in Last Year=8345)
-16-20
28.4%
-21-30
41.7%
Age (N=8345)
-31-40
14.9%
-41-79
15.0%
-Male
75.5%
Sex (N=8345)
-Female
23.6%
-Transgender
0.9%
Time of First Joint (N=7033)
>60mins
78.0%
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Time of Last Joint (N=7034)

Mixing Tobacco with Cannabis
(N=8345)
Cannabis Used Per Session
(Grams) (N=7667)
Number of Hours Stoned in a
Session (N=6970)
Number of Days Cannabis was
Used in the Last Year
(N=7389)

Preferred Form of Cannabis
(N=7565)

Most Common Mode of
Cannabis Consumption
(N=7913)

<60mins
-Last Thing before Bed
-1-2 hours before bed
-3-4 hours before bed
-More than 4 hours before bed
No
Yes
Median

Median
Interquartile Range
Median

22.0%
31.3%
49.1%
15.4%
4.2%
78.0%
22.0%
0.5
0.1251.000
4
3.0-6.0
250

Interquartile Range

50-360

-High potency herbal cannabis
-Resin/hash

62.1%
11.2%

-Normal weed/bush/pressed
-Edibles
-Kief
-Oil
-Butane Hash Oil
-Smoked in a joint with tobacco
-Smoked in a joint without tobacco
-Smoked in a blunt with tobacco
-Smoked in a blunt without tobacco
-Smoked in a pipe with tobacco
-Smoked in a pipe without tobacco
-Smoked in a bong/water pipe with tobacco
-Smoked in a bong/water pipe without tobacco
-Bucket bong
-Hot knife
-Vaporizer
-Eaten in food
-Tincture/drank as tea
-Medical spray

1.7%
1.3%
8.3%
8.0%
7.6%
3.8%
11.3%
0.7%
7.5%
0.5%
33.3%
2.6%
23.0%
1.5%

Interquartile Range

0.2%
12.7%
2.4%
0.4%
0.1%
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Sample
A total of 10,183 respondents from the United States completed the survey between
November 2016 and January 2017. Of these respondents, 8345 (82%) participants reported
cannabis use in the past year. There was missing data on some variables, and I have indicated
the total number of cases for each variable (see Table 1). Males accounted for 75.48% of the
sample, with a median age of 23 (interquartile range (Interquartile range): 19-32, Range: 16-79,
see Table 1).
Characteristics of Cannabis Use
Of those who reported cannabis use in the past year, most (78%) reported consuming their
first joint more than an hour after waking, and about half the sample had their last joint 1-2
hours before bed (49%) (see Table 1). The majority (78%) tended not to mix tobacco with
cannabis. Respondents reported using cannabis for a median of 250 days in the last year
(almost daily), with 0.500 grams the median per session. Respondents spent a median of four
hours a day stoned when cannabis was used. Most (62%) of respondents reported high
potency herbal cannabis as their preferred cannabis preparation in the last year, followed by
resin/hash (11%). About a third (33%) of participants smoked cannabis in a pipe without
tobacco, followed by (23%) smoking it in a bong/water pipe without tobacco.
Discussion
I sought to provide a descriptive report on cannabis use among a large sample of United
States-based survey respondents, largely young men, including time of first and last joint,
mixing cannabis with tobacco, and other patterns of use. A low proportion of respondents
used cannabis within the first hour of waking, suggesting limited preference for waking and
baking162 within young males. By avoiding waking and baking, young male cannabis users may
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possibly mitigate reductions in poor judgement later in the day, a common outcome when
drugs are consumed earlier in the day.162 Factors that affect altered judgment are key for a
demographic prone to risky behaviors.163,164 The high proportion of respondents stating time
of last joint just before bed may indicate cannabis being used as a sleep aid. Thus, interventions
to reduce problematic cannabis use may target young male users who indicate sleep issues as
a symptom when purchasing legal cannabis. Most participants do not mix cannabis with
tobacco, perhaps indicating an awareness of tobacco’s harmful properties165 within young men.
Recent research has indicated the increasing use of electronic nicotine delivery systems,166,167
and perhaps such developments are associated with low levels of mixing cannabis with tobacco
by young men. Most participants smoked cannabis in a pipe without tobacco. There is some
evidence that this may not be the safest way to consume cannabis.168 Nevertheless, consuming
cannabis without tobacco may be safer than the less popular option of combining the product
with tobacco,169 adding to research around lower risk use. Near daily cannabis use was reported
by the majority of respondents, a possible health concern not in line with lower risk cannabis
use152 and such patterns of use may be related to growing United States cannabis markets.
High potency herbal cannabis was the preferred variant, which may be less harmful compared
to more potent, but less popular concentrates.170,171 High potency herbal cannabis can contain
up

to

15%

tetrahydrocannabinol,172

but

concentrates

can

have

up

to

40%

tetrahydrocannabinol content.173 The factors underpinning such a product preference may aid
understandings around the long-term trajectory of United States cannabis use, especially
within young men. Several studies, primarily utilizing the National Survey on Drug Use and
Health, National Epidemiologic Survey on Alcohol and Related Conditions and Monitoring
The Future report the prevalence of United States cannabis use, cannabis use disorder and
frequency of use, along with demographic associations.74,149,162 I extend their work by providing
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granular data around usage practices, such as cannabis product preferences and time of use,
primarily in the young male demographic. Such nuanced data on usage preferences is key given
the large range of cannabis products and modes of use. In addition, previous studies were
conducted prior to the recent legalization of recreational cannabis in several states, and thus I
extend past authors’ work by providing recent data possibly more reflective of current
practices.
Limitations
To the best of my knowledge, this study is the largest United States-based study detailing
cannabis use patterns. This research design has advantages and disadvantages, such as
reliability and validity at a population-based level.158,174,175 Online surveys are considered valid
and useful when data are scarce, as with the current study. As hidden samples cannot be
efficiently analyzed in generalized population-based surveys, comparable probability samples
and ethnographic fieldwork may also be necessary to increase the external validity of the
sample.176 Also, as I used an online survey of drug users, the sample was skewed toward
younger male participants, and may draw more regular cannabis users.
Conclusion
I provided data on United States cannabis use patterns with largely young male participants,
in the wake of rapid growing United States legal cannabis markets. Overall, respondents
engaged in less problematic modes of cannabis consumption, such as in a pipe without
tobacco or in a bong without tobacco. However, the sample were stoned almost daily. High
potency herbal cannabis was the preferred variant, which may be less harmful compared to
more potent, but less popular concentrates. Frequent drug use may not be an issue, but
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repeated use of any drug may increase risk of health harms, and thus I suggest that future
research explore patterns of cannabis use in the changing United States market.
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Correlates of Cannabis-related emergency department Visits in New York City
The analysis for this paper was conducted while I was employed at the New York City
Department of Health and Mental Hygiene. Due to data restrictions, I was not allowed to
use the tables in my thesis till approval had been obtained from my supervisors. Currently,
most of the Department has been repositioned toward pandemic-related efforts. Thus, I
have not been able to contact my past supervisors at the Department for data access, either
to provide tables below or for further analysis.
In 2017, in the United States, there are approximately 40.9 million people (15.0%) aged 12
or older who used cannabis in the last year.177 In 2017, 49.4% of men and 41.2% of women
aged ≥12 years reported cannabis use in their lifetime.177 In the same period, the prevalence
for white, Black and Hispanic persons was 50.8%, 42.4% and 33.4% respectively.177 For
those aged 12-17, 18-25 and ≥26, the prevalence was 15.3%, 52.7% and 47.5%
respectively. Cannabis is available through the New York State Department of Health
Medical Marijuana Program to treat a select number of medical conditions, but is not legal
for use in the state otherwise.178 From 2015-2016, 16% of New York City residents
reported cannabis use at least once in the past year.178 Use prevalence has been stable since
2009-2010.178 In New York City, 19% of men and 13% of women indicated cannabis use
in the past year.178 Sixteen percent of New York City youth in 2017 reported cannabis use
in the last month.178 The prevalence was greater in white residents (24%) compared to
Black (14%) and Latinx residents (12%).178
In the United States, about one in 11 cannabis users aged 15 or older develops dependent
patterns of use, with about 4.2 million people meeting diagnostic criteria for frequent or
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problematic use.179 Such patterns of cannabis use are associated with psychotic symptoms,
suicidal ideation, and major depressive disorder.180–182 These findings are not causal and it
is not clear if cannabis is used as self-medication for mental health conditions. Multiple
studies have detailed cannabis use prevalence146,183,184 but the possible impact of cannabis
use on emergency department visits has not been sufficiently explored.183,185,186
In the United States, in 2011, there were 456000 emergency department visits associated
with cannabis use, a 21% increase from 2009.187 About 1.7% of lifetime adult cannabis
users reported an emergency department visit188 and 12.1% of adults nationally who sought
medical care in emergency department used cannabis in the past year compared with 9.7%
of adults receiving emergency department care.189 Post-cannabis legalization in Colorado,
there were increases in cannabis abuse-related hospitalizations and overdose injuries.190 In
California, cannabis use disorder patients were more likely to have an emergency
department admission compared to those without.191 Thus, cannabis may related to
increased emergency department admissions. Although there are concerns about the
negative effects of cannabis use on health and healthcare utilization,192 there is minimal
data on cannabis-centric emergency department admission.186
A Colorado study detailing 2005-2015 cannabis-related emergency department visits
indicated that most (71%) had a comorbid psychiatric diagnosis.193 Similarly, the prevalence
of mental health conditions in emergency department visits with cannabis-related
International Classification of Diseases codes is higher than those without cannabis.194,195
cannabis use disorder patients in California with co-occurring psychiatric conditions had
higher odds of emergency department admission compared to those without.191 Anxiety,
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mood and bipolar disorders were also most common among daily cannabis users.
However, other studies indicate no association between cannabis use and anxiety

196,197

197,198

or

mood disorders.199
Cannabis in combination with alcohol is associated with violence-related injuries and
motor vehicle accidents,200,201 perhaps due to reduced risk perception.202 Along with
cannabinoids, there is a higher prevalence of alcohol in blood samples from drivers
involved in traffic accidents, compared to controls.201,203 Cannabis may also function as a
medication for opioid use disorder,204 especially since the New York State Department has
added opioid replacement therapies as a qualifying condition for medical cannabis.205 Of
those who had been prescribed opioids to relieve chronic non-cancer pain, users reported
more pain relief in combination with cannabis compared to when only opioids were
used.206
Males are generally more likely than females to have cannabis use disorder.207 About 13%
of adolescents nationally used cannabis in the past year and adolescent users were more
likely to meet cannabis use disorder criteria in the past year compared to adults.207 From
2004-2011, there was a 61% increase in cannabis-related emergency visits for adolescents
nationally208 with similar increases for those >12 years of ages, with the greatest prevalence
for non-Hispanic Black persons.186 Black adolescents were more likely than white
adolescents to have used cannabis and to have cannabis use disorder in the past year.209
When detailing frequent cannabis use, adolescents of a lower socioeconomic status tend
to have a greater odds ratio of use compared to those of a higher socioeconomic status.210
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These studies indicate that there is a need to detail the associations between cannabisrelated emergency department visits and sex, age, socioeconomic status, co-morbid
psychiatric conditions, and other drug use.186 I am interested in the relationship between
the above characteristics and cannabis-related emergency department diagnoses. I used the
Statewide Planning and Research Cooperative System for New York City to identify
groups with higher odds of discharge from emergency department with cannabis-related
diagnoses. These findings will inform cannabis-related emergency department utilization
and identify demographic groups disproportionally affected by cannabis-related emergency
department utilization.
To my knowledge, this study is one of the first to detail the sociodemographic factors
associated with cannabis-related emergency department visits in New York City. Findings
will have timely clinical implications for informing demographic groups impacted by
cannabis-related emergency department visits, especially as New York state moves closer
to legalization of recreational cannabis.211–213
Methods
Data source
Data was obtained from the 2016 Statewide Planning and Research Cooperative System,
which is a comprehensive, all payer data reporting system. Statewide Planning and
Research Cooperative System collects patient level detail on patient characteristics,
diagnosis and treatments, services and charges for each hospital inpatient and outpatient
visit in New York state.214 This study focused on a subsample of unintentional emergency
department visits for admitted patients aged ≥13 years in New York City. The use of
46

Statewide Planning and Research Cooperative System dataset was determined to be
exempt from review by the Institutional Review Board of the New York City Department
of Health and Mental Hygiene.
Statistical analysis
I first indicated the number of unintentional emergency department visits, stratified by
cannabis and non-cannabis related (see Appendix for more info on study variables). I
performed binomial logistic regression analysis to determine associations between
demographic characteristics, co-occurring diagnoses and cannabis-related emergency
department visit. I also provide age-adjusted rates in the demographic breakdown of
emergency department visits. Comparing crude age-specific rates over time and between
populations may not be accurate if the underlying age compositions differ in the
populations of interest.215 age-adjusted rates may allow for more accurate comparison of
different groups.216 Analysis was conducted using R.217
Results
FIGURES AND TABLES CURRENTLY UNDER EMBARGO
Characteristics of cannabis-related emergency department visits
In 2016, there were 2397417 emergency department visits in New York City, with 15016
cannabis-related visits. The largest age group, 25-34, represented 30.8% of cannabis-related
visits (see Table 1). The next largest age group, 18-24, represented 24.7% of visits.
Compared to those aged 65-84, all age groups were more likely to receive a cannabis-related
diagnosis (see Table 2). The age groups of 13-17 (adjusted odds ratios 12.26; CI 12.1-12.4)
and 18-24 (adjusted odds ratios 15.07; CI 14.9-15.2) had the greatest adjusted odds ratios.
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Males (70.8%) and Black non-Hispanic persons (43.4%) were the greatest proportions for
gender and ethnicity, respectively. Compared to women, men were more likely to receive
a cannabis-related emergency department diagnosis (adjusted odds ratios 2.67; CI 2.6-2.7).
Compared to white residents, Black (adjusted odds ratios 2.11; CI 2.1-2.2) and Hispanic
residents (adjusted odds ratios 1.16; CI 1.1-1.2) were more likely to get a cannabis
diagnosis. Neighborhoods with 20 to <30% poverty represented the largest (34.3%) group
of cannabis-related visits. Compared to those in neighborhoods with <5% poverty, those
living in neighborhoods with 5% to <10% (adjusted odds ratios 0.87; CI 0.6-1.1), 10% to
<20% (adjusted odds ratios 0.78; CI 0.5-1.0) and 30% to <40% (adjusted odds ratios 0.82;
CI 0.6-1.1) poverty were less likely to receive a cannabis-related emergency department
diagnosis. However, those in 20% to <30% (adjusted odds ratios 1.04; CI 0.8-1.2) and
≥40% (adjusted odds ratios 1.20; CI 0.9-1.4) poverty neighborhoods were more likely to
receive a cannabis-related diagnosis. Most people reporting for cannabis-related emergency
department visits did not receive a comorbid diagnosis for other drug use (alcohol, opioids,
cocaine) or mental health conditions (anxiety disorder, mood disorder and schizophrenia
and other psychotic disorders). Those who received an alcohol (adjusted odds ratios 3.96;
CI 3.9-4.0), opioid (adjusted odds ratios 2.60; CI 2.5-2.7) or cocaine (adjusted odds ratios
10.63; CI 10.6-10.7) diagnosis were more likely to receive a cannabis-related diagnosis.
Similarly, those who received a diagnosis for anxiety disorder (adjusted odds ratios 2.35;
CI 2.3-2.4), mood disorder (adjusted odds ratios 4.34; CI 4.3-4.4) or schizophrenia and
other psychotic disorders (adjusted odds ratios 6.37; CI 6.3-6.4) were more likely to receive
a cannabis-related emergency department diagnosis.
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Discussion
This study utilized a New York City-based sample of emergency department visits to
inform demographic predictors of cannabis-related emergency department visits. The
results indicate that younger people, men, nonwhite residents, those in neighborhoods with
the greatest poverty levels, those with alcohol, opioid, cocaine, anxiety disorder, mood
disorder or schizophrenia and other psychotic disorders were more likely to receive a
cannabis-related emergency department diagnosis. These findings may indicate that
cannabis use may add burden to the healthcare system for those already disproportionately
affected.
The results extend research around cannabis use and cannabis-related health conditions,
such as cannabis use disorder and respiratory illnesses. The health effects of cannabis use
are not just dependent on cannabis prevalence, but also potency, dose, type of cannabis
product and interactions with other drugs184,218 Cannabis potency in seized samples seems
to be steadily increasing219 and high potency products may be linked to heavier use.157,220
The results are in line with reports indicating greater likelihood of cannabis-related
emergency department visits among adolescents and Black persons,186 and increasing
proportions of cannabis-related admissions to addiction-related treatment facilities among
those aged ≥12 years.221 As more states legalize recreational cannabis, the results reinforce
the need for research on identifying demographics at increased risk for cannabis use
disorder and healthcare utilization. This should be understood keeping in mind the data
does not include larger structural factors like stigma and discrimination.
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Emergency department visits and gender
I indicated that men were more likely than women to receive a cannabis-related emergency
department diagnosis. This could mean that men are at greater risk for problematic
cannabis use, although it must be noted that men are more likely to visit emergency
departments.222,223 From 2002-2014, men used more cannabis than women, with an
increasing gender gap.224 Men also reported more frequent and larger amounts of cannabis
use, along with higher potency products compared to women.225 In general, men are more
likely to engage in substance use and other risky behaviors compared to women,226 which
may explain increased emergency department visitations for cannabis use.
Emergency department visits and age
I found that all age groups within 13-64 were more likely than those 64-84 to receive a
cannabis-related emergency department diagnosis. The age groups of 13-17 and 18-24 had
the greatest adjusted odds ratios. This finding may indicate that adolescents are at greater
risk for problematic cannabis use. However, Statewide Planning and Research Cooperative
System data represents treatment admissions and the results may be influenced by a subset
of adolescents who had frequent cannabis-related admissions.186
Emergency department visits and ethnicity
I found that Black and Hispanic residents were more likely than white residents to receive
a cannabis-related diagnosis. The ethnicity-based results may indicate a combination of the
effects of family socioeconomic status and neighborhood socioeconomic status on the
likelihood of a cannabis-related visit.227 In line with other studies, I suggest the need to
monitor cannabis-related health events and develop interventions for Black and Hispanic
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cannabis users. Past studies reaffirm the results, where past year-cannabis use and cannabis
use disorder among Black adults increased between 2001-2002 and 2012-2013.183
Emergency department visits and poverty level
Our findings indicate that those of medium poverty level were less likely to receive a
cannabis emergency department diagnosis compared to those with low poverty. However,
those with high and very high poverty were more likely to receive a cannabis diagnosis
compared to those with low poverty. I put forward the need to develop interventions
targeted specifically at cannabis users of a lower socioeconomic status. Previous work
indicates that cannabis use, especially heavier use,210,228 is common among those facing
socioeconomic disadvantage.229
Emergency department visits and alcohol use
The results demonstrate that those with an alcohol diagnosis were more likely to receive a
cannabis-related diagnosis. These results may indicate that those with possibly problematic
alcohol use may be at increased risk for risky cannabis use. While there is an association
between alcohol and cannabis for young adults, users tend to use one substance
predominantly at a particular time.230 More research is thus required to determine how
cannabis and alcohol use are related, resulting in possible emergency department visits.
Emergency department visits and opioid use
Findings indicate that those with an opioid diagnosis had a greater likelihood to receive a
cannabis diagnosis. These findings may suggest that those with possibly problematic
patterns of opioid use may be at greater risk for increased risky cannabis use. Past studies
reinforce the results. Usage of cannabis was common for those with chronic non-cancer
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pain and had an opioid prescription, despite no evidence of cannabis improving patient
outcomes.231,232 Problematic opioid use is more prevalent than problematic cannabis use
for those with a medical cannabis recommendation.233
Emergency department visits and cocaine use
Our findings indicate that people with a cocaine diagnosis were more likely to receive a
cannabis-related diagnosis. These results may represent the need for cannabis use related
interventions for cocaine users. Cannabis onset may trigger cocaine use234 and for a subset
of at-risk users, cannabis use may be related to later cannabis use.235 Participants in the
study may demonstrate problematic substance use behavior and thus may exhibit
concurrent problematic cocaine and cannabis use.
Emergency department visits and psychiatric conditions
The results indicate that those with anxiety disorders, mood disorders or schizophrenia
and other psychotic disorders were more likely to receive a cannabis-related diagnosis.
These findings may put forward the need to target interventions around problematic
cannabis for those with psychiatric conditions such as anxiety, mood disorder and
schizophrenia and other psychotic disorders. Past research reaffirms the results, around
the increased prevalence of mental health conditions for cannabis-related emergency
department visits.194,195 Similarly, heavy cannabis use (at least daily) is associated with
anxiety and mood disorders.196,197 Further research is thus key in determining the
relationship between problematic cannabis use and various psychiatric conditions.
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Limitations
These results should be interpreted in line with several limitations. While cannabis use may
be considered a direct cause for an emergency department visit, causality between cannabis
use and emergency department visits cannot be assumed. The data also does not include
information about cannabis use frequency and dose, nor larger sociocultural and
contextual variables that may confound or serve as mediators in the relationships
described.
Conclusion
Younger age, nonwhite ethnicity, increased neighborhood poverty, other drug use and
mental health conditions were associated with greater likelihood for cannabis-related
emergency department visits. Infrequent screening for problematic drug use and lack of
treatment for drug use disorders within healthcare setting may relate to emergency
department admissions.236 Adolescents, parents and healthcare providers may overlook
cannabis-related health concerns,237 and toxicology screening may improve identification
of problematic cannabis use, especially for adolescents.238 The data also indicates the
importance of age, ethnicity and psychiatric conditions in conducting screening for
cannabis use and related interventions to reduce cannabis use.239,240 There is a need to
develop risk-stratified screening and targeted interventions for high risk groups, especially
in emergency department settings where drug-related events are more common.
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Understanding Motivations for Large United States Cannabis Firms’
Participation in the Cannabis Space: Qualitative Study Exploring Views of Key
Decision-Makers
This section has been published as: Kumar N, Puljević C, Heimer R. Understanding
Motivations for Large United States Cannabis Firms’ Participation in the Cannabis Space:
Qualitative Study Exploring Views of Key Decision‐makers. Drug Alcohol Rev. February
2020:dar.13040. Doi:10.1111/dar.13040
In the 1990s, United States activists such as the civil rights movement, drug reformers and
libertarians, campaigned to legalize medical cannabis. In 1996, California became the first
state to approve a citizen-initiated referendum that legalized medical cannabis.241 By 2010,
23 states and the District of Columbia allowed medical cannabis use in some form.242 In
November 2012, Colorado and Washington voters endorsed a legal cannabis market for
non-medical use.242 In the years that followed, other states have allowed for recreational
markets, while other states are preparing to push for legalisation.243 Although several states
have legalised recreational or medical cannabis, the United States federal government
prohibits cannabis sale, resulting in conflict between United States federal and state
cannabis legislation.244 However, as of September 2018, there have been no injunctions or
lawsuits filed by the Department of Justice regarding these conflicts.245
In the United States, legal cannabis is sold and cultivated by a range of firms, ranging from
moderately-sized owner-operated dispensaries to large firms which own multiple
dispensary licenses and plantations.246 I define firms as business organizations, such as
corporations, that sell goods or services primarily for profit. The United States cannabis
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space, market or industry represents firms involved in the sale of cannabis, including those
involved with the plant (e.g. Growers, dispensary owners, concentrate manufacturers) or
related equipment (e.g., hydroponic equipment manufacturers, pipe manufacturers), firms
that invest in or acquire firms involved in cannabis sale, information providers and service
providers to cannabis firms.247
The United States legal cannabis market has been growing rapidly in recent years, from
$2.7 billion in 2014248 to $10.4 billion in 2018249 and this continued growth seems to have
attracted big-name investors to the space.250 Given burgeoning United States cannabis
markets, heavy frequent use and cannabis use disorder are a concern.198 In the United
States, about one in 11 cannabis users aged 15 or older develops dependent patterns of
use, with about 4.2 million people meeting diagnostic criteria for frequent or problematic
use.179 Such patterns of cannabis use are often associated with psychotic symptoms,
suicidal ideation, and major depressive disorder.180 Research conducted in states with
medical cannabis laws found that residents had higher odds of cannabis use and cannabis
use disorder compared to residents in states without such laws.149 Thus, changing patterns
of cannabis usage may be affected by profit-centric legal cannabis markets.251
A major driver of legal cannabis markets are large cannabis firms.252 Such firms may be
engaging in actions that could contribute to changes in cannabis usage patterns.253 For
example, cannabis advertising and availability has been associated with greater likelihood
of use.254 The use of cannabis concentrates, developed by large firms following pressure
from retailers to make high-potency products255 has also been linked to heavier use.220
55

Lobbying by large cannabis firms is also a concern, with well-organized industry interests
influencing legislation.252
However, this is not to suggest that growth in the legal cannabis markets or efforts by large
cannabis firms which may contribute to nationwide legalization, may solely result in
negative effects. Cannabis legalization also heralds benefits, such as greater ease in
monitoring the amount of cannabis sold and increased research on therapeutic benefits of
the plant.256 A leading drug advocacy group cites harm reduction, job creation and reduced
government spending on law enforcement and incarceration as further benefits of
legalisation.257 Other gains include improved environmental conditions in cannabis
growing areas, and state revenue increases.258
Some large cannabis firms are claiming their product and its marketing are socially
responsible259 and leverage the medical potential of cannabis260 to possibly increase sales.
A few firms provide free cannabis to cancer patients, and mentor newcomers to the
space,261 portraying cannabis companies as benevolent actors, in line with the potential
role of firms in indirectly reducing arrests and incarcerations262 and improving medical
outcomes.263 Such actions create the impression that firms are concerned about improved
social outcomes. However, firms may also have a role in greater availability of legal
cannabis and similar rises in frequency of use.264 Firm actions thus appear to have
counterintuitive motivations: Augmenting social outcomes and contributing to possibly
problematic cannabis usage practices. Firms’ motivations can inform their decisions in the
market,265 and thus better understanding of motivations can provide insight on how the
cannabis market will develop. By gaining insight on the cannabis market, I can understand
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possible shifts in usage practices.266 Thus, by providing information around firms’
motivations for engaging in the space I can better comprehend cannabis usage patterns.
There has been little study of cannabis firms’ motivations for participating in the market.
Despite firms attempting to improve social outcomes, past research generally has focused
on firms having a possibly singular motivation of increasing the size of the market to
generate profit.252,267 In addition, previous work252 does not provide data from key
decision-makers in the cannabis space. I define key decision makers as upper-level
management such as the Chief Executive Officer, Chief Operating Officer, and vicepresident etc. Given their position, key decision makers may have information unavailable
to lower ranking staff and may influence firm decision making268 consequently affecting
shifts in usage practices. Key decision makers may thus be able to provide deeper insight
on the cannabis space, expanding on firms’ motivations explored in previous research. To
provide some understanding on this gap in the literature, I used ethnographic data
collected at a cannabis firm and interviews with key decision makers from large for-profit
cannabis firms, and major non-profit organizations in the cannabis space, to address the
following question: What are the views of key decision makers on motivations for large
United States cannabis firms’ participation in the space?
The cannabis investment landscape
This section provides information about the legal cannabis investment space, using data
drawn from an online platform which provides information about investment activity in
the cannabis space from 2009-2016. The online platform drew from publicly available
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records released by the United States Securities and Exchange Commission. Investment
activity was used to construct social network diagrams.
Figure 1 indicates investments in the cannabis space, from 2009 – 2016, against a map of
the contiguous United States. Edges in the network represent mergers and acquisitions or
investments between two firms. Each node represents a cannabis firm, with subsidiaries
and holding companies represented as a single node. Firms were coded based on the state
they were headquartered in. Investment activity between companies in the same state is
displayed with a single point. From 2009 – 2011, activity was sparse. In 2012, there was
investment between California and Colorado, and Arizona and Wyoming. While
California, Colorado and Arizona already allowed medical cannabis by 2012, cannabis was
still illegal in Wyoming. In 2014 and 2015 investment in the space became more fevered,
with ties from coast to coast. In 2016, investment continued to occur across the map, not
confined to specific regions, with firms in states not traditionally associated with cannabis,
such as Utah and Ohio.
Methods
An exploratory qualitative study design was used. Data were collected through a 320-hour
ethnographic field study at Green For-profit, a cannabis firm, and 37 semi-structured
interviews with key decision makers in the cannabis space, representing both major forprofit and non-profit organizations. As key decision makers in large cannabis firms may
distort the data by providing an overly positive impression of the space,269 the study design
attempted to mitigate this risk by including key decision makers in the non-profit space,
who could confirm or oppose themes brought up by for-profit counterparts. For
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anonymity, organization names were replaced with colors, and one of two suffixes allotted
to indicate that the participant represented either a major for-profit organization (e.g.
Yellow For-profit) or non-profit firm (e.g. Blue Non-profit). Pseudonyms were assigned
to all participants. The study received university institutional review board approval from
the Yale Human Subjects Committee #2000020385.
Green For-profit is a New York City based financial services firm specializing in the
cannabis space. Services Green For-profit provided include advising cannabis companies
on mergers and acquisitions, and capital raising. Green For-profit also aids in
professionalizing companies prior to a capital raise, by forming a board of directors,
developing financial controls, and creating forecasts and budgets. Green For-profit has
three in-house office staff; the Chief Executive Officer, and two analysts, as well as several
others who work remotely. Pseudonyms were assigned for all Green For-profit staff. The
Chief Executive Officer, James, is in his 50s and was previously an investment banker in
another industry. Both analysts were in their 20s. One analyst, Thomas, acts as a personal
assistant for James. The other analyst, Nick, looks for potential investment opportunities.
I spent an average of 40 hours each week for eight weeks observing, assisting and
interacting with staff at Green For-profit. Observations and informal interviews were
conducted at Green For-profit. At Green For-profit, I served as an intern, specializing in
data analysis, where I drafted reports about the state of the cannabis space for use by Green
For-profit’s clients. My status as a researcher and a staff member was consistently revealed
to all employees at Green For-profit.270 Consent to collect data during the internship and
publish findings was obtained from Green For-profit’s Chief Executive Officer prior to
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the start of the position. Field notes were typed directly into a laptop in real time to ensure
high fidelity capture of the conversations and observations.271
Green For-profit’s staff wore standard business attire and nothing about the firm logo or
any items in the office suggested a link to the cannabis space. At first glance, Green Forprofit is indistinguishable from any other boutique investment bank.272 All introductory
calls are taken by James, who starts the call by narrating the history of the firm. Prior to
entering the cannabis space, the firm specialized in investment banking for companies in
the physical and cyber security industry. Seeing the lack of professionalism and possible
profit in the space, the Chief Executive Officer decided to reorient his business toward
cannabis. When asked why Green For-profit felt a need to provide such a spiel, Thomas
said that clients want to hear these things.
Coupled with the small staff size and open office environment, this meant I could engage
in unstructured interviews with staff members during the internship. My interpretations of
the cannabis space and Green For-profit’s role in the industry clearly affected the data
from the informants. The key to rigor when studying an organization one is part of, is to
be reflexive and transparent about one’s own impact and to triangulate insights with a
multiplicity of data sources, along with considering one’s own role when theorizing about
organizational processes observed .273,274 I endeavored to follow these prescriptions
throughout the work and specifically when crafting the theoretical insights.
The two months of in-office observation included many opportunities for spontaneous
participant observation, in contexts where it was easy to observe and record processes
through which Green For-profit engaged with the cannabis space. In informal
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conversations and interviews, participants were highly frank throughout the two months
of observation, sharing their views on the cannabis space, the broader business
environment and their firm’s relationship with various stakeholders. I believe that this
access and openness were facilitated by two factors. Firstly, I was viewed as a valuable
member of the team due to his data analysis skills, in line with Green Capital’s tagline of
being a data-driven financial advisory firm. Secondly, investment bankers are rather candid
about their experiences and thoughts with team members,275 possibly due to the teamoriented nature of the job.
I also attended a half-day cannabis conference organized by Green For-profit, about
gender and ethnic diversity in the cannabis space, where I collected observational data.
Several organizations, mostly non-profits, had rented booths at the conference. About 200
people attended the conference, with founders of cannabis startups, activists,
representatives from institutional funds, and college students present. I took note of
promotional materials given out by Green For-profit at the conference and wrote field
notes at the end of the day.
For the semi-structured interviews, I identified potential participants using a range of
sources, including attendee lists for major U.S. Cannabis conferences, a list from major
U.S. Universities of those employed in the cannabis space (assembled through publicly
available LinkedIn data), and referrals. Attendee lists for the indicated cannabis
conferences were publicly available, and thus, I did not have to obtain email consent.
Referrals were obtained from participants emailed in the initial contact phase.
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I ensured that participants were distributed across the United States, to account for
differences in U.S. Cannabis legislation. I then contacted academic experts and key decision
makers in the for-profit and nonprofit cannabis spaces to ensure that the list of potential
interviewees represented a variety of for-profit firms within the cannabis space, as well as
firms that were likely to have key decision makers who may make decisions which possibly
affect health outcomes. For each firm in the final list, I sent two personalized emails to an
organization contact: An initial email requesting a phone interview and a reminder a week
later. The introductory email introduced me as a PhD student researching the legal
cannabis space, briefly introduced the project, and asked the potential participant to
nominate a convenient time for a phone interview.
To identify upper level management, I used the list of employee titles provided in past
research.276 Within an organization, I emailed all staff in upper level management. I
successfully sent email requests to 350 contacts and received email responses from 37
people from 32 organizations, for a total response rate of 11%. In some organizations,
multiple key decision makers responded, but in most firms, only one key decision maker
responded. It was not clear why some firms were more willing to participate compared
with others. All participants who replied to the email offered to participate; thus, I was not
aware of reasons for declining to participate.
To develop the interview schedule, I first collected relevant literature using the following
databases: PubMed, MEDLINE, Embase, PsycINFO, and Sociological Abstracts. I used
keywords derived from themes such as major cannabis and tobacco firms, their public
health impact, cannabis legalization, and cannabis usage preferences. I used the resultant
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literature in combination with the research questions to develop a set of 20 interview
questions. I then refined these interview questions with academic, industry, and nonprofit
experts, resulting in 15 interview questions.
Academic research in cannabis spans several areas. Thus, I selected three academic experts,
one each from public health, sociology, and criminology. I identified key scholars in each
of these subject areas through the number of articles published on the cannabis space. I
then contacted the identified researchers and asked them to assist. I emailed 30 researchers
(10 per subject area) and five agreed to assist. Of those who replied, I selected one
researcher per subject area based on the number of articles they had published on cannabis
in 2015–2018.
To select industry and nonprofit experts, I identified the largest for-profit and nonprofit
cannabis organizations by revenue and overall budget, respectively. I emailed 10 key
decision makers each from the for-profit and nonprofit spaces to assist with the study; five
for-profit and six nonprofit key decision makers agreed to assist. I then selected two key
decision makers, one each from the nonprofit and for-profit spaces, based on greatest
revenue and overall budget, respectively. All key decision makers who successfully
contacted for the drafting of the interview schedule were also interviewed for the study.
The feedback from these experts allowed us to align the questions with the academic
literature and to be jargon-free and succinct. Examples of removed questions include the
following:
How is cannabis analogous to other stigmatized substances?
Do you think the cannabis space is in line with hegemonic business norms?
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Examples of final interview questions are as follows:
What do you characterize cannabis as?
What are large firms’ motivations for being in the space?
What is the dynamic between nonprofits and firms?
The open-ended semi-structured interview questions primarily focused on exploring
participants’ opinions about why firms would participate in the cannabis space. The
interview schedule, or set of interview questions, facilitated the development of new
themes that could occur during the interview.277 Examples of new themes were
participants’ personal motivations for entry into the space and their interest in the
legalization of other illicit substances. The interview schedule contained cues and prompts
to encourage further discussion, especially when the interviewee provided an unclear or
brief answer.278 Examples of such cues included making encouraging noises, reflecting on
remarks made by participants, and probing the last remark made by the participant.279
Following verbal informed consent procedures, I conducted telephone interviews with
each participant, averaging 25 min in length. Interviews were recorded, using publicly
available mobile phone call recording software, with participant consent. I hired a
professional transcriber through a freelance jobs website to transcribe the interviews.
Theoretical saturation on the study’s key topics of interest—that is, the point when no new
themes are identified and no further issues come up regarding a new data category280—was
reached by the 34th participant, and thus, further participant recruitment was not
conducted.
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I removed from the transcripts identifiable quotes and accounts that potentially could
affect individuals’ and firms’ reputations. Cannabis firms often list their motivations for
entering the space on their respective websites. Quotes that were exceedingly like their
employers’ publicly available narratives were removed from the transcripts to ensure
anonymity. It is possible that this process of omission affected the veracity of the findings.
However, I believe this process likely allowed for data variant from firms’ official narrative
to arise, expanding the diversity of emergent themes.
I exported all field notes and interviews into NVivo 11,281 a qualitative data analysis
software. I used thematic analysis to analyze the data. Thematic analysis is apt for detailing
the views of a multitude of research participants282 and reducing large data sets into easily
identifiable categories.283 Given the nature of the study and familiarity with the topic, there
were likely to be several possible preconceptions about the motivations for cannabis firms’
participation in the space. Thus, I applied a deductive approach to craft themes,282 and
used a reflexive approach throughout analyses to account for researcher biases and fluency
with the literature that may possibly predispose the identification of emergent themes.282,284
Deductive techniques are those which test theory beginning with an established theory and
then seeing if that theory applies to specific instances.285 A self-reflexive approach is one
that harnesses an awareness of the relationship between the investigator and the research
environment.286 I used the six-phase protocol indicated by Virginia Braun and Victoria
Clarke (2006) to identify themes which emerged in the qualitative dataset and that also
were relevant to the views of key decision makers on why cannabis firms participate in the
space. After repeated familiarization with the data, I identified initial recurring patterns of
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responses and meaning in the data. Examples of recurring themes were participant
motivations for entering the market, profit, and mitigating inequity. After this procedure,
I re-read the data several times, critically analyzed the emergent patterns, and coded and
collated them into broader themes. Once themes had been developed, I reread the
transcripts to see if the themes provided insight into participant narratives. These themes
were then stratified by groups (for-profit vs. Nonprofit organizations). I then discussed
the codes and themes extensively with my co-authors to resolve minor coding
discrepancies and to maintain consistency. I discussed the interpretive scheme with the key
decision makers selected to review the interview schedule. The indicated key decision
makers confirmed that the interpretive scheme was sensible to and affirmed by those in
the phenomena of interest.287 I emailed the previously indicated team of experts about the
interpretive scheme and asked them to provide feedback. Specifically, I asked whether
terms used in the interview schedule would be easily comprehensible in the cannabis space,
whether interview questions were neutral—neither favoring nor maligning the cannabis
space—and whether the schedule was representative of recent developments in the
cannabis space.
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Results

67

Table 1. Informant Characteristics
Pseudonym Gender Organization
Elizabeth
F
Blue For-profit
Clarence

M

George

M

Louis
Ruth

M
F

Raymond
Anthony

M
M

Catherine
Fred

F
M

Jack
Randy

Role
Vice-president
Chief Executive
Beige For-profit
Officer
Chief Financial
Purple For-profit Officer
Lavender ForSenior viceprofit
president
Teal Nonprofit
Director
Senior Vice
Orange For-profit President
Teal For-profit
President

M
M

Green Nonprofit
Olive For-profit
Maroon Forprofit
Teal Nonprofit

Director
Director
Chief Executive
Officer
Founder

Patrick

M

Blue Nonprofit

Founder

Samuel
Ryan
Ronald
Kelly

M
M
M
F

Pink Nonprofit
Brown For-profit
Black For-profit
Blue For-profit

Manager
Founder
Founder
Founder

Paula

F

Blue Nonprofit

Jesse
Ann

M
F

Coral For-profit
Cyan For-profit

Earl
Heather

M
F

Grey For-profit
Lime For-profit

Director
Chief Executive
Officer
Founder
Chief Executive
Officer
Founder

Lilian

F

Phillip

M

Lime Nonprofit
Magenta Forprofit

Founder
Chief Executive
Officer

F

Mahogany
Nonprofit

Chief Executive
Officer

Emma

Description
Cultivator

Reach
State

Retailer
Agriculture
Technology

National

Market Research
Research

National
National

Private Equity
Private Equity

National
National

Legalization
Advocacy
Social Media

National
National

National

Private Equity
Research
Legalization
Advocacy
Legalization
Advocacy
Consulting
Consulting
Accessories
Legalization
Advocacy

National
National

Private Equity
Private Equity

National
National

Consulting
Private Equity
Legalization
Advocacy

National
National

Private Equity

National

Dispensary

National

National
National
National
National
National
National

State
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Roger
Ernest

M
M

Mint For-profit
Navy For-profit

Noah

M

Ochre Nonprofit

F

Orange
Nonprofit

F
F
M
M

Orange
Nonprofit
Purple Nonprofit
Red Nonprofit
Pink For-profit

Ashley

F

Vermillion
Nonprofit

James
Thomas
Nick
Tina

M
M
M
F

Green For-profit
Green For-profit
Green For-profit
Yellow Nonprofit

Barbara

Helen
Deborah
Matthew
Douglas

Chief Executive
Officer
Manager
Chief Executive
Officer

Retailer
Consulting

National
National

Consulting

National

Director

Gender
Representation
Advocacy

National

State Director
Founder
Director
Partner

Gender
Representation
Advocacy
Education
Trade Organization
Private Equity

National
State
National
National

Ethnic
Representation
Advocacy

National

Private Equity
Private Equity
Private Equity
Government

National
National
National
State

Chief Executive
Officer
Chief Executive
Officer
vice-president
vice-president
Director

Table 1 summarizes interviewees’ characteristics, including respondent pseudonym,
organization pseudonym, role, organization description, and reach (state/national). Thirtyseven participants, representing 32 organizations, took part in this study. Twenty-three
(62.2%) of the respondents were men and 14 (37.8%) were women. Twenty-six (70.3%)
participants were from for-profits, and 11 (29.7%) were from non-profits. Within forprofits, 11 participants were from cannabis financial services firms, followed by consulting
firms (5), growers/retailers (4) and others (6), such as market research and social media
firms. Within non-profits, five participants were from legalization advocacy organizations,
followed by gender representation advocacy organizations (2), research organizations (2),
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education organizations (1) and ethnic representation advocacy entities (1). Legalization
advocacy organizations generally push for greater access to medical or recreational
cannabis. Gender and ethnic representation advocacy organizations support increased
representation of women and ethnic minorities in the cannabis market, respectively.
Education organizations support increased education around the responsible use of
medical and recreational cannabis. I present the results according to the themes of the
analysis. The terms for-profit and firm are used to connote large for-profit cannabis
companies.
Motivations for large cannabis firms’ participation in the space
To seek profit
This section summarizes participants’ views on major cannabis firms participating in the
space largely for profit. Profit-centric motivations were the most identified theme.
Green For-profit sought greater representation of profit-oriented versus socially conscious
firms in the cannabis space. This may indicate that profit was a primary driver for some,
but not all, members of large cannabis firms. Green For-profit did not connect non-profits
with other organizations. When Green For-profit put for-profits in touch with each other
for potential business opportunities, it only referred firms with two variants of board
leadership composition: (1) a mix of directors from within the cannabis space and
industries outside the space, or (2) all directors hailing from outside the cannabis space.
Firms that drew most or all their leadership from the cannabis space, especially activist-led
firms, were not recommended. Activist-led companies were apparently not profit-oriented,
and thus unsuitable to be recommended:
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You (activists) fight so hard, but don’t want to profit. (Thomas, Green For-profit)
Similarly, Green For-profit indicated the clear superiority of firms led by people not from
the cannabis space:
A real firm and not a bunch of potheads trying to raise money. (Thomas, Green Forprofit)
A non-profit representative noted that more business-oriented, and perhaps largely profitmotivated people were now involved in the cannabis space.
Now we are seeing more and more business types who are less inclined to help others. (Catherine,
Green Non-profit)
Similarly, a firm employee indicated a shift toward a more profit-minded approach in the
cannabis space:
There's a…capitalistic approach that has gained momentum as the industry has grown. There
has been a transition as the industry is growing, where you are getting a lot more…Wall Street
type people who are very effective at running businesses but really don't come in with that social
element to it. They don't bring that same commitment or orientation towards some of the advocacy
and some of the community aspects that are central to this industry today. (Louis, Lavender
For-profit)
Within the theme of cannabis firms participating in the space for profit, some key decision
makers touched on the synergistic relationship between for-profits and non-profits. Many
large cannabis firms donated money to non-profits, but for most, their motivations behind
funding non-profits were not entirely altruistic. A respondent from a large cannabis firm
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was clear that contributing funds to a non-profit had to result in some benefit for the firm
itself:
So, when I'm making a decision here, I mean, a lot of it is, how much they're asking for?…I'm
looking for how much they're asking for, what it is they going to support, and then also what is
Yellow For-profit getting out of the deal. (Elizabeth, Yellow For-profit)
Several large cannabis firms donated to non-profits, in the hope that non-profits would
change laws around cannabis, thus increasing the size of the United States cannabis market:
We're a publicly traded for-profit corporation…most of our money right now is going to policybased organizations. People are lobbying at same federal level to change laws because obviously if
there are more states that have legal cannabis, that's a bigger market for us to sell
our…products. (Fred, Olive For-profit)
Non-profits are actively working to change the laws, and the more laws they can change, the larger
the market will be for the businesses. (Jack, Maroon For-profit)
…for-profits, some of them then donate back to the NGOs to try to help expand the states that
will have the medical marijuana laws. (Randy, Purple Non-profit)
Some non-profits were aware that large cannabis firms saw them as vehicles to increase
the size of the United States cannabis market. A few non-profits accepted funding from
large cannabis firms and in return, allowed firms to add provisions into non-profit
initiatives:
Let’s say he’s (Chief Executive Officer of major non-profit) drafting a legalization initiative in
[redacted], if he could get the distributors to contribute money to the initiative in return for putting
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a provision that helps them, then he would do that…There was one significant industry player I
met, he…offered to put up a couple of million dollars and be part of the partnership…I think he
was able to get a few provisions that he wanted into the initiative. (Patrick, Blue Non-profit)
To mitigate social inequality
This section details participants’ views on cannabis firms participating in the space to
mitigate social inequality. Green For-profit organized conferences about twice a year.
Conference promotional materials indicated how the cannabis industry could mitigate
stigma and inequity:
Successful women who used their skill sets that helped them lead businesses or climb corporate
ladders are quickly rising to the top in the cannabis industry. Our [redacted] panel will highlight
the successes of some of the women in the cannabis industry as our panelists share their stories of
transitioning, fighting stigmas, and leading organizations and businesses (Conference panel
description)
While the majority of large firms indicated profit-oriented motivations for participating in
the space, a few appeared to be driven by socially conscious motives:
Everybody that's involved in the business believes that businesses are part of the community and
are not independent from the community they exist in and have a responsibility to that
community…I should dedicate some portion of our efforts, it might be just one percent, to the
community. (George, Purple For-profit)
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When firms referred to socially conscious motives or responsibility to the community, they
generally indicated activities such as funding criminal record expungement initiatives or
training minority entrepreneurs:
I funded the largest expungement clinic in [redacted] to date. We've helped some 800 people and
not just with expungements but also with services like housing and job training, healthcare.
(Raymond, Orange For-profit)
Another firm created a manual to train minority entrepreneurs in the cannabis market:
We're going to create a syllabus to train potential entrepreneurs from minority backgrounds…so
that if somebody wants to get in this business, we'll provide them with access to a curriculum and
our management teams, so that they can learn from our experience and prepare them for getting
into this industry. (Clarence, Beige For-profit)
To provide cannabis as medicine
This section indicates key decision makers’ views on cannabis firms participating in the
space as providers of medicine. Several large cannabis firms have characterized cannabis
as medicine 288,289, and in this vein, a firm representative described cannabis as a medicine:
Now for cannabis, it’s a weird situation because it is a medicine like pharmaceutical drugs but
safer than pharmaceutical drugs. (Elizabeth, Yellow For-profit)
In the cannabis-as-medicine vein, some firms set aside funds to purchase cannabis for
marginalized medical cannabis patients.
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All of the employees from our firm contribute a portion of their salary into a fund… that provides
access to patients who don't have the financial means to purchase medical cannabis without the
assistance of insurance. (Clarence, Beige For-profit)
In line with views that firms were motivated to participate in the space as providers of
medicine, several firms gave free cannabis to medical cannabis patients who typically could
not afford it, perhaps to reinforce the idea of cannabis as medicine or to provide what
firms perceived as free medical assistance. This point seems to have some overlap with the
previous theme, given that firms wish to help the less fortunate.
There’s a dispensary in…that offers a couple of programs for…low income medical patients in
the community…they give away very cheap or inexpensive clones for the patient who're consuming
very high quantities of cannabis... In that way, they are not spending as much money on the
product. (Louis, Lavender For-profit)
Some dispensaries have huge programs for people who can’t afford medicine. (Ruth, Teal Nonprofit)
Discussion and Conclusion
Given concerns around changing usage patterns and potency in line with growing United
States cannabis markets,149,255 this study provides improved understanding around the
cannabis space specifically regarding views on motivations for large United States cannabis
firms’ participation in the space. Key decision makers’ views are important as they may
possess information not available to lower ranked employees, may influence firm
decisions268 and consequently impact United States cannabis usage patterns. Participants
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reported that large cannabis firms participated in the space because of three, non-exclusive
reasons: To seek profit, to mitigate social inequity, to provide cannabis as medicine.
Firstly, participants indicated that cannabis firms may participate in the space largely to
seek profit. Participants detailed that there seemed to be more business-centric persons
becoming involved in the space, given the perceived lucrative nature of cannabis. A greater
business-oriented focus in the cannabis market could mean an increased likelihood of the
product being marketed to a broader range of demographics, shifting usage practices, and
causing a reduced public health agenda. Firm engagement with socially conscious causes
was generally motivated by larger cannabis markets. If firms’ engagement in socially
conscious causes are driven primarily by profit motivations, only causes that generate the
greatest perceived increase in the bottom line may be selected and thus some marginalized
groups may not benefit from cannabis firms’ socially conscious activities. In addition, while
the profit-centric nature of firms may lead to possibly deleterious public health outcomes,
firms’ desire to increase the size of the cannabis market may reduce stigma around cannabis
and make it easier to conduct research around the plant.
Within the theme of firms participating in the space for profit, participants indicated the
synergistic dynamic between for-profit and non-profits in the cannabis arena. Some nonprofits were aware that large cannabis firms saw non-profits as means to increase the size
of the legal market, and engaged with firms, in exchange for funding. Participants seemed
to indicate that the cannabis space is a business, but also one with social benefits and
stigma, and limited growth potential that working with a non-profit might help to ease,
through facilitating larger markets and more business-friendly legislation. Thus, for-profit
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and non-profit organizations in the space may be symbiotic and possibly cognizant of the
other’s goals and their relationship could possibly be described as synergistic rather than
parasitic.
Although agendas of nonprofits and for-profits are ostensibly somewhat different, this is
a complicated arena where no group is wholly oriented toward the social good and against
profiteering, but the bottom line for both groups is to expand access. So policy-makers
should be aware of that fact, consider the two groups as a unified whole and set policies
with a watchful eye to the evidence of potential benefit or detriment to public health.
Policymakers should thus avoid characterization of non-profits as countervailing powers
to for-profits. If non-profits are conceptualized as checks on for-profits, I may
underestimate the growth of the cannabis market. As both groups appear to be working
together cohesively, growth of the cannabis space and the resultant changes in usage
practices may be more rapid than previously predicted.
Secondly, while participants mostly indicated that firms participated in the space with
largely profit-oriented notions, some firms seemed to participate in the space perhaps to
mitigate social inequality290 through community-oriented programs such as criminal record
expungement initiatives likely funded by cannabis profits. Such firms appeared at least
partially driven by socially conscious motives, perhaps encouraged by the perceived ability
of the plant to mitigate social concerns such as increasing incarceration rates and associated
costs.257 These firms may herald a cannabis space that is not wholly profit-motivated and
can serve as models for other cannabis corporations. Finally, participants reported that
some firms entered the space as providers of medicine.288 Past research indicates that
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cannabinoids, the active ingredients in cannabis may be useful in treating cancer
chemotherapy-induced nausea, anorexia relating to AIDS wasting syndrome and cancerrelated pain.291 In the United States, some have utilized cannabis for anxiety, chronic pain
and poor appetite.292 However, as of January 2019, the United States Food and Drug
Administration has not approved cannabis as a safe and effective drug.293 It is not clear
whether firms espoused cannabis-as-medicine views to increase sales, because they
genuinely believed in cannabis’ therapeutic properties or both. Such rhetoric may mitigate
stigma around cannabis and aid research efforts into its medical use, while also increasing
sales and affecting usage practices.
I provide support to Subritzky et al.’s (2016) study by providing evidence on the role of
non-profits in facilitating more favorable legislation. More importantly, I extend their work
by providing information on the dynamic between non-profits and firms, and specific
instances of non-profit activities that grow the cannabis market. In addition, I support
Barry and Glantz’s (2016) position that large firms are motivated to participate in the
cannabis space to increase cannabis use. I extend their argument by providing evidence on
techniques used by such firms to grow the market. However, I differ from Barry and
Glantz’s (2016) argument by suggesting that some firms enter the market not solely for
increasing cannabis use, but also to mitigate social inequity and to provide cannabis as a
medicine. In addition, while the authors center on the role of firms in expanding the
market, they neglect how non-profits are helping to grow the space. I support the role of
key decision makers in research studies as they can provide valuable insights not known to
lower level staff, and I believe that the extensions to past work are underpinned by
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harnessing key decision makers’ insights. Broadly, I support past research around cannabis
firms trying to grow the market and increase use. I extend and develop previous arguments
by suggesting that firms may have reasons to enter the space that are not necessarily
centered on simply increasing use, and also highlight the role of non-profits in expanding
the cannabis market.
The results and analysis presented here used qualitative research techniques, which may be
limited in generalizability. Nevertheless, given the sampling strategy, number of
interviewees, feedback received from academic, industry and non-profit experts in the
space, and the theoretical saturation achieved, I believe that the data provided a broad
range of participants’ viewpoints within the United States cannabis space. In addition,
given the exploratory nature of this study, underpinned by a desire to understand
motivations for large cannabis firms’ participation in the cannabis market, qualitative
methods are appropriate.294 Conducting ethnographic observations at a financial services
firm may have biased the data, compared to research at a production or sales firm.
However, Green For-profit performed key financial services in the space, such as
investment advice, and had numerous visitors from major firms each day, and thus is a
suitable site for understanding motivations of large firms in the cannabis space. As the
conference the first author collected ethnographic data at was organized by a financial
services firm, there may have been some bias in terms of conference content. However,
the range of content at the conference was broad, comprising gender and ethnic diversity
in the space, as well as various investment opportunities. Another limitation is that I
conducted a cross-sectional study, where findings represented a snapshot in time. Future
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research can utilize longitudinal research techniques to study changes in legislation over
time. In addition, non-profit participants in the study tended to see medical and
recreational cannabis as part of the larger cannabis legalization process and did not view
these as distinct policy goals. Some smaller non-profits may view medical and recreational
cannabis as orthogonal concepts, but such viewpoints were not represented due to the
sampling strategy. Future research could incorporate a larger range of non-profit
viewpoints.
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Conclusion: Chapter One
I first described cannabis usage preferences among United States Global Drug Survey
respondents, primarily young men. I suggested that frequent use of cannabis may increase
risk of health harms and highlighted the need to mitigate problematic use. With the rapidly
developing United States cannabis market, possibly problematic usage patterns may
indicate potential for cannabis use disorder especially within young men. I then explored
if sociodemographic indicators were associated with increased likelihood for cannabisrelated emergency department admissions in New York City. Findings may indicate that
cannabis use adds burden to the healthcare system for those already disproportionately
affected. As more states legalize recreational cannabis, results reinforce the need for
research on identifying demographics at increased risk for cannabis use disorder and
emergency department visits. I finally presented the findings of a qualitative study
investigating the views of key decision-makers in the cannabis market, on large cannabis
firms’ motivations for participation in the space. I suggested that firms may have reasons
to enter the space not necessarily centered on increasing use. Although non-profits and
for-profits have different agendas, the bottom line for both groups is to expand access.
Policymakers should be aware of that fact and set policies which consider the two groups
as a unified whole.
I suggest that increasing proliferation of legal cannabis may disproportionately affect
marginalized communities. While cannabis use is not necessarily harmful, the possible
harms of psychoactive substances often fall on marginalized communities. I propose that
policymakers ensure that cannabis firms do not engage in predatory targeting of
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marginalized communities. Harm reduction may also be a salient theme. By promoting
harm reduction practices within cannabis use, communities may be able to engage in
moderate recreational use while also minimizing possible harms. It is not clear if cannabis
use causes psychosis and other similar conditions.295 Thus, any attempts by policymakers
to educate possibly at-risk demographics about risks of cannabis use should be done with
caution and avoid stigmatizing people who use cannabis.
Firms involved in the cannabis space may not be solely motivated by profit. The diversity
of viewpoints in the cannabis space may be a platform for a cannabis space that attempts
to profit from a substance that may have risks but is cognizant of the possible health harms
relating to marginalized communities. Cannabis firms that engage in socially responsible
behaviors may be a platform for other industries that market potentially addictive
substances. With the recent rise in use of e-cigarettes by adolescents,296 firms that sell such
products may benefit from a socially responsible framework pioneered by the cannabis
space.
The proliferation of legal cannabis in the United States may lead to a greater burden of
health harms in marginalized communities. However, within this paradigm of reduced
agency, people who use cannabis engage in harm reduction and cannabis firms seek to
mitigate forms of marginalization. Thus, I suggest that while marginalization may relate to
health harms and diminish agency, actors in these spaces still seek to mitigate risk and
retain agency.
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Chapter 2: Sexually Transmitted Infection Testing in The Chinese Men Who
Have Sex with Men Environment
This chapter will explore concerns within sexually transmitted infection testing in the
Chinese men who have sex with men environment. The first section details a behavioral
strategy to increase sexually transmitted infection testing rates, and the second section
details the association between men who have sex with men community-centric behaviors
and contribution towards another’s sexually transmitted infection testing cost. The third
portion explores sexual role and choice of test. The fourth section characterizes
determinants of antisocial online behavior among Chinese men who have sex with men.
The final section examines the relationship between sexual behavior disclosure and the
number of HIV self-test kits distributed and completed. Through these studies, I hope to
provide insight on a key marginalized population, mitigating stigma and informing policy.
Determinants of altruism in interventions for men who have sex with men in
China
This section is currently under review at BMJ Global Health, with Marcus Alexander and
Laura Forastiere et. al as co-authors.
While experiments show that humans express social preferences in decision-making,297,298
benefiting others even at a cost to themselves, little is known about what explains
heterogeneity in altruism across the human population.299 To provide insight, I detailed a
novel intervention (pay-it-forward) designed to mobilize social preferences to increase
rates of sexually transmitted infection testing among men who have sex with men in China,
currently experiencing a sexually transmitted infection epidemic.300,301 Pay-it-forward is a
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variant of cooperative behavior where people who have benefited from others return the
favor anonymously to persons other than their original benefactor. While there are many
types of social preferences, my focus is on altruism as measured by the amount contributed
to a pay-it-forward experiment. Pay-it-forward chains can arise spontaneously in everyday
settings, such as among coffee shop customers.302 In medicine, features of pay-it-forward
can be seen in kidney transplant matching mechanisms, where undirected living donor
kidney transplant programs serve to increase availability of donors and shorten waiting
times for renal failure patients.303
The public health setting allows us to examine how specific sexual behaviors (anal sex role
and disclosure of sexuality) may be related to different variants of altruism in the pay-itforward context. Previous work on sexuality and cooperation has been limited to studies
on the role of biological sex and sex-related hormones in the expression of cooperation,
including testosterone,304 and oxytocin.305 Limited research has explored human sexual
behavior and altruism. This study explores how sexual behaviors are related to
participation and contribution levels in two pay-it-forward experiments. The study may
provide insight around the relationship between altruism and sexual behaviors, which may
have implications for promoting contributions toward public health initiatives especially
in stigmatized settings.
Methods
Study design
The first study was conducted from December 2017 to February 2018 in Guangzhou,
China, in partnership with a sexually transmitted infections clinic in a hospital and local
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community-based organizations. This was a quasi-experimental study with two arms: Payit-Forward, and Standard of Care. In the pay-it-forward arm, men who have sex with men
waiting for free HIV or syphilis testing received information about a gonorrhea and
chlamydia test (cost ¥150/$23.87) and were told that that the previous respondent had
donated money to cover the cost. Subjects decided whether to test and after testing were
given an option to contribute to the next person. Donations were optional and could be
any amount. Test costs were covered by participant donation and an initial sum from the
sexually transmitted infection clinic. Participants were told all data would be confidential
and test results sent after a week. After the test, participants decided whether to make their
contributions in cash or via WeChat, a messaging and mobile payment smartphone app.
Regardless of their decision to participate, individuals also

reported their

sociodemographics, and their attitudes towards the pay-it-forward experiment if they
decided to participate. Test results were disseminated through WeChat. In the standard of
care arm, participants were offered a test and had to pay the full cost if they wanted to get
tested.
The second study was conducted from December 2019 to January 2019 in Guangzhou
and Beijing, China, at three sites with community-based organizations. This was a
randomized controlled trial with three arms: Pay-it-Forward, Pay-as-you-Want, and
Standard of Care (NCT03741725). The second study was like the first, with the addition
of randomization and new pay-as-you-what condition. In pay-as-you-what, instead of
being asked to pay-it-forward, subjects were asked to pay as they wished for their own test.
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Participants and study sites in both studies were not provided incentives. Free gonorrhea
and chlamydia testing were not normally provided at study sites.
Ethical review
Participant anonymity was maintained during the entire project and participant consent
was obtained prior to study participation. No identifying information was collected.
Institutional Review Board approval was obtained from the Dermatology Hospital of
Southern Medical University (GDDHLS-20180503) and the University of North Carolina
at Chapel Hill (18-1358).
Statistical Analysis
Prior to analysis, I coded responses to the question 'What do you believe are the main
benefits to participating in the pay-it-forward program?' to reflect overall, directed, and
generalized altruism. The option 'More men who have sex with men can get tested' was
denoted as directed altruism, and 'Someone has helped me, and I can help someone else'
was coded as generalized altruism. These two options were combined to denote overall
altruism. The option 'Discounted sexually transmitted infection test' was denoted as selfinterest.
I calculated descriptive statistics for all men who have sex with men surveyed. I conducted
the following analyses for the first study: 1) assessed factors associated with participation
in the pay-it-forward arm; 2) explored factors associated with pay-it-forward contribution
levels. For the second study, I: 1) estimated contribution levels across the pay-it-forward
and pay-as-you-what arms; 2) divided the sample by sexual behavior (sex role, disclosure
of sexuality) and then assessed if the relationship between altruism and contribution level
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differed by sexual behavior. Covariates used in the analysis were: Sexual behavior [male
partners (number of male partners in the past three months), unprotected anal sex (anal
sex without condom use in the past three months), previous HIV test (whether men who
have sex with men had received HIV testing prior), HIV test frequency (frequency of HIV
testing), symptoms (whether men who have sex with men had noticed any sexually
transmitted infection-related symptoms), sexual role (role during anal sex with men),
outness (disclosure of men who have sex with men sexual behavior to wife, family, friends
healthcare provider or no one)], altruism (overall, directed, generalized altruism, selfinterest), sociodemographic categories (income, age, marital status), pay-it-forward arm
assignment (assignment to pay-it-forward or pay-what-you-want arm).
To estimate the factors associated with contribution levels, I used the Heckman selection
model. The first stage of the model was the selection equation, which modelled whether a
subject decided to take the test. The model included sociodemographic and sexual history
variables. In this model, I included all variables from the outcome equation except medical
and personal history items which may explain the decision to test for chlamydia and
gonorrhea, to achieve formal identification. The outcome stage of the equation modelled
contribution levels. Site fixed effects were included in the selection equation since they
were correlated with the probability of testing. Finally, given the small sample of subjects
who were out to their health provider, I was limited in the number of controls I could
include, leaving out those co-linear with other key variables (e.g. Marital status, unprotected
sex or previous HIV test). I reported coefficient estimates and standard errors for all
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models. I also reported unconditional marginal effects computed using both selection and
outcome equations coefficients, and the inverse mills ratio from the first stage probit.
Results
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Figure 1. Differences in motivations for participating in pay-it-forward, by variants of
sexual behavior disclosure (in the closet, out to family, out to friends, and out to health
providers), for Chinese men who have sex with men, collected from a quasi-experimental
study in Guangzhou, China.

Figure 2. A) Distribution of contribution level by treatment arm, conditioning on sexual
behavior disclosure to healthcare provider, for Chinese men who have sex with men,
collected from a randomized controlled trial in Beijing and Guangzhou, China. (b)
Differences in contribution level, divided by sexual behavior disclosure to healthcare
provider and treatment arm, for Chinese men who have sex with men, collected from a
randomized controlled trial in Beijing and Guangzhou, China. (c) Distribution of
contribution level by treatment arm, conditioning on anal sex role, for Chinese men who
have sex with men, collected from a randomized controlled trial in Beijing and Guangzhou,
China. Pay-it-forward has stronger effect on contributions among those who preferred
receptive anal sex (bottom). (d) Differences in contribution level, divided by anal sex role
and treatment arm, for Chinese men who have sex with men, collected from a randomized
controlled trial in Beijing and Guangzhou, China. Pay-it-forward has a stronger effect on
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contributions for all participants but appeared to have the greatest effect for those who
preferred receptive anal sex. All values were mean predictions and standard errors
estimated using the Heckman selection model controlling for confounders. Each column
estimated two models, where the sample is divided by a different sexual behavior.
Table 1: Participant characteristics for Chinese men who have sex with men
from two studies in Guangzhou and Beijing, China
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Table 2: Multivariate analysis of sexual behaviors and participant contribution
levels, for Chinese men who have sex with men, collected from the pay-itforward arm of a quasi-experimental study in Guangzhou, China.
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Table 3: Multivariate analysis of altruism, sexual role, and participant contribution
levels, for Chinese men who have sex with men, collected from a randomized
controlled trial in Beijing and Guangzhou, China.
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In the pay-it-forward arm, participants paid forward ¥61.96/$9.87 on average
(SD=¥56/$8.92), and the median contribution was ¥50.00/$7.96 (see Table 2). I found
that receptive partners contributed ¥26.98/$4.30 more than insertive partners (p=0.04).
Subjects practicing anal sex with a condom gave ¥21.47/$3.42 more (p=0.04). Higherincome participants gave more, with a single income category translating into
¥20.44/$3.25 higher contributions (p<0.011). Subjects in the pay-it-forward arm
perceiving altruistic benefits in the program contributed ¥12.17/$1.94 more (p<0.001)
compared to than those who did not see such benefits.
Finally, I found that outness was positively associated with directed altruism (p<0.05).
Those who did not disclose their sexual identity were more likely to perceive only selfinterested benefits of the program. In contrast, those out to their family, friends, and/or
health providers (outside the men who have sex with men sexually transmitted infection
clinic) were more likely to report altruistic motivations (Figure 1). Similarly, those who had
disclosed their sexual behavior to a healthcare provider tended to have higher contribution
levels (see Figure 2a, 2b).
In the second, randomized controlled trial study, out of the 103 subjects who participated
in testing (pay-it-forward arm: 57/101; pay-as-you-what arm: 46/100), 96 contributed (payit-forward arm: 54/57; pay-as-you-what arm 42/46). The sociodemographic profile of
participants was like the first study. In the combined analysis of both arms, like the first
study, I found that men who have sex with men who preferred a receptive sexual role
contributed ¥16.94/$2.70 more (p<0.05, Table 3). I also found that of 15 individuals who
paid the full cost of the test or more, 14 preferred the receptive sexual role. I then explored
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the role of the sexual role on contributions. For those who preferred a receptive role in
anal sex, I found that the pay-it-forward intervention was associated with ¥15.90/$2.53
higher contributions compared to the Pay-as-you-Want condition (p<0.001, see Figure 2c,
2d, Table 3).
Discussion
The main finding was that sexual behavior disclosure (outness) was associated with
altruism as a motivation for pay-it-forward participation, which was itself positively related
to higher contribution levels. Results were consistent with previous research which
suggested that sexual behavior disclosure was associated with increased HIV testing rates
and linkage to care.306,307 Past work in the Chinese context indicated that larger disclosure
networks were associated with greater propensity of HIV testing.308,309 The strength of this
study is that I measured the relationship between sexual behavior disclosure and its
relationship to intervention outcomes. Such outcome measurement is key to
demonstrating the importance of sexual behavior disclosure, both for mitigating stigma
and optimizing sexually transmitted infection testing interventions for sexual minorities.
Men who preferred receptive anal sex tended to contribute more funds to the intervention.
While there is research on reducing levels of unprotected receptive anal sex among men
who have sex with men,310 studies on how preference for receptive anal sex may influence
intervention outcomes is limited. As men who have sex with men preferring receptive anal
sex may have a greater sexually transmitted infection risk,311 they may contribute more to
interventions to reduce their own overall exposure by ensuring others get tested.
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Alternatively, men who have sex with men preferring receptive sex may be more engaged
in the men who have sex with men community and thus contribute more.
Future research can explore how the utility of a person’s ties in a social network and
concern for collective group well-being, are positively associated with altruism. The study
has policy implications for improving health outcomes. Men who have sex with men in
many settings face discrimination, limiting access to health services.312 There is potential
for targeted interventions to harness collective altruism in settings of marginalization,
helping improve cost-effectiveness and reach of public health programs by drawing on the
positive role of different identities.
Limitations
Results should be read in line with some limitations. While the Heckman model is a
standard approach to dealing with selection bias, its power depends on the exclusion
criterion: Previous testing and symptoms must correlate with participation but not with
the contribution decision. I found strong correlation of symptoms with the decision to
participate, and no such correlation with the level of contributions. But ultimately
exclusion cannot be empirically proved and remains an assumption of the model.
Additional limitations to the study were those inherent in observational research relying
on subject-reported data. While the outcome variable was measured objectively
(contributions made), subject baseline data is subject to recall error and subjective biases.
There may be social desirability bias that can be accounted for in future studies. For
example, some men may feel pressure to participate in the intervention as recruitment was
conducted with other men who have sex with men present. The results may not be
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generalizable to other contexts as there may be substantial cultural differences between
men who have sex with men in China compared to other nations.
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Community-centric Behaviors and Chinese Men who have Sex with Men
Introduction
A range of evidence-based preventive services are not affordable for those in the Global
South.313,314 Individuals in such settings routinely pay out-of-pocket fees for vaccines, drugs
and diagnostic services.315 Compulsory fee payment decreases the uptake of health services
and disproportionately affects marginalized communities.316,317 Government run
preventive services have come under increasing strain,318 with the cost of such services
often determined by for-profit entities.319 Programs that decrease fees associated with
preventive services have not been scaled up315,320 and thus, innovative techniques are
necessary to stimulate access to preventive services.
An example of a novel technique for promoting service uptake in healthcare is pay-itforward.321 Pay-it-forward has one person receive a gift and then asks whether they would
like to provide another person with a similar gift.322 A previous study used pay-it-forward
where men who have sex with men received a free gonorrhea/chlamydia test and then
decide whether to donate toward the next person’s test, where pay-it-forward increased
gonorrhea/chlamydia test uptake among men who have sex with men.321 pay-it-forward
changes the transactional exchange between buyer and seller to a social exchange between
a gift-giver and receiver.323 This technique may augment trust and community engagement
in health service uptake which are commonly associated with sexually transmitted infection
test uptake and wellbeing.324
This study draws data from a multi-site, three-arm, cluster randomized controlled trial that
evaluated the effectiveness of a pay-it-forward model in promoting gonorrhea/chlamydia
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test uptake compared to a standard fee-based system. The primary outcome of the
randomized controlled trial was gonorrhea/chlamydia test uptake. Gonorrhea/chlamydia
test is available in most Chinese hospitals for about USD22.325 gonorrhea/chlamydia test
rates among Chinese men who have sex with men are low despite a gonorrhea and
chlamydia epidemic.326 Gonorrhea and chlamydia are often asymptomatic and associated
with increased risk of HIV transmission and acquisition.327,328
Within men who have sex with men communities, engaging in community-centric
behaviors can improve HIV/sexually transmitted infection testing outcomes and augment
overall wellbeing.329 Community engagement is associated with community-centric
behaviors such as donating money and providing feedback.330 Thus, men who have sex
with men who engage in community-centric behaviors may contribute more toward others’
testing within a pay-it-forward program. I operationalize community-centric behaviors into
being part of a community and being an advocate for the community, leading to the
following hypotheses: H1: Men who have sex with men who feel they are part of the men
who have sex with men community are more likely to make a greater pay-it-forward
contribution; H2: Men who have sex with men who believe that it is important to be an
advocate for the men who have sex with men community are more likely to make a greater
pay-it-forward contribution. I test these hypotheses using data from the indicated
randomized controlled trial. Deeper understanding of the relationship between the extent
of participation in community-centric behaviors and pay-it-forward contributions may aid
in improving the efficacy of programs designed to reduce costs of paid testing services.
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Methods
Study Design and Participants
I draw data from a randomized controlled trial to study sexually transmitted infection test
uptake in men who have sex with men from December 2018 – January 2019. The
randomized controlled trial was conducted in Guangzhou, China (two sites in hospital
sexually transmitted infection clinics) and Beijing, China (community-based organization).
All sites provided free HIV testing and were selected based on men who have sex with
men input and ability to deliver testing. Sites were staffed with a mix of men who have sex
with men volunteers, nurses, and public health staff. No physicians were present. Blood
draws, testing, results reporting, and test follow-up was conducted by site staff. Sites had
identical study procedures. The inclusion criteria was as follows: Born biologically male; ≥
16 years of age; reported anal intercourse with other men; did not have a
gonorrhea/chlamydia test in the past year; did not previously participate in the study; were
willing to provide a mobile number or WeChat ID (popular Chinese mobile application)
for sexually transmitted infection results notification. Institutional Review Board approval
for the study was received from the University of North Carolina at Chapel Hill (IRB 182142), Southern Medical University Dermatology Hospital (China) and Yale University.
The parent randomized controlled trial was registered on ClinicalTrials.gov
(NCT03741725).20 Written informed consent was obtained from all men.
Randomization
Clusters of ten participants were randomly assigned to pay-it-forward and two other arms
(pay-what-you-want, standard of care) at each study site. A cluster was ten eligible men
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who have sex with men who arrived in order and agreed to participate. A cluster size of
ten was selected based on sample size calculation. All in the same cluster were assigned to
the same study arm. Those who came with partners were assigned to the same cluster.
STATA 15331 was used to generate the randomization sequence. Study organizers and
participants were not masked to arm assignment.
Procedures
The pay-it-forward program was developed through community feedback and
crowdsourcing.321 Program procedures were designed through an iterative process of
consultation with community partners and pilot trials at each site. Through results from
the pilot trial, the pay-it-forward procedure was modified accordingly.20 The program’s
Chinese name was developed through crowdsourcing.332 Handwritten notes were also
presented to participants in the pay-it-forward arm. Figure 1 demonstrates the key
concepts of pay-it-forward and the other two study arms. Those assigned to the pay-itforward program were introduced to gonorrhea/chlamydia test, followed by an overview
of pay-it-forward. Participants were told the standard price of gonorrhea/chlamydia test
(USD22/RMB150) and that previous participants donated toward test fees to cover the
cost. Men could thus receive a free test and contribute towards others’ testing. Participants
were also shown postcards with messages from previous participants and told that they
could write a message for the next person. Testing and donation were voluntary and men
who have sex with men could donate any amount after receiving the test.
Men who decided to test were asked about their sexual practices and advised to consider
urethral, rectal, or both urethral and rectal gonorrhea/chlamydia test. Irrespective of the
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testing decision, men were asked to complete a survey about their sexual history, testing
history, attitudes toward the testing program and the men who have sex with men
community (see Appendix). Samples collected were stored at room temperature overnight
and transported to laboratories for testing. Men who received a positive test result were
counseled and directed to the website of the designated partner hospital in each city, where
they could make an appointment.
Outcome
The primary outcome was the contribution for pay-it-forward. Data from the other two
arms was not considered.
Statistical analysis
I used the following survey items to represent being part of the men who have sex with
men community and being proud of the men who have sex with men community,
respectively: You feel that you are a part of the men who have sex with men community;
It is important for you to be an advocate for the men who have sex with men community.
These questions had the following options: Strongly Agree; Agree; Disagree; Strongly
Disagree. These questions were not formally validated, but have been used in multiple
studies in the China research environment.321,333,334 Selection bias was a concern in the
analysis. Those who did not want a gonorrhea/chlamydia test may be different from those
who received a gonorrhea/chlamydia test. Such issues are common in most testing
environments. Gonorrhea/chlamydia test selection may lead to inaccurate results of the
factors responsible for the decision around test taking are related to the main variables of
interest. I used the Heckman selection model to estimate whether the indicated items were
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associated with the level of pay-it-forward contributions. I simultaneously modeled the
decision to take the test and the subsequent test choice.
Test uptake (selection stage) was operationalized as a dichotomous variable indicating
whether men had selected the gonorrhea/chlamydia test. Level of pay-it-forward
contribution was the variable of interest for the outcome stage. Statistical analysis was
conducted with R.335 P<.05 was considered statistically significant. The first-stage model
applied a probit model to represent the propensity to choose a gonorrhea/chlamydia test
based on certain variables (see Table 2). The first model’s assessment of the probability of
gonorrhea/chlamydia test choice was then used in the second stage to adjust the estimates
produced from a probity model that accounted for selection bias. To use the Heckman
model, I had to understand the factors that influenced pay-it-forward contribution
amounts and the decision to receive a gonorrhea/chlamydia test. The following variables
likely influenced test uptake: Number of male partners last three months; Frequency of
condomless anal intercourse last three months; Number of partners last three months;
Frequency of HIV test; Possible sexually transmitted infection Symptoms; Out to health
provider; Site. The following are likely to have influenced level of pay-it-forward
contribution: Top; Bottom; Age; Income; Part of the men who have sex with men
community; Advocate for the men who have sex with men community.
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Results

Figure 1. Concepts of standard of care, pay-it-forward, and pay-what-you-want
gonorrhea/chlamydia testing. This schematic illustrates respective trial arms from the
perspective of a participant. In standard of care, participant was offered a test at standard
price (USD22). In pay-it-forward, the participant was offered a gift of a free test (“test kit”)
and told that previous men donated to make this test possible as well as shown postcards
written by previous men (“caring”). Then, the participant was asked whether they would
donate toward testing for future men (“voluntary donation”). In pay-what-you-want, the
participant was offered a free test (“test kit”). Then, the participant was told they could pay
any desired amount for their own test (“voluntary payment”).
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Figure 2. Study flow chart, 2018-2019.
* There is no loss-to-follow-up in this study. Participants made decisions on whether to
test immediately after the interventions.
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TABLE 1-Characteristics of Participants
Variable
Age
Number of male partners last three months
Gonorrhea test site
Rectal
Urethal
Anal Sex Role
Bottom
Top
Versatile

Yearly income, $
<2690.88
2690.88 - 5381.64
5381.64 - 8,969.40
8969.40 – 14351.04
>14351.04

Experienced sexually transmitted infection symptoms
No
Yes
HIV test frequency
<Once every two years
Once a year
Once every six months
Once every three months
Monthly
Previous HIV test
No
Yes

Mean (SD)
28.10 (7.10)
2.30 (2.98)
%
43.9
56.1
n=114
31.8
37.8
30.4
n=283

11.5
9.0
14.9
26.4
38.2
n=288

11.2
88.8
n=285
16.9
23.0
28.1
26.3
5.8
n=278
9.0
91.0
n=288
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Frequency of condomless anal intercourse last three months
0% condom use
<50% condom use
>50% condom use
100% condom use
Out to anyone
No
Yes
Out to health provider
No
Yes
Gonorrhea test result
Negative
Positive
Chlamydia test result
Negative
Positive
You feel that you are a part of the men who have sex with men
community
Strongly Disagree
Disagree
Agree
Strongly Agree

It is important for you to be an advocate for the men who have
sex with men community
Strongly Disagree
Disagree
Agree
Strongly Agree

6.0
10.3
29.5
54.3
n=234
35.1
64.9
n=288
79.5
20.5
n=288
98.3
1.7
n=114
93.7
6.3
n=114
3.2
8.5
57.6
30.7
n=283

1.1
10.6
56.4
31.9
n=282
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TABLE 2: Pay-it-forward Contribution Amounts and Gonorrhea and Chlamydia Test Choice Among Chinese
men who have sex with men
Variable

Coefficients (SE)

P

Coefficients (SE)
H2

P

H1
Outcome stage. Dependent variable:
Rectal test
Top
Bottom
Age
Income

-63.088 (18.497)
-50.428 (17.694)
2.605 (1.055)
11.036 (5.544)

.001
.005
.016
.050

-56.971 (18.403)
-41.476 (17.366)
3.001 (1.090)
9.748 (5.626)

.002
.019
.007
.087

Part of the men who have sex with men
community

26.262 (10.041)

.011

-

-

-

-

25.941 (9.786)

.010

Number of male partners last three
months

0.072 (0.080)

.373

0.072 (0.080)

.373

Frequency of condomless anal
intercourse last three months

0.010 (0.179)

.953

0.010 (0.179)

.953

0.072 (0.080)
-0.088 (0.120)

.373
.463

0.072 (0.080)
-0.088 (0.120)

.373
.463

5.709 (361.380)
0.060 (0.388)

.987
.877

5.709 (361.380)
0.060 (0.388)

.987
.877

-0.468 (0.595)
0.190 (0.517)
82

.434
.714

-0.468 (0.595)
0.190 (0.517)
82

.434
.714

Advocate for the men who have sex
with men community
Selection stage. Dependent variable: Test
uptake

Number of partners last three months
Frequency of HIV test
Possible sexually transmitted infection
Symptoms
Out to health provider
Site
Site 2
Site 3
N
Note: Coefficients of probit with sample
selection.

Between December 2018 and January 2019, four hundred and thirty-one men intending to
test for HIV were approached. Fifteen were deemed ineligible for having participated in
pay-it-forward before (n=6), having received a gonorrhea/chlamydia test in the last year
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(n=5), having never had anal intercourse with men (n=3), and not born biologically male
(n=1). In addition, 115 eligible men declined to participate due to lack of interest or time
conflict. There was a final sample of 301 men who were enrolled and assigned to clusters
within the three arms (see Figure 2). After accounting for missing data, 283 records
remained. Descriptive statistics are presented in Table 1. Most men who have sex with
men (88.3%) felt that they were a part of the men who have sex with men community.
Similarly, a large proportion (62.7%) indicated that they were proud of the community.
The majority (88.3%) believed that it was important to be an advocate for the men who
have sex with men community.
Proportions of receiving gonorrhea/chlamydia test in the pay-it-forward, pay-what-youwant, and standard of care arms were 56%, 46% and 18% respectively. Of the 121 who
tested for gonorrhea and chlamydia, five (4.1%) had gonorrhea and 19 (15.7%) had
chlamydia. Of the 57 who received testing through pay-it-forward, 54 (94.6%) donated to
future participants. The total amount donated in the pay-it-forward arm was $472.78
(mean=$8.29, SD=$7.35).
With two separate models, I detailed results regarding the hypotheses, exploring if men
who have sex with men community-centric behaviors are related to pay-it-forward
contribution (see Table 2). The model for H1 indicates that increased belonging to the
men who have sex with men community was associated with greater pay-it-forward
contribution. The model for H2 details that increased importance assigned to being an
advocate for the men who have sex with men community was associated with greater payit-forward contribution.
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Discussion
The aim of this study was to determine the association between men who have sex with
men community-centric behaviors and contribution towards another’s sexually transmitted
infection testing cost. I found that increased support for community-centric behaviors was
associated with greater pay-it-forward contribution in the sexually transmitted infection
testing environment. This extends the literature by drawing data from a randomized
controlled trial and suggests that community-centric behaviors may be associated with a
reduction in testing service cost that would otherwise be associated with fees.
The possible cost-saving effect of men who have sex with men community-centric
behaviors is consistent with research indicating that gay community participation can help
to create safe environments for testing and care.329 Similarly, identification with the gay
community protected against HIV risk and younger men who have sex with men who
identified with the gay community reported reduced sexual risk.336 Results may add to a
more complex view of men who have sex with men community-centric behaviors.
Compared to non-MDMA users, MDMA users were more likely to participate in and
indicate affiliation to men who have sex with men community.337 In the same vein, gay
social engagement was associated with a HIV positive serostatus, unprotected anal
intercourse with regular partners and high frequency of HIV/sexually transmitted
infection testing.338 Perhaps increased community-centric behaviors may be related to
improved frequency and prosocial behavior around HIV/sexually transmitted infection
testing, but possibly more risky sexual behavior.
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While previous research demonstrates associations between community-centric behaviors
and aspects of sexual health, results provide evidence that community-centric behaviors
can reduce testing costs. Such findings are relevant to China and other Global South
environments where limited resources have been allocated to sexually transmitted infection
prevention and treatment.326,339 Harnessing community-centric behaviors in the Chinese
men who have sex with men environment could allow more to receive free or subsidized
sexually transmitted infection testing services. On a broader arc, community-centric
behaviors may also be relevant in settings where groups of individuals pay mandatory fees
for preventive services.
Results should be interpreted in line with a few limitations. The study was conducted in
two metropolitan cities in China and generalizability may be limited. Even so, there are
several settings in the Global South where well-defined communities pay fees for
preventive health services. The study was conducted in a controlled research setting and it
is not clear if community-centric behaviors can be similarly utilized in non-research
contexts.
Findings have several implications for research and policy. From a research standpoint,
this study expands on the limited data detailing how community-centric behaviors are
related to the efficacy of behavioral interventions. Further research is key to better
understand the role of community-centric behaviors in testing provision. From a policy
perspective, the intervention does not seek to replace public provision of sexually
transmitted infection testing. Instead, results may lead to exploration on how communitycentric behaviors can be drawn upon when needed to reduce costs and allow for a more
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financially sustainable model of sexually transmitted infection testing, before large scale
public programs are rolled out. In conclusion, community-centric behaviors may improve
pay-it-forward contributions in the Chinese men who have sex with men environment.
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Lack of Sexual Behavior Disclosure May Distort sexually transmitted infection
Testing Outcomes
This section has been published as: Kumar N, Forastiere L, Zhang T, et al. Lack of Sexual
Behavior Disclosure May Distort sexually transmitted infection Testing Outcomes. BMC
Public Health. 2020;20(1):616. Doi:10.1186/s12889-020-08768-5
Men who have sex with men globally have a high burden of curable sexually transmitted
infections.340 The World Health Organization estimates that there are annually 131 million
and 78 million new cases of Chlamydia trachomatis and Neisseria gonorrhoeae,
respectively.341 Among men who have sex with men worldwide, gonorrhea and chlamydia
are the two most common bacterial sexually transmitted infections.342 The World Health
Organization recommends men who have sex with men receive regular gonorrhea and
chlamydia testing.343
The risk of contracting sexually transmitted infections can vary with sexual behaviors.344
There are a variety of ways men who have sex with men engage in intercourse, some related
to preference and some not. Sometimes the reason for sexual positioning is strategic e.g.
Seropostioning.345 Some men who have sex with men prefer to engage in receptive anal
intercourse (top), others prefer insertive anal intercourse (bottom) and some enjoy all types
of intercourse (versatile).346 A preference for receptive anal intercourse is associated with
increased likelihood of a gonorrhea and chlamydia infection.344 Men who have sex with
men do not frequently receive rectal sexually transmitted infection testing because of
several barriers, including: Stigma, shame, fear of invasive sampling, confidentiality
concerns and clinician's time pressures.347 Thus, both clinician and patient factors are key
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to rectal sexually transmitted infection testing. While clinician factors are important, I
center on patient factors because: 1) Self-testing and self-collection now allow rectal testing
at home, prior to seeing a clinician.348 Self-testing also happens in clinical settings.348
Moreover, home-based self-testing has had several innovations, such as internet-based
testing which obviates the need to see a clinician349 and social entrepreneurship models
that promote self-testing;350 2) Substantial heterogeneity in men who have sex with men
preferences may drive rectal test uptake339 along with a range of unaccounted factors such
as disclosure of sexual behavior (outness); 3) The broader randomized controlled trial,
from which I drew data to conduct secondary analysis of a cross-sectional survey, provided
a unique context where all providers were offered rectal testing, allowing us to observe
differences in men who have sex with men rectal sexually transmitted infection uptake.351
Within these factors, the main barrier for testing is lack of disclosure. 352 If men who have
sex with men are unwilling to disclose their sexual behavior, the likelihood of getting tested
is low.353 I explore the relationship between outness and rectal sexually transmitted
infection testing.
The objectives of the study were to assess if men who have sex with men are more likely
to select the gonorrhea and chlamydia test most representative of their sexual behavior,
compared to a test less representative of their behavior; and if outness is related to the
decision to select a rectal vs urethral test. Research on men who have sex with men sexual
behavior does not often account for patient factors. The study may shed light on how
sexual behavior and outness may affect gonorrhea and chlamydia test provision, improving
men who have sex with men sexually transmitted infection testing efforts.
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Methods
Study Design and Participants
I conducted secondary analysis of baseline data from a cross-sectional survey collected
through an randomized controlled trial that sought to improve on sexually transmitted
infection testing rates in men who have sex with men from December 2018 - January 2019
in China.351 This randomized controlled trial is henceforth referred to the parent
randomized controlled trial, from which I drew data to conduct secondary analysis to
evaluate how outness can affect sexually transmitted infection test uptake. The parent
randomized controlled trial was conducted in Guangzhou at two sites, and Beijing in a
single site. All randomized controlled trial sites provided free HIV testing and were
administered by men who have sex with men community-based organizations. Sites were
selected based on men who have sex with men input, provided free HIV and syphilis
testing for men who have sex with men, and had capacity to deliver sexually transmitted
infection testing services during the study period. All sites were staffed with a mix of men
who have sex with men volunteers, nurses, and public health staff, with no physicians.
Blood draws, testing, results reporting, and test follow-up were handled by site-based staff.
Sites followed similar procedures. The inclusion criteria was that subjects were assigned
male sex at birth and identified as male, >16 years of age, reported anal intercourse with
other men, did not have a gonorrhea and chlamydia test in the past year, did not previously
participate in the study and were willing to provide a mobile number or WeChat ID
(popular Chinese mobile application) for sexually transmitted infection results notification.
The study was approved by the Human Subjects Committee at the University of North
Carolina at Chapel Hill (IRB 18-2142), Southern Medical University Dermatology Hospital
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(China) and Yale University. The parent randomized controlled trial351 was registered on
ClinicalTrials.gov (NCT03741725). Written informed consent was obtained from all
participants.
Procedures
All testing sites offered gonorrhea and chlamydia tests to men who have sex with men
waiting for free HIV and syphilis testing. After a short introduction to the gonorrhea and
chlamydia test, participants decided whether to receive testing. After obtaining informed
consent, I conducted patient interviews (survey instrument in Appendix) from all men
approached about a gonorrhea and chlamydia test, even if they declined testing. I
developed the survey for study purposes. Men who have sex with men were surveyed about
their sexual history, sexually transmitted infection testing history, sexual behavior, and
sociodemographic variables. Men who have sex with men were offered gonorrhea and
chlamydia tests and were given a choice to get tested either at rectal or urethral sites but
not both, because of limits to free testing at the clinics. While guidelines generally suggest
triple site testing (urethral, rectal, pharyngeal),354 this is not always possible in resource
limited settings, such as this study. I thus provide implications generalizable to other
resource-scarce settings. With men who have sex with men limited to a single test, I can
understand the relationship between disclosure of sexual behavior and test choice. Men
who have sex with men were told that the urethral test was appropriate for those preferring
insertive anal intercourse, while the rectal test was for those preferring receptive anal
intercourse---given that gonorrhea and chlamydia infections can be site-specific.355 There
was no unique choice specific to versatile behavior. Men who have sex with men could
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select to receive both tests but would have to pay 150RMB (USD21). Men were told that
their information would be kept confidential and gonorrhea and chlamydia test results sent
after a week. Program organizers updated respondents of test results through WeChat.
HIV, syphilis and gonorrhea and chlamydia tests were conducted in the clinic and the
results recorded. Participants with positive test results were counselled and directed to
hospital resources to receive paid treatment and follow-up care. Due to resource
limitations, I was not able to pay for participant treatment, but note that Chinese sexually
transmitted infection treatment is relatively affordable.356 These tests would likely not have
been done if the study had not happened, as Chinese men who have sex with men have
low gonorrhea and chlamydia testing rates.339 The parent randomized controlled trial
increased gonorrhea and chlamydia testing rates and reduced cost, with the control being
the community standard of care.351
The question on disclosure was as follows: "In the past, have you told anyone about your
sexuality or sexual history with men?" The following options were provided: (1) "Yes, my
long-term female partner/wife"; (2) "Yes, my family members"; (3) "Yes, my friends"; (4)
"Yes, my healthcare providers"; (5) "No one". Options four and five were coded as binary
variables to detail sexual behavior disclosure to health providers and non-specific
disclosure respectively. Option five captures disclosure in a non-specific sense i.e. Anyone
and is associated with improved health outcomes.357 Option four indicates disclosure to
health providers, which is key to receiving appropriate healthcare,306 more so than the other
group-specific disclosure options. For example, men out to their healthcare provider are
more likely to get HIV testing compared to those out to their family.308 Although
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participants attended a specialized men who have sex with men testing clinic, this does not
reflect their disclosure to their primary care or other health providers. There is significant
stigma around men who have sex with men sexual behavior in China358 and thus men may
be comfortable going to a men who have sex with men-centric health provider, yet not be
out to their primary health provider. For example, while men were out within the context
of the health clinic in the study, 35% were not out to anyone and 80% were not out to
their primary health provider. Given the high rates of non-disclosure outside the testing
clinic, I suggest that broader non-disclosure may affect in-study outcomes.
Statistical analysis
To analyze study data I used inferential statistical methods. First, a probit model with
sample selection was used to assess the relationship between receiving a rectal sexually
transmitted infection test and various sexual behaviors (receptive, insertive, versatile).
Then, I used a probit model with sample selection to assess the relationship between
receiving a rectal sexually transmitted infection and sexual behavior disclosure/outness
(non-specific disclosure, disclosure to health provider). I used STATA 13.0. All models
included demographics, socioeconomic measures, and sexual history as controls. Further
information about statistical methods is in Appendix. P<0.05 was considered significant.
Results
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Table 1 Participants characteristics
Variable
Age
Number of male partners last three months
Gonorrhea test site
-rectal
-urethal
Sexual behavior
-receptive
-insertive
-versatile

Yearly income, $
-<2690.88
-2690.88 - 5381.64
-5381.64 - 8,969.40
-8969.40 - 14351.04
->14351.04

Experienced sexually transmitted infection symptoms
-no
-yes
HIV test frequency
-<once every two years
-once a year
-once every six months
-once every three months
-monthly
Previous HIV test
-no
-yes

Mean (SD)
28.10 (7.10)
2.30 (2.98)
%
43.9
56.1
n=114
31.8
37.8
30.4
n=283

11.5
9.0
14.9
26.4
38.2
n=288

11.2
88.8
n=285
16.9
23.0
28.1
26.3
5.8
n=278
9.0
91.0
n=288
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Frequency of condomless anal intercourse last three months
-0% condom use
-<50% condom use
->50% condom use
-100% condom use
Out to someone (Non-specific disclosure)
-no
-yes
Out to health provider (Disclosure to health provider)
-no
-yes
Gonorrhea test result
-negative
-positive
Chlamydia test result
-negative
-positive

6.0
10.3
29.5
54.3
n=234
35.1
64.9
n=288
79.5
20.5
n=288
98.3
1.7
n=114
93.7
6.3
n=114
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Table 2 Multivariate analyses of men who have sex with men propensity to select the rectal test compared to the urethral test, in line with sexual behavior

Marginal Effects (95%
CI)
Receptive

Marginal Effects (95%
CI)
Insertive

Marginal Effects (95%
CI)
Versatile

Variable
P
P
Sexual behavior
Dependent variable: Rectal test
Insertive
-0.51 (-0.59, -0.44)
< .001
Receptive
0.45 (0.34, 0.57)
< .001
Versatile
0.006 (-0.18, 0.19)
Age
0.006 (-0.001, 0.013)
.12
0.004 (-0.009, 0.018)
.52
0.003 (-0.012, 0.019)
Income
0.012 (-0.036, 0.060)
.64
0.050 (-0.027, 0.128)
.2
0.05 (-0.05, 0.14)
Number of male partners last three
months
-0.022 (-0.042, -0.001)
.04
-0.019 (-0.035, -0.002)
.03
-0.01 (-0.04, 0.01)
Frequency of condomless anal
intercourse last three months
0.12 (-0.031, 0.28)
.12
0.37 (0.17, 0.57)
< .001
0.26 (-0.13, 0.65)
Non-specific disclosure
-0.08 (-0.19, 0.03)
.16
-0.093 (-0.34, 0.15)
.46
0.12 (-0.1, 0.33)
Disclosure to health provider
0.04 (-0.11, 0.18)
.6
-0.041 (-0.29, 0.20)
.74
-0.046 (-0.29, 0.20)
N
85
85
85
Predicted mean for receiving a rectal
test
0.33
0.41
0.32
Note: Marginal effects of probit with sample selection (outcome equation results shown). Confidence interval (CI) estimated using jackknife with
clustering by sites and within-site groups. Receptive: Compared to men who have sex with men not indicating the receptive role, men who have sex
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with men indicating the receptive role are more likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test; Insertive:
Compared to men who have sex with men not indicating the insertive role, men who have sex with men indicating the insertive role are less likely
to select the rectal gonorrhea and chlamydia test, compared to the urethral test; Versatile: Compared to men who have sex with men not indicating
the versatile role, men who have sex with men indicating the versatile role have no gonorrhea and chlamydia test preference.
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Table 3 Multivariate analyses of men who have sex with men propensity to select the rectal test compared to the urethral test, in
line with non-specific disclosure and disclosure to health provider
Variable
Marginal Effects (95% CI)
P
Marginal Effects (95% CI)
P
Type of disclosure
Non-specific disclosure
Disclosure to health provider
Dependent variable: Rectal test
Insertive
Receptive
0.58 (0.5, 0.66)
< .001
0.58 (0.53, 0.64)
< .001
Versatile
0.26 (-0.23, 0.78)
0.29
0.26 (0.12, 0.41)
< .001
Age
0.01 (-0.01, 0.02)
.45
0.01 (-0.01, 0.02)
.35
Income
0.03 (-0.04, 0.1)
.47
0.02 (-0.04, 0.08)
.54
Number of male partners last three months
-0.02 (-0.1, 0.05)
.51
-0.03 (-0.06, 0.002)
.07
Frequency of condomless anal intercourse
last three months
0.23 (0.06, 0.4)
.01
0.23 (0.1, 0.36)
.001
Non-specific disclosure
-0.08 (-0.32, 0.15)
.49
Disclosure to health provider
-0.04 (-0.25, 0.17)
.72
N
85
85
Predicted mean for receiving a rectal test
0.4
0.41
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Note: Marginal effects of probit with sample selection (outcome equation results shown). Confidence interval (CI) estimated using
jackknife with clustering by sites and within-site groups. Non-specific disclosure: Compared to those not out to anyone, those out
to someone are more likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test; Disclosure to health
provider: Compared to those not out to their health provider, those out to their health provider are more likely to select the rectal
gonorrhea and chlamydia test, compared to the urethral test.
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Table 4 Multivariate analyses of versatile men who have sex with men propensity to select the rectal test compared to the urethral test, in line with nonspecific disclosure and disclosure to health provider
Variable
Marginal Effects (95% CI)
P
Marginal Effects (95% CI)
P
Type of disclosure
Non-specific disclosure
Disclosure to health provider
Dependent variable: Rectal test
Insertive
Receptive
Versatile
Age
Income

0.61 (0.52, 0.70)
0.36 (0.23, 0.48)
0.004 (-0.01, 0.01)
0.03 (-0.02, 0.08)

< .001

Number of male partners last three months
Frequency of condomless anal intercourse last three
months
Non-specific disclosure
Versatile*non-specific disclosure
Disclosure to health provider
Versatile*disclosure to health provider
N
Predicted mean for receiving a rectal test

< .001

< .001
.46
.24

0.56 (0.46, 0.67)
0.15 (0.03, 0.26)
0.005 (0.001, 0.01)
0.02 (-0.02, 0.05)

-0.03 (-0.06, 0.003)

.08

-0.03 (-0.05, -0.01)

.01

0.2 (0.09, 0.32)
-0.2 (-0.36, -0.05)
0.27 (0.06, 0.48)
85
0.41

.001
.01
.01
-

0.19 (0.05, 0.33)
-0.16 (-0.29, -0.04)
0.29 (0.06, 0.53)
85
0.39

.01
.01
.01

.01
.01
.39
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Note: Marginal effects of probit with sample selection (outcome equation results shown). Confidence interval (CI) estimated using jackknife with clustering by
sites and within-site groups. Non-specific disclosure: Compared to versatile men who have sex with men not out to someone, versatile men who have sex with
men who are out to someone (disclosed sexual identity) are more likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test;
Disclosure to health provider: Compared to versatile men who have sex with men not out to their health provider, versatile men who have sex with men out
to their health provider are more likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test.
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Table 1S Outness, Sexual Behavior and Gonorrhea and Chlamydia Test Choice Among Chinese men who have sex with men
Variable

Coefficients
(95% CI)

P

Coefficients
(95% CI)

P

Insertive

Receptive
Outcome
stage.
Dependen
t variable:
Rectal test

Coefficients
(95% CI)

P

Versatile

Coefficients
(95% CI)
Non-specific
disclosure

P

Coefficients
(95% CI)
Disclosure to
health provider

.0
0
3

-

-

-

-

-

P

Coefficients (95% CI)
Versatile men who have sex with
men-Non-specific disclosure

P

Coefficients (95% CI)
Versatile men who have sex with
men-Disclosure to health provider

P

<.
00
1

-

-

-

3.3 (2.11, 4.48)

3.24 (1.64, 4.85)

.02

1.92 (1.13, 2.71)

<.
00
1
<.
00
1

0.86 (0.02, 1.69)

.04
<.
00
1

.38

0.02 (-0.04, 0.08)

.47

0.03 (0.01, 0.06)

.02

Insertive

-

-

-2.12 (-3.58,
-0.82)

Receptive

1.98 (0.94,
3.03)

.00
1

-

-

-

-

3.04 (-2.79,
8.87)

.2
9

3.13 (1.7, 4.56)

0.03 (-0.01,
0.06)

.09

0.02 (-0.04,
0.08)

.5
5

0.02 (-0.55,
0.6)
0.01 (-0.04,
0.06)

.9
5
.7
1

1.38 (0.18,
2.58)
0.03 (-0.04,
0.09)

.0
3
.4
2

1.41 (0.24,
2.57)
0.031 (-0.04,
0.1)

0.05 (-0.17,
0.28)

.66

0.22 (-0.2,
0.64)

.3

0.13 (-0.15,
0.42)

.3
4

0.13 (-0.4,
0.67)

.6
1

0.11 (-0.26,
0.47)

.56

0.26 (-0.13, 0.46)

.34

0.09 (-0.14, 0.32)

.42

-0.1 (-0.2,
0.01)

.07

-0.08 (-0.16,
-0.002)

.0
4

-0.04 (-0.11,
0.03)

.2
7

-0.13 (-0.75,
0.5)

.6
9

-0.15 (-0.33,
0.03)

.1

-0.14 (-0.32, 0.04)

.12

-0.17 (-0.36, 0.01)

.06

0.56 (-0.22,
1.31)

.15

1.6 (0.38,
2.82)

.0
1

0.76 (-0.29,
1.81)

.1
5

1.2 (-0.89,
3.33)

.2
5

1.22 (0.38, 2.06)

.01

1.09 (0.35, 1.83)

.01

1.08 (-0.1, 2.07)

.03

Versatile
Age
Income
Number
of male
partners
last three
months
Frequency
of
condomle
ss anal
intercours
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e last three
months
Nonspecific
disclosure
Versatile*
nonspecific
disclosure
Disclosure
to health
provider
Versatile*
disclosure
to health
provider

-0.34 (-0.88,
0.19)

.2

-0.4 (-1.65,
0.85)

.5
2

0.35 (-0.28,
0.98)

.2
7

-0.44 (-1.54,
0.66)

.4
2

-

-

-1.09 (-1.96, -0.22)

.02

-

-

-

-

-

-

-

-

-

-

-

-

1.45 (0.29, 2.61)

.02

-

-

0.17 (-0.52,
0.89)

.62

-0.18 (-1.32,
0.97)

.7
6

0.13 (-0.62,
0.89)

.7
2

-

-

-0.21 (-1.45,
1.03)

.73

-

-

-0.95 (-1.67, -0.23)

.01

-

-

-

-

-

-

-

-

-

-

-

-

1.7 (0.37, 3.04)

.02

0.03 (-0.31,
0.38)

-

-0.08 (-0.44,
0.28)

.6
7

-

-

-

-

-

-

0.057 (-0.35, 0.46)

.77

0.05 (-0.32, 0.43)

.77

0.03 (0.002, 0.07)
-0.16 (-0.34,
0.02)

.0
6
.0
8

.7
8
.0
7
.0
8

.76

-

0.56 (-0.15,
1.27)
0.03 (0.003, 0.07)
-0.16 (-0.34,
0.02)

0.06 (-0.33,
0.46)

-

-

.7
6
.6
5
.0
6
.0
8

-

.85

0.06 (-0.36,
0.49)
0.09 (-0.33,
0.52)
0.03 (-0.001,
0.07)
-0.16 (-0.33,
0.02)

.73

0.3 (-0.34, 0.94)

.34

-0.08 (-0.56, 0.41)

.75

.1

0.03 (-0.003, 0.06)

.07

0.03 (-0.01, 0.06)

.1

.1

-0.14 (-0.32, 0.03)

.1

-0.14 (-0.31, 0.02)

.09

Selection
stage.
Dependen
t variable:
Test
uptake
Insertive
Receptive
Versatile
Age
Income

0.03 (0.002,
0.06)
-0.16 (-0.32,
0.003)

.04
.05

0.07 (-0.36, 0.5)
0.03 (-0.01,
0.07)
-0.15 (-0.32,
0.03)
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Number
of male
partners
last three
months
Frequency
of
condomle
ss anal
intercours
e last three
months
HIV test
frequency
Previous
HIV test
Possible
sexually
transmitte
d infection
Symptoms
Nonspecific
disclosure
Versatile*
nonspecific
disclosure
Disclosure
to health
provider
Versatile*
disclosure
to health
provider

0.05 (-0.07,
0.17)

0.06 (-0.07,
0.18)

.3
6

0.05 (-0.07,
0.17)

.3
6

0.06 (-0.07,
0.18)

.3
5

0.06 (-0.07,
0.18)

-0.42 (-1.53,
0.7)
-0.003 (0.24, 0.23)

-0.42 (-1.53,
0.68)
-0.003 (-0.22,
0.21)

.00
3

1.03 (0.38,
1.67)

1.04 (0.41,
1.68)

.4
5
.9
8
.0
0
2

-0.41 (-1.56,
0.73)
-0.000 (0.22, 0.22)

1.01 (0.37,
1.65)

.4
4
.9
7
.0
0
3

.4
7

.94

-0.43 (-1.57,
0.7)
-0.004 (0.23, 0.22)

0.60 (-0.03,
1.23)

.06

0.6 (-0.09,
1.28)

.0
9

0.56 (-0.15,
1.27)

0.22 (0.19,
0.63)

.28

-

-

-

-

-

0.19 (-0.28,
0.66)

.42

-

-

-0.41 (-1.56,
0.73)
-0.01 (-0.21,
0.19)

.38

.46

.35

0.06 (-0.07, 0.18)

.37

0.06 (-0.06, 0.17)

.34

.44

-0.41 (-1.7, 0.89)

.53

-0.41 (-1.62, 0.81)

.5

.98

-0.009 (-0.22, 0.21)

.93

0.003 (-0.21, 0.22)

1

1.04 (0.38,
1.7)

1
.0
0
3

0.97 (0.36, 1.59)

.00
3

1.12 (0.5, 1.73)

.00
1

0.96 (0.33, 1.59)

.00
4

.1
2

0.62 (-0.05,
1.28)

.0
7

0.62 (-0.07, 1.3)

.07

0.63 (-0.06, 1.32)

.07

0.63 (-0.04, 1.3)

.07

0.24 (-0.23,
0.7)

.3
1

0.27 (-0.19,
0.73)

.2
4

-

-

0.09 (-0.52, 0.7)

.76

-

-

-

-

-

-

-

-

-

0.62 (-0.67, 1.9)

.33

-

-

0.11 (-0.45,
0.66)

.7

0.11 (-0.43,
0.64)

.6
8

-

-

0.21 (-0.33,
0.75)

.43

-

-

0.06 (-0.56, 0.68)

.85

-

-

-

-

-

-

-

-

-

-

0.61 (-1.03, 2.25)

.45
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Site
-site 2
-site 3

-0.61 (-1.18,
-0.03)
-0.18 (-0.59,
0.24)

.39

-0.69 (-1.93,
0.55)
-0.3 (-1.45,
0.84)

1.36 (0.71,
2.01)

<.
00
1

1.31 (0.57,
2.04)

.0
0
1

1.29 (0.52,
2.05)

.2
5

1.34 (0.61,
2.06)

.0
0
1

1.31 (0.59, 2.04)

.00
1

0.99 (0.32,
1.68)

.01

0.97 (0.18,
1.78)

.0
2

1.02 (0.27,
1.77)

.0
1

0.97 (0.2,
1.75)

.0
2

0.96 (0.17, 1.76)

.02

.04

.2
6

.2
5

.6

-0.7 (-1.93,
0.53)
-0.29 (-1.39,
0.82)

.6

-0.68 (-1.88,
0.53)
-0.28 (-1.41,
0.85)

.2
6
.6
1

-0.66 (-1.85,
0.54)
-0.28 (-1.4,
0.84)

.27

-0.68 (-1.87, 0.51)

.25

-0.66 (-1.56, 0.24)

.14

.61

-0.29 (-1.4, 0.82)

.6

-0.26 (-1.07, 0.56)

.53

1.38 (0.66, 2.09)

.00
1

1.3 (0.64, 1.97)

<.
00
1

1 (0.2, 1.8)

.02

0.95 (0.17, 1.737)

.02

Arm
-pay-itforward
-paywhat youwant

N
85
85
85
85
85
85
85
Note: Coefficients of probit with sample selection. Confidence interval (CI) estimated using jackknife with clustering by sites and within-site groups. Receptive: Compared to men who have sex with men not indicating
the receptive role, men who have sex with men indicating the receptive role are more likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test; Insertive: Compared to men who have sex
with men not indicating the insertive role, men who have sex with men indicating the insertive role are less likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test; Versatile: Compared to
men who have sex with men not indicating the versatile role, men who have sex with men indicating the versatile role have no gonorrhea and chlamydia test preference; Non-specific disclosure: Compared to those not
out to anyone, those out to someone are more likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test; Disclosure to health provider: Compared to those not out to their health provider,
those out to their health provider are more likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test; Versatile men who have sex with men-Non-specific disclosure: Compared to versatile
men who have sex with men not out to someone, versatile men who have sex with men who are out to someone (disclosed sexual identity) are more likely to select the rectal gonorrhea and chlamydia test, compared to
the urethral test; Versatile men who have sex with men-Disclosure to health provider: Compared to versatile men who have sex with men not out to their health provider, versatile men who have sex with men out to
their health provider are more likely to select the rectal gonorrhea and chlamydia test, compared to the urethral test.
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431 men were approached intending to test for HIV and syphilis. After exclusion criteria and
decision to participate, 301 men were enrolled, and sexually transmitted infection test uptake
was 40%. Seven men chose to get both tests and were dropped from the analysis. As I am
exploring whether sexual behavior is related to the choice of rectal over urethral testing, those
who took both tests were not a focus of the analysis. Forty-four % (50/114) chose the rectal
gonorrhea and chlamydia test and 56% (64/114) picked the urethral gonorrhea and chlamydia
test. Among the randomized controlled trial participants, 35% (187/288) had disclosed sexual
behavior to someone (non-specific disclosure) and 21% (59/288) of men had disclosed sexual
behavior to their health provider. Five men who have sex with men were diagnosed with
gonorrhea (urethral - two, rectal - three) and 19 with chlamydia (urethral - six, rectal - 13). I
present descriptive statistics in Table 1.
Using three separate models, I explored if men who have sex with men made a test choice in
line with their indicated sexual behavior. Table 2 indicated that receptive sexual behavior was
associated with 45.2% (95%CI=33.8, 56.5) increased likelihood for selecting a rectal test.
Insertive sexual behavior was related to 51.1% (95%CI=-58.7, -43.5) decreased likelihood for
selecting the rectal test. Finally, versatile sexual behavior was not significantly associated with
selecting a rectal test, possibly indicating that versatile men who have sex with men have no
preference for a rectal gonorrhea and chlamydia test.
I then explored disclosure and likelihood to select the rectal gonorrhea and chlamydia test.
Table 3 indicated that there was no significant relationship between non-specific disclosure or
disclosure to one's health provider and selecting a rectal gonorrhea and chlamydia test. Table
4 indicated that, for versatile men who have sex with men, non-specific disclosure was
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associated with a 26.8% (95%CI=6.1, 47.5) increased likelihood of selecting the rectal
gonorrhea and chlamydia test, compared to the urethral test. I also found that for versatile
men who have sex with men, disclosure to one's health provider was associated with a 29.4%
(95%CI=6.3, 52.6) greater likelihood for selecting the rectal gonorrhea and chlamydia test,
compared to the urethral test. These results were visualized in Figure 1, focusing on the
interaction effects between disclosure and versatile sexual behavior. While being versatile alone
was not significantly associated with rectal test uptake, once non-specific disclosure or
disclosure to health providers comes into the picture, the model suggested a large and
significant increase in rectal test uptake. Note that this was a marginal effect, controlling for
sociodemographics, sexual history and medical history relevant to sexually transmitted
infection testing.
Discussion
I first demonstrated that men who have sex with men selected tests in line with their preferred
sexual behavior. I then indicated that versatile men who have sex with men out to a nonspecific individual or one's health provider (outside the study context) had increased likelihood
for selecting the rectal gonorrhea and chlamydia test, compared to the urethral test. The
findings are in line with past research and reinforce the need to screen men who have sex with
men for sexually transmitted infections through a full scope of transmission routes, ensuring
no sexually transmitted infections are undiagnosed. I detailed how patient factors such as
sexual behavior and outness may affect gonorrhea and chlamydia test provision in a clinical
setting.
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Many men who have sex with men in the sample with indications for rectal sexually
transmitted infection testing did not receive it. This is consistent with research in China and
globally. A China-based study found a higher prevalence of rectal chlamydia infection (24.4%)
compared to urethral infection (5.3%).359 Similar findings were indicated in several other
studies, where rectal prevalence of sexually transmitted infections was greater than the urethral
prevalence.326 Other global studies indicated similar findings. Among asymptomatic men
screened for chlamydia, 9.8% were positive for rectal infection vs 2.3% for a urethral infection.
However, the same study reported higher prevalence of urethral gonorrhea (5.0%) vs rectal
gonorrhea (3.0%).360 Other studies indicated higher rates of rectal sexually transmitted
infection infections compared to urethral infections.361 Rectal sexually transmitted infections
were associated with an increased risk for HIV seroconversion.362 A retrospective men who
have sex with men cohort study found that greater than two prior rectal gonorrhea or
chlamydia infections were associated with eight times greater risk of HIV conversion. 328
Findings indicated there could be a large number of missed infections and underestimation of
sexually transmitted infection prevalence. Undetected and consequently untreated cases may
exacerbate the Chinese men who have sex with men sexually transmitted infection epidemic.363
I extended previous research suggesting the importance of rectal sexually transmitted infection
testing in men who have sex with men. Men who have sex with men in marginalized contexts
and resource limited settings may need to receive a combined rectal, urethral, and pharyngeal
gonorrhea and chlamydia test, as pharyngeal gonorrhea and chlamydia testing is also
recommended for men who have sex with men.364 However, when resources are scarce, as per
the study, stigma-free settings may allow for providing a single test most appropriate to sexual
behavior.
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Finally, I found that men who have sex with men who had disclosed their sexual behavior to
someone (non-specific disclosure) or their healthcare provider (outside the study context)
were more likely to select rectal sexually transmitted infection testing compared to urethral
testing. Past China research indicated that larger disclosure networks were associated with
greater propensity of HIV testing.308 Increased probability of never testing for HIV or syphilis
was associated with non-disclosure to anyone or health professionals.365 The odds of disclosure
to a healthcare professional was greater for men who have sex with men who had received a
sexually transmitted infection or HIV test.366 In global literature, disclosure to healthcare
providers was associated with HIV and sexually transmitted infection testing among young
men who have sex with men.367 Closeted men who have sex with men were less likely to have
tested for HIV compared to out men who have sex with men.306 Being completely out or even
disclosure to a healthcare provider is clearly key to receiving sexually transmitted infection and
HIV testing, as Chinese men who have sex with men often express fear of being ostracized
because of their sexual behavior, a common barrier preventing testing.368 When men who have
sex with men are given a choice between a rectal or urethral test, it is possible that patient
factors affect test selection decision. I extend the literature to suggest that disclosure can
improve testing outcomes.
Limitations
This work has limitations. First, other unmeasured factors, such as knowledge levels about
sexually transmitted infections and site of sexually transmitted infection symptom (urethral or
rectal), may have driven selection of the urethral gonorrhea and chlamydia test. I partially
addressed this by controlling for previous HIV test, HIV test frequency, and possible sexually
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transmitted infection symptoms in estimating the decision to test, but not the choice between
the tests (since these measures are not site specific). I also conducted the analysis including
education level as a control but excluded it from the final analysis due to near collinearity with
income. I did not consider how the psychological effects of testing would affect results.
Sexually transmitted infection testing can be viewed as a form of commitment in a
relationship369 or cause significant distress.370 Further work can model this through a survey
item or qualitative techniques. Second, the gonorrhea and chlamydia test randomized
controlled trial was conducted at sites catered to men who have sex with men sexually
transmitted infection testing. Such site selection may have limited analysis to men who have
sex with men connected with community-based organizations and already interested in HIV
testing.371 Despite limited generalizability to hospitals and other provider settings, the results
remain relevant since specialized community men who have sex with men clinics remain major
providers of testing in China372 and globally373 where patient factors drive health outcomes. As
participants would have to pay an additional amount to take both tests, it could be that some
selected a single test due to lack of funds. I utilized income as a control to account for this
concern. Due to resource limitations, I was unable to offer rectal and urethral testing to all
participants and then determine the number of mismatches between a positive test at a
particular site and sexual behavior (e.g. Men who have sex with men reporting insertive sexual
behavior but with a positive rectal test). Future research will incorporate such a study design.
Conclusion
Greater efforts are needed to ensure that patient factors do not adversely affect men who have
sex with men testing outcomes. Sexual behavior and outness may affect gonorrhea and
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chlamydia testing provision. Apart from clinicians, community-based efforts may reduce
stigma-based barriers to testing.
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Blocking and being blocked on gay dating apps: Implications for online sexual
health interventions from a study of Chinese men who have sex with men
This section is currently under review at Sexual Health, with Marcus Alexander and Laura
Forastiere et. al as co-authors.
Introduction
Although most men who have sex with men in China do not disclose their sexual orientation
to anyone,374 there is a rich and expanding digital social life for these men.375,376 The world’s
largest gay social networking app, Blued, is based in China and provides news, health services,
shopping, and gaming.375,376 Blocking, both being blocked and blocking someone, are in-app
antisocial ties produced when men who have sex with men use gay apps. Blocking someone
is when users select a function on an app to prevent another user from contacting them and
being blocked is when someone is prevented from contacting another user.377 Users may block
others because of harassment, lack of attractiveness, screening for time-wasters, racism,
perceived HIV risk, privacy and safety concerns.377–380 Blocking is associated with increased
anxiety, distress, isolation;377,378 and HIV risk.379 Blocking behaviors can cascade through social
networks381,382 and thus the correlates of blocking warrant future study. Moreover, while the
role of social networks in the spread of positive health-related behaviors is well
understood,383,384 less is known about how antisocial ties affect health. We note that blocking
is not always antisocial, but can be protective of abusive or harassing behavior.379
App-based health interventions among men who have sex with men are becoming increasingly
common,385,386 but several features on such apps, such as blocking, and their public health
implications are not well understood. Such understudied features may have unintended
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consequences on men who have sex with men sexual networks and HIV risk.379 While studies
on blocking and men who have sex with men health outcomes have been conducted in other
nations, albeit limited and mostly using qualitative techniques,378,379 no such study has been
conducted in China, despite its large men who have sex with men population56 and relationship
between Chinese men who have sex with men gay app use and health outcomes.387 I
characterized the determinants of blocking among Chinese men who have sex with men, to
better understand blocking and its association with health outcomes. As Chinese men who
have sex with men are a marginalized community, understanding potential correlates of
marginalization is key to mitigating reduced health outcomes.
Methods
Study design and participants
I conducted a quasi-experimental study among men who have sex with men in Guangzhou,
China that sought to promote male partner testing through social network-based distribution
of HIV self-test kits in a cohort study, where index participants were offered HIV self-test kits
and asked to distribute kits to their social network alters. Alters are index men’s social contacts
who received HIV self-testing kits. Men who have sex with men were recruited from May
2019 to December 2019 through a social media account run for men who have sex with mencentric studies via advertisements within the account, and through a men who have sex with
men-friendly clinic at the Guangdong Provincial Center for Skin Diseases and Sexually
Transmitted Infection Control via approaching participants who came for sexually transmitted
infection testing. Men who have sex with men were first recruited for the treatment arm and
once recruitment for the treatment arm had been completed, men who have sex with men
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were recruited for the control arm. Participants interested in HIV testing at the clinic could
book appointments online or enroll in the study at the clinic. Men who have sex with men
were screened for the following criteria: 1) aged ≥ 18 years; 2) born biologically male; 3) ever
had sex with men; 4) willing to provide phone number and willing to be surveyed at baseline
and follow-up. Eligible participants were provided with study information, such as, potential
risks, benefits, procedures, and outcomes. Participants unable to provide informed consent
were excluded. A baseline survey was administered to eligible participants via a QR code they
could scan and thereby complete the survey on their mobile device.
Survey items
I collected participants’ baseline data such as, sociodemographic characteristics, sexual
behavior, HIV testing history, social network data and blocking behavior (survey instrument
in Appendix). Survey instrument was not validated but had been used multiple times in past
studies.321,334,388 Sexual behavior items included number of male partners in the last three
months, and main sexual role. Examples of sexual behavior items were: In the past three
months, with approximately how many different male sexual partners did you have anal sex?;
your main sexual role is (pick one) insertive/receptive/both. To represent sexual behavior
disclosure to family and medical professional, I used the following item: If you have told others
about your sexuality or sexual history with men, who are they?. This item had the following
options: medical professionals; family members; friends with no sexual relationship;
coworkers; employers; other. I recoded the medical professionals option into a binary variable
representing sexual behavior disclosure to medical professionals. I similarly recoded the family
members option to a binary variable representing sexual behavior disclosure to one’s family.
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Social network survey items included name generator and descriptor questions to measure
degree (number of people whom you have a social tie to) and weighted degree (degree
weighted by the frequency of contact).389 Degree was based on the sum of people listed in the
question: Besides your family members, who are the people you spend your free time with?
(list up to five). For example, if someone listed four people to the indicated question, their
assigned degree was four. Weighted degree was based on the following item: How often do
you contact the indicated person? This item had the options: Once a year; once every 6
months; once a month; once a week; daily. I treated this as an ordinal variable (scale of 1-5)
and summed the item across each alter listed in the degree question. For example, if someone
had a degree of four and contacted each person once a month, the weighted degree was
3+3+3+3=12. These items were based on validated instruments used to measure social
network characteristics.389
Blocking items included likelihood of engaging in blocking, both directed (blocking someone
or getting blocked) and undirected (blocking someone or getting blocked were treated
collectively as undirected blocking behavior. 0=participant neither was blocked or blocked
someone, 1=participant blocked someone or was blocked), and level of distress caused by
being blocked (see below for details). The time frame for all blocking items was since inception
i.e. Had men ever blocked someone? Examples of questions were: Have you ever blocked
someone on a Blued?; Have you ever been blocked by someone else on Blued?. I did not ask
why participants blocked someone e.g blocking someone was not necessarily a response to
being blocked, harassed, or stigmatized. To identify the distress of being blocked in relation
to other life events, I used the Gay Life Events Scale,390 where participants had to rate being
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blocked in relation to a serious illness. With the Gay Life Events Scale, I compared being
blocked to events such as: You were harassed because you were gay; you find out your partner
has AIDS; you failed an important exam; you had to work more hours in the office.
Ethical review
Participant anonymity was maintained during the entire project. No identifying information
was collected. Institutional Review Board approval was obtained from the Dermatology
Hospital of Southern Medical University (GDDHLS-20180503) and the University of North
Carolina at Chapel Hill (18-1358).
Statistical analysis
I calculated descriptives (Table 1) using data obtained from all men who have sex with men
surveyed. I modeled blocking behavior (undirected blocking behavior, blocking someone,
being blocked) using multivariate logistic regression and reported adjusted odds ratio estimates
for each independent variable. Covariates represented sexual behavior (sexual role, number of
male partners in the past three months, condom use, disclosure of men who have sex with
men sexual behavior to family, disclosure of men who have sex with men sexual behavior to
medical professional, prior HIV test), participant social network structure (degree, weighted
degree), and sociodemographic categories (income, age). The Income variable was
denominated in the survey as RMB/month and I converted it to USD/year for clarity. Degree
and weighted degree were calculated as indicated in the Survey Items section, and all other
variables were used unaltered from the survey instrument. Analysis was conducted in R.217
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Missing data
There was significant missing data on sexual role, condom use, number of social ties, and
number of sexual partners so I did not use these as control variables for regression analyses.
There was also significant missing data on variables used in our analysis, constraining the
dataset. Complete case analysis was used as this technique generally remains unbiased, attains
precision similar to or superior to multiple imputation, and has high statistical coverage when
data is missing at random, as per this dataset.
Results
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Table 1: Participant characteristics for 208 Chinese men who have sex with men, collected in a quasi-experimental study in Guangzhou,
China
Variable

Mean (SD)

Age

27.9 (7.1)

Number of male partners in the past three months 1.7 (1.1)
Degree

2.3 (1.1)

Weighted degree

8.5 (4.2)
%

Yearly income (USD/year)
Less than USD36,000

20.7

USD36,000 - USD72,000

35.1

USD72,000 - USD120,000

30.8

More than USD120,000

13.5
n=208

Condom use
Never used

5.7

Occasionally (Less than half of the time)

7.4

Often used (More than half of the time)

24.6

Every time

62.3
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n=122
Sexual behavior disclosure to family
Yes

22.9

No

77.1
n=166

Sexual behavior disclosure to medical professional
Yes

66.3

No

33.7
n=166

Prior HIV test
Yes

83.7

No

16.4
n=208

Sexual role
Insertive

42.6

Receptive

20.5

Versatile

36.9
n=122

Undirected blocking behavior
Yes

74.6

No

25.4

143

n=181
Blocked by someone
Yes

46.4

No

53.6
n=181

Blocked someone
Yes

62.4

No

37.6
n=181
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Table 2: Comparative distress from being blocked by someone, for 208 Chinese men who have sex with men, collected in a
quasi-experimental study in Guangzhou, China.
Variable

Mean (SD)

Comparative distress from being blocked by someone a
Harassed because you were gay

6.1 (6.1)

Partner has AIDS

11.7 (8.0)

Failed an important exam

10.0 (6.5)

Had to work more hours in the office
7.3 (5.8)
Note: A Being blocked by someone has been given a value of 10 on a scale of 0 (no emotional distress) to 20 (maximum emotional distress).
If the event is more distressing, participants chose a number more than 10, and less than 10 if otherwise. If equal in distress, they chose the
number 10.
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Table 3: Multivariate analysis of blocking among 208 Chinese men who have sex with men, collected in a quasi-experimental
study in Guangzhou, China
adjusted odds ratio
adjusted odds ratio
adjusted
odds
Variable
(95% CI) a
P
(95% CI)
P
ratio (95% CI)
P
Undirected blocking
Blocked
by
behavior
Blocked someone
someone
Income

1.02 (0.33, 1.71)

0.004

1.84 (1.21, 2.46)

p<0.001 0.71 (0.06, 1.36)

0.033

Age

0.98 (0.87, 1.09)

p<0.001 0.95 (0.87, 1.03)

p<0.001 1.02 (0.92, 1.11)

p<0.001

Insertive

-

-

-

-

-

-

Receptive

0.20 (1.26, 2.77)

0.817

0.72 (-0.50, 1.93)

0.249

0.40 (-0.86, 1.65)

0.534

Versatile
0.10 (-1.42, 1.52)
Number of male partners in the past
three months
2.02 (1.26, 2.77)

0.903

0.33 (-0.79, 1.44)

0.566

0.14 (-1.00, 1.29)

0.806

p<0.001 1.10 (0.62, 1.56)

p<0.001 1.87 (1.29, 2.46)

p<0.001

Condom use

0.97 (0.30, 1.64)

0.005

0.79 (0.19, 1.39)

0.010

0.82 (0.23, 1.41)

0.007

Degree

1.05 (-0.22, 2.32)

0.106

2.01 (0.92, 3.11)

p<0.001 1.29 (0.20, 2.40)

0.021

Weighted degree

1.05 (0.73, 1.37)

p<0.001 0.83 (0.56, 1.10)

p<0.001 0.90 (0.62, 1.17)

p<0.001

Sexual behavior disclosure to family
2.66 (1.28, 4.04)
Sexual behavior disclosure to medical
professional
1.35 (0.21, 2.50)

p<0.001 1.52 (0.44, 2.59)

0.006

1.67 (0.53, 2.80)

0.005

0.021

1.52 (0.50, 2.55)

0.004

1.06(0.00, 2.12)

0.051

Prior HIV test

1.98 (0.09, 3.87)

0.040

1.69 (0.11, 3.27)

0.037

7.90 (5.86, 9.95)

p<0.001

Intervention

1.82 (0.68, 2.98)

0.002

1.77 (0.80, 2.75)

p<0.001 1.15 (0.11, 2.18)

N

94

Sexual role

94

0.031

94
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Note: I estimated all adjusted odds ratios with logistic regression models. Adjusted Odds Ratios account for intervention assignment. Adjusted
odds ratio=adjusted odds ratio.
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Sociodemographic characteristics
Two hundred and eight men who have sex with men enrolled in the study. I conducted
complete case analysis on a final sample of 94 men who have sex with men. I presented
descriptive statistics in Table 1. Men who have sex with men had a mean age of 27.9 years
(SD=7.1) and mean of 1.7 (SD=1.1) sexual partners in the last three months. Participants had
a mean of 2.3 social ties (SD=1.1) and a mean weighted degree of 8.5 (SD=4.2). Men who
have sex with men generally fell into two yearly income groups: USD36,000 - USD72,000
(35.1%) and USD72,000 - USD120,000 (30.8%). In the last three months, most men who have
sex with men (62.3%) used condoms every time during anal sex with men. Most had not
disclosed sexual behavior to their family (77.1%) but had disclosed sexual behavior to their
medical professional (66.3%). Most had a prior HIV test (83.7%) and an insertive main sexual
role (42.6%). Blocking was a common behavior. Most men who have sex with men (75%) had
engaged in undirected blocking behavior in their lifetime i.e. They had blocked someone or
had been blocked. About 62% had blocked someone in their lifetime and 46% had been
blocked in their lifetime. Data was not collected on recent blocking e.g. six months.
Using an instrument derived from Gay Life Events Scale, I identified the distress of being
blocked in relation to other life events (see Table 2). Being blocked seemed similar in distress
to failing an important exam, but more distressing than getting harassed for being gay or
having to work more hours in the office.
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Multivariate analyses of blocking correlates among Chinese men who have sex
with men
Men who used condoms were 21% (adjusted odds ratio= 0.79, 95%CI=0.19, 1.39) less likely
to block someone and 18% (adjusted odds ratio=0.82, 95%CI= 0.23, 1.41) less likely to get
blocked. Men with more social ties were more likely to block someone and get blocked. Each
additional social tie increased the chance of blocking someone by 101% (adjusted odds
ratio=2.01, 95%CI=0.92, 3.11) and the chance of being blocked by 29% (adjusted odds
ratio=1.29, 95%CI= 0.20, 2.38). Older men were more likely to get blocked (see Table 3).
Each year increase in age was associated with a 2% increase in getting blocked (adjusted odds
ratio=1.02, 95%CI= 0.92, 1.11).
Discussion
I found that blocking other men was common on gay social media apps and getting blocked
was as distressful as failing an exam (see Table 2). Men using condoms blocked less and were
less likely to get blocked. Men with more social ties, such as friends or co-workers, were more
likely to block someone and get blocked. Older men were more likely to be blocked compared
to younger men. There is limited empirical research on blocking,378,379 and none on the public
health implications of blocking. Blocking is likely associated with men who have sex with men
HIV risk379 and other health outcomes but its correlates are unclear. Moreover, studies on
blocking are predominantly conducted in high income nations, but not in low- and middleincome nations such as China, where there is a large men who have sex with men HIV
burden.391
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Getting blocked was as distressful as failing an exam. Past research related blocking to mental
distress among men who have sex with men.392,393 Mental distress is related to reduced health
outcomes,394 indicating the importance of studying blocking.
Men using condoms blocked less and were less likely to get blocked. Findings suggest a
mechanism by which online behaviors related to blocking could impact social and sexual
networks. Those who block less may feel the need to use condoms more frequently, with the
same men who have sex with men viewing reduced blocking and increased condom use as
morally appropriate behaviors.395
Men with more social ties, such as friends or co-workers, were more likely to block someone
and get blocked. Past work indicated that having more social ties was associated with a greater
amount of negative social ties.396 I expand on previous work by detailing a similar relationship
within a men who have sex with men sample. Having many friends is related to more negative
social ties on other online networks,397 which may explain the findings. While having more
friends is related to improved health,398 increased social ties may be linked to negative
outcomes on gay apps. Larger online and offline men who have sex with men social networks
were associated with risky sexual behavior,399 and blocking may also be a similar negative
consequence of a larger network.
Older men were more likely to be blocked compared to younger men. Past work suggested
that older men were not preferred on gay dating apps,377,393 younger men who have sex with
men were more likely to use such apps,400,401 and there was some preference on apps for
contacting men in the same age group.393 Blocking could be used to select potential partners
by attractiveness,378 and with age being a barometer of attractiveness among men who have
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sex with men,402 older men who have sex with men may be blocked for perceived
unattractiveness. Alternatively, given the preference for same age partners, 393 the age gap
between men who have sex with men may result in younger men blocking older men.
Overall, with more detailed epidemiological data, I suggest that future work expand on the
indicated correlates of blocking. While I am uncertain on the direction of causality, designing
interventions on gay dating apps to target certain behaviors and demographic groups may
minimize blocking. An example of such an intervention may be sanctioning users who block
excessively within a certain time frame, a technique previously used on social media to reduce
racism.403 By curtailing blocking, we may be able to reduce risky sexual behaviors and improve
health outcomes among subsets of men who have sex with men.378,379 On the policy front, I
suggest that regulatory organizations ensure that blocking on gay dating apps does not facilitate
increased men who have sex with men HIV risk.
Limitations
Unmeasured factors, such as time of blocking event and reciprocal blocking may have driven
the results. I did not ask why participants blocked someone e.g blocking someone was not
necessarily a response to being blocked. Participants might have reported lower amounts of
blocking than experienced, especially since men may not know if they were blocked. I was
unable to control for such effects but plan future study to use data drawn directly from apps
rather than relying on participant self-report. I did not ask participants why they engaged in
blocking and future qualitative work can detail the underlying factors behind blocking. The
high rate of missing data may have biased the results, and future research can ensure a higher
response rate using techniques such as emailing follow-ups and a providing a larger cash
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incentive. Data was collected at sites catered to men who have sex with men sexually
transmitted infection testing. Such site selection may have limited the sample to men who have
sex with men connected with community-based organizations and perhaps biased the results.
Conclusions
Blocking other men was common on gay social media apps and getting blocked was as
distressful as failing an exam. Age, condom use, and number of social ties may be associated
with antisocial behavior, with implications for the design of online sexual health interventions.
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Improving HIV Self-testing Social Network Interventions: The Role of Sexual
Behavior Disclosure among Chinese Men who have Sex with Men
This section has been published as: Kumar N, Forastiere L, Janmohamed K, et al. Improving
HIV Self-testing Social Network Interventions: The Role of Sexual Behavior Disclosure
among Chinese Men who have Sex with Men. AIDS Behav. 2020.
Introduction
There is growing evidence to support social network-based interventions for sexual
minorities.308,404 Social network characteristics and structures influence individual-level
behavior and HIV transmission.300,405 Thus, social network analysis is key to HIV interventions.
Social network analysis can identify intervention targets and pathways,406 and has been used to
detail the relationship between social networks and HIV prevention behavior, like condom
use.407 Several studies also related social network analysis to HIV testing. In a study of
undiagnosed HIV-infected individuals in the United States, researchers used social networks
to achieve a 5% positivity rate.408 In a Chinese study of men who have sex with men, those
with a larger same-sex disclosure network were more likely to have received HIV testing.308 To
further improve social network-based HIV testing, some studies combined social network
analysis with HIV self-testing, successfully implemented globally.409,410 HIV self-testing is
where individuals self-collect specimens and then conduct and read tests themselves.411 HIV
self-testing may overcome issues around low testing rates, especially among men who have
sex with men, via increasing privacy, convenience and anonymity.412,413
While social network-based interventions are important to mitigate the spread of HIV, it is
not clear how we can optimize such interventions.300 There also remain several issues with
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social network HIV-testing. For example, most studies tend to be conducted in high-income
nations,300 despite the HIV burden being mostly in low- and middle-income countries.414 In
addition, many studies tend to be unlinked (where the relationship between members in the
social network is unknown),415 with a need for more data on linked HIV testing distribution
networks, possibly improving HIV surveillance and testing efforts.416
About half of Chinese men who have sex with men had never received HIV testing and 62%
had not been tested in the past year.372 HIV self-testing augmented by social network
techniques, may expand HIV testing among men who have sex with men.324 When conducting
social network-based HIV self-testing interventions among men who have sex with men, the
characteristics of the initial participant, also called seed or index participant, are important, as
some index participants are better able to reach alters for testing compared to others.417 Alters
are index men’s social contacts who receive HIV self-testing kits. Disclosure of men who have
sex with men sexual behavior is positively associated with both HIV testing uptake387,418,419 and
referral of alters to testing among Chinese men who have sex with men.420 Disclosure of sexual
behavior may thus relate to index men who have sex with men HIV self-testing kit
distribution.
In partnership with a larger team, I conducted a quasi-experimental study among men who
have sex with men in Guangzhou, China, that evaluated the use of HIV self-testing in testing
men who have sex with men alters for HIV. Index men who have sex with men were provided
HIV self-testing to distribute to their alters. Alters could upload test results through an online
system monitored by the research team. The purpose of this analysis was to examine the
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relationship between index sexual behavior disclosure and the number of HIV self-testing kits
distributed and completed.
Methods
Study design and participants
The parent quasi-experimental study conducted among men who have sex with men in
Guangzhou, China sought to promote male partner testing through social network-based
distribution of HIV self-testing kits, where index participants were offered HIV self-test kits
and asked to distribute kits to their social network alters. Men who have sex with men were
recruited from May 2019 to December 2019 through a social media account run for men who
have sex with men-centric studies via posts within the account, and through a men who have
sex with men-friendly clinic at the Guangdong Provincial Center for Skin Diseases and
Sexually Transmitted Infection Control via approaching participants who came for sexually
transmitted infection testing.
Participants interested in HIV testing could book appointments online or enroll at the clinic.
Men who have sex with men were screened for the following criteria: 1) aged ≥ 18 years; 2)
born biologically male; 3) ever had sex with men; 4) willing to provide phone number and
willing to be surveyed at baseline and follow-up. Eligible participants were provided with study
information, such as, potential risks, benefits, procedures, and outcomes. A baseline survey
was administered to eligible participants via a QR code they could scan and thereby complete
the survey on their mobile device.
Upon survey completion within the treatment arm, participants were given up to five HIV
self-test kits and encouraged to distribute the kits to their social network over one
155

month. Instruction materials were included with each kit. Participants could return for more
kits and received RMB20 ($3) for baseline survey completion. Tests included instructions and
a list of Centers for Disease Control and Prevention clinics where confirmatory testing could
be sought. The alter of each index participant received RMB20 ($3) when they uploaded the
test result to study team through an online system. The online system was a platform where
participants could upload HIV self-testing results. Alters were aware that they would receive
money upon test report. Each participant received RMB20 ($3) when his alters submitted the
test result.
Survey items
I collected participants’ data such as: sexual behavior disclosure; treatment arm outcomes;
socio-demographic characteristics; previous HIV testing history; number of social ties. Sexual
behavior disclosure items included whether the participants had disclosed their sexual
behavior to their family or healthcare providers. The survey item for sexual behavior disclosure
was: If you have told others about your sexuality or sexual history with men, who are
they? This item had the following options: medical professionals; family members; friends
with no sexual relationship; coworkers; employers; other. I recoded the medical professionals
option into a binary variable representing sexual behavior disclosure to healthcare providers.
I similarly recoded the family members option to a binary variable representing sexual
behavior disclosure to one’s family. I used three treatment arm outcomes, as
follows. Successful receipt of test results uploaded by alters was a binary variable (0=alters of
an index did not upload any test results from the HIV self-testing kits given to that index; 1=at
least one alter of the index uploaded a test result). Number of kits requested by index
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participant was a count variable representing the number of HIV self-testing kits each index
received-index participants could obtain additional kits if they wanted. Number of test results
successfully uploaded by alters was a count variable indicating the number of test results
uploaded by the alters of an index. Previous HIV testing history item was: Prior to this selftest, have you tested for HIV before? Number of social ties was based on the sum of people
listed in the question: Besides your family members, who are the people you spend your free
time with? (list up to five). For example, if someone listed four people for the indicated
question, their assigned number of social ties was four.
Ethical review
Participant confidentiality was maintained during the entire study. No identifying information
was collected. Institutional Review Board approval was obtained from the Dermatology
Hospital of Southern Medical University (GDDHLS-20180503) and the University of North
Carolina at Chapel Hill (18-1358).
Statistical analysis
I calculated descriptives (Table 1) using data obtained from all men who have sex with men
surveyed in the treatment arm. I used logistic regression for analyzing successful receipt of test
results uploaded by alter, and negative binomial regression models for number of kits
requested by index participant and number of test results successfully uploaded by alters. I
used forms of sexual behavior disclosure (disclosure to family, disclosure to healthcare
provider) as key independent variables. All models included socio-demographic characteristics
(age, income) and HIV testing history (prior HIV test) as control variables, reporting adjusted
odds ratios or adjusted incidence rate ratios for each independent variable. Income variable
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was denominated in the survey as RMB/month and I converted it to USD/year for clarity.
Analysis was conducted in R.

Fig 1. Self-reported social ties of index men who have sex with men collected from
the treatment arm of a quasi-experimental study in Guangzhou, China for 106
Chinese men who have sex with men (index), and 143 Chinese men who have sex
with men (alters) reached by index participants. Numbers (1-106) correspond to 106
index participants who initiated HIV self-testing distribution (see Table 1 for characteristics
of index and alters). Index men who have sex with men are ordered from top to bottom
based on number of social ties reported.
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Table 1: Participant characteristics for 106 Chinese men who have sex with men
(index), collected from the treatment arm of a quasi-experimental study in
Guangzhou, China, and 143 Chinese men who have sex with men (alters) reached by
index participants
Index
Alter
Variable

Mean (SD)

Mean (SD)

Age

27.0 (5.3)

24.1 (5.0)

Number of male partners in the past 6 months

1.9 (1.2)

1.6 (1.0)

Number of social ties

2.3 (1.1)

1.3 (0.6)

%

%

Yes

69.0

32.1

No

31.0

67.9

n=84

n=84

Sexual behavior disclosure to healthcare provider

missing=21%
Sexual behavior disclosure to family
Yes

23.8

8.9

No

76.2

91.1

n=84

n=79

missing=21%
Yearly income (USD/year)
Less than USD36,000

23.6

39.4

USD36,000 - USD72,000

34.0

29.2

USD72,000 - USD120,000

32.1

20.4

More than USD120,000

10.4

10.9

n=106

n=137

missing=0%
Sexual role
Insertive

47.7

35.8

Receptive

23.1

35.8

Versatile

29.2

28.3

n=65

n=53

missing=40%
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Condom use
Never used

4.6

7.5

Occasionally (Less than half of the time)

9.2

9.4

Often used (More than half of the time)

21.5

20.8

Every time

64.6

62.3

n=65

n=53

missing=40%
Prior HIV test
Yes

78.3

68.6

No

21.7

31.4

n=106

n=137

missing=0%
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Table 2: Multivariate analysis of sexual behavior disclosure and successful receipt of
test results uploaded by alters, for 106 Chinese men who have sex with men (index),
collected from the treatment arm of a quasi-experimental study in Guangzhou, China
Variable

adjusted odds ratio1 (95%
CI)
P

Sexual behavior disclosure to family
3.59 (2.00, 4.78)
Sexual behavior disclosure to healthcare
provider
1.33 (0.20, 2.45)

p<0.001

Age

0.90 (0.81, 1.00)

p<0.001

Income

1.89 (1.29, 2.45)

p<0.001

Prior HIV test

0.90 (-0.54, 2.33)

0.220

N

94

1

0.021

I estimated all adjusted odds ratios with logistic regression models. Adjusted Odds Ratios
account for baseline age, income, and prior HIV test. Adjusted odds ratio=adjusted odds
ratio.
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Table 3: Multivariate analysis of sexual behavior disclosure and treatment arm
outcomes for 106 Chinese men who have sex with men (index), collected from the
treatment arm of a quasi-experimental study in Guangzhou, China

Variable

Adjusted
incident risk
ratio1 (95% CI) P
Number of kits
requested by
index participant

Adjusted
incident risk
ratio (95% CI)
Number of test
results
successfully
uploaded by
alters

P

Sexual behavior disclosure to family 1.46 (1.18, 1.73)
Sexual behavior disclosure to
healthcare provider
0.90 (0.61, 1.20)

p<0.001

2.87 (2.13, 3.61)

p<0.001

p<0.001

1.33 (0.54, 2.13)

0.001

Age

0.99 (0.97, 1.01)

p<0.001

0.93 (0.86, 0.99)

p<0.001

Income

1.03 (0.89, 1.18)

p<0.001

1.53 (1.12, 1.94)

p<0.001

Prior HIV test

0.97 (0.59, 1.34)

p<0.001

1.35 (0.24, 2.47)

0.018

N
78
78
I estimated all adjusted incident rate ratios with negative binomial regression. Adjusted
incident rate ratios account for baseline age, income, and prior HIV test.
1

Missing data
There was significant missing data on sexual role, condom use, number of social ties, and
number of sexual partners so I did not use these as control variables for regression analyses.
There was also significant missing data on variables used in our analysis, constraining the
dataset. Complete case analysis was used as this technique generally remains unbiased, attains
precision similar to or superior to multiple imputation, and has high statistical coverage when
data is missing at random, as per this dataset.
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Results
Sociodemographic and behavior characteristics
A hundred and six index men who have sex with men enrolled in the treatment arm and 143
men who have sex with men alters successfully uploaded their test results. I presented
descriptive statistics in Table 1. Index men who have sex with men had a mean age of 27.0
years (SD=5.3), mean of 1.9 (SD=1.2) sexual partners in the last six months and mean of 2.3
(SD = 1.1) social ties. Index men who have sex with men generally fell into two annual income
groups: USD36,000 - USD72,000 (34.0%) and USD72,000 - USD120,000 (32.1%). In the last
three months, most index men who have sex with men (64.6%) reported using condoms every
time during anal sex with men. Most index men who have sex with men had a prior HIV test
(78.3%) and had an insertive main sexual role (47.7%). About 24% of index men who have
sex with men had disclosed their sexual behavior to their families and 69% to healthcare
provider. Overall, index men who have sex with men had higher disclosure of men who have
sex with men sexual behavior compared to their alters. For alters, 9% had disclosed their
sexual behavior to their families, and 32% to their healthcare provider. Index men had a
greater mean number of social ties compared to their alters, contradicting the friendship
paradox.421
Index men who have sex with men social ties
I detailed the self-reported social ties of index men who have sex with men (see Figure 1). All
index men who have sex with men who reported ≥four social ties had disclosed their sexual
behavior to their family and/or healthcare provider. Based on this observation, a larger selfreported social network may be positively related to sexual behavior disclosure.
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Index men who have sex with men HIV self-testing kit distribution
characteristics
Index men who have sex with men who disclosed their sexual behavior to their family or
healthcare provider were 259% (adjusted odds ratio=3.59, 95%CI= 2.40, 4.78, p<.001) or
33% (adjusted odds ratio=1.33, 95%CI= 0.20, 2.45, p=.021) more likely to have alters upload
completed test results, respectively (see Table 2). Index men who have sex with men who
disclosed their sexual behavior to their family were more likely to request (adjusted incident
rate ratio=1.46, 95%CI= 1.18, 1.73) a larger number of HIV self-testing kits (see Table 3).
Similarly, index men who disclosed their sexual behavior to their family (adjusted incident rate
ratio=2.87, 95%CI= 2.13, 3.61, p<.001) or healthcare provider (adjusted incident rate
ratio=1.33, 95%CI= 0.54, 2.13, p=.001) were more likely to yield an increase in number of
test results successfully uploaded by alters.
Discussion
I found that index men who have sex with men who disclosed sexual behavior tended to
request more HIV self-testing kits and yield an increase in completed tests by alters. Previous
work on HIV self-testing kit distribution applied social network techniques to improve kit
uptake,422 but there is limited empirical research on selecting index men who have sex with
men to optimize testing coverage. The strength of this study is that I measured the actual
number of HIV self-testing kits collected by index men who have sex with men and alters’
submitted test results, instead of relying on self-report. Such outcome measurement is key to
demonstrating the importance of selecting index participants who have disclosed their men
who have sex with men sexual behavior, thus optimizing interventions.
164

Men who have sex with men who disclosed their sexual behavior tended to request multiple
HIV self-testing kits. In the United States and China, men who have sex with men disclosure
was associated with increased HIV testing.367,423 While studies related disclosure to increased
HIV testing, there is limited research around behavior disclosure and HIV self-testing kit
request. Findings indicated that index men who have sex with men who had disclosed their
sexual behavior tended to have a larger social network,337 possibly explaining why they
requested more kits.
men who have sex with men who disclosed sexual behavior were more likely to have alters
upload completed tests. As above, United States and China research indicated that disclosure
was related to increased HIV testing,367,423 but there was limited work on behavior disclosure
and alters completing tests. It may be that men who have sex with men who had disclosed
sexual behavior sought those who had not disclosed their sexual behavior, to provide
support,424 perhaps influencing alters to upload completed tests.
A few index men who have sex with men were responsible for most alters’ completed tests.
Similar research among United States men who have sex with men indicated that some men
who have sex with men reached most of the alters for HIV testing.425 Among Chinese men
who have sex with men, most alters were reached by a handful of index men who have sex
with men.426 I provide further insight around social network interventions in LMICs, indicating
that such interventions may need to be designed around a select group of index participants
to optimize testing coverage.
To optimize testing coverage within HIV testing social network interventions, I suggest that
men who have sex with men who have disclosed their sexual behavior be selected as index
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participants, as they may obtain more HIV self-testing kits and result in more completed tests
by alters. Future work can expand on the use of other characteristics to improve upon social
network-based HIV testing interventions. On the policy arc, reducing the stigma around sexual
behavior disclosure in China427 may aid overall HIV self-testing use rates.
Limitations
I did not ask participants the reasons for sexual behavior disclosure and future research can
detail underlying factors. Data was collected at sites catered to men who have sex with men
sexually transmitted infection testing. Such site selection may have limited the sample to men
who have sex with men connected with community-based organizations and perhaps more
likely to engage in sexual behavior disclosure, as indicated by the sample’s greater levels of
sexual behavior disclosure to healthcare providers, compared to past research (16.3%).366 The
high rate of missing data may have biased the results, and future research can ensure a higher
response rate using techniques such as emailing follow-ups and a providing a larger cash
incentive.
Conclusions
Index men who have sex with men who disclosed sexual behavior tended to request more
HIV self-testing kits. Similarly, index men who disclosed their sexual behavior tended to yield
an increase in number of test results successfully uploaded by alters. Findings have
implications for the development of social network-based interventions for key populations.
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Conclusion: Chapter Two
I first described factors associated with contribution amounts in a gonorrhea and chlamydia
testing program for men who have sex with men. Expression of altruism may be linked to
certain sexual behaviors and can promote contributions toward public health initiatives
especially in stigmatized settings. I then detailed the association between men who have sex
with men community-centric behaviors and contribution towards another’s sexually
transmitted infection testing cost. I found that increased support for community-centric
behaviors was associated with greater pay-it-forward contribution in the sexually transmitted
infection testing environment. I suggested that community-centric behaviors may be
associated with a reduction in testing service cost that would otherwise be associated with fees.
I then evaluated whether men who have sex with men selected a sexually transmitted infection
test (urethral vs rectal) appropriate for their sexual behavior (insertive and/or receptive role in
anal sex). I proposed that not disclosing sexual identity to treatment providers may lead to
missed diagnoses and under-reporting of men who have sex with men rectal sexually
transmitted infections. I also detailed the correlates of antisocial behavior on the world's largest
gay dating app among Chinese men who have sex with men. I suggested that age, condom
use, and number of social ties may be associated with antisocial behavior, with implications
for the design of online sexual health interventions. Finally, I assessed if same-sex sexual
behavior disclosure of Chinese men who have sex with men was related to number of HIV
self-testing kits requested, and number of test results successfully uploaded by alters in a
network-based HIV self-testing intervention. Findings had implications for the development
of network-based interventions for key populations.
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Stigma is common among Chinese men who have sex with men,428 often leading to reduced
participation in HIV/AIDS and other sexually transmitted infection testing programs.428 While
stigma and other systemic factors reduce test uptake, findings seem to indicate that men who
have sex with men do participate in testing and can aid peers in getting tested. Even in
environments that are inimical to a men who have sex with men identity, men who have sex
with men still seek testing and encourage others to do so. Such findings are encouraging on
two fronts. Firstly, despite systemic factors eroding the agency that marginalized communities
face, marginalized populations still find ways to mitigate poor health outcomes. Given the risk
borne from an environment hostile toward men who have sex with men,429 men engage in
altruistic behaviors toward each other. Secondly, the cohesiveness and reacquiring of agency
in the men who have sex with men environment could act as a platform for other marginalized
communities. For example, almost half of United States HIV infections are concentrated in
the Black community.430 Black populations in the United States have faced poorer health
outcomes431 and discrimination,432 but even in such environments, Black faith leaders may
increase uptake of HIV prevention strategies.433 Such strategies are relatively novel in Black
communities and perhaps drawing lessons from the Chinese men who have sex with men
environment could produce synergies that reduce risk and thus alleviate poor health outcomes
in a range of marginalized communities.
Even in the Chinese men who have sex with men environment where being out can result in
reduced wellbeing,434 findings indicate that disclosure of sexual identity seems to improve
sexually transmitted infection testing outcomes. These results suggest that a more supportive
environment for Chinese men who have sex with men may relate to better health outcomes.
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In addition, while the studies were conducted in men who have sex with men-friendly
environments, there was stigma around certain men who have sex with men roles or identities.
Thus, support is likely essential to men who have sex with men both in the broader public
space and men who have sex with men-only environments. Destigmatization of men who
have sex with men identities could thus facilitate the promotion of sexually transmitted
infection testing and reduce risk and poor health outcomes.
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Chapter 3: Social Support and Medication for Opioid Use Disorder
This chapter will detail a systematic review exploring how social support is associated with
medication for opioid use disorder treatment outcomes. Through this chapter, I hope to
provide insight on a key public health strategy in combating the opioid epidemic.435,436
The Role of Social Support on Treatment Outcomes regarding Medication for
Opioid Use Disorder: A Systematic Review
This section has been published as: Kumar N, Oles W, Howell BA, et al. The role of social
network support in treatment outcomes for medication for opioid use disorder: A systematic
review.
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Introduction
Increasing access to medications for opioid use disorder is a key public health strategy in
combating the opioid overdose epidemic.435 Medication for opioid use disorder has several
benefits such as decreases in mortality, increases in treatment adherence, decreases in heroin
use, and augmented health, social and criminal justice.437,438 World Health Organization
recommendations indicate that access to medication for opioid use disorder is key to treatment
for opioid use disorder.439 Medication for opioid use disorder refers to several medications,
but primarily opioid agonist medications, like methadone and buprenorphine, but also opioidantagonist medications such as naltrexone.440 Although medication for opioid use disorder
models are the most efficacious evidence-based treatment for opioid use disorder,441 there
remains a high percentage of patients with unfavorable treatment outcomes.442 Greater
understanding of how social support functions with respect to medication for opioid use
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disorder treatment outcomes may improve treatment outcomes. Social support are the kinds
of support, such as assistance or help, that people receive from friends, family, peers and
neighbors, paid or unpaid, in their social network.443
Although clinical delivery characteristics, baseline substance use behaviors, comorbid mental
health or substance use disorders and patient demographics influence treatment outcomes, 444
less research has focused on how social support is associated with treatment outcomes. Novel
treatment paradigms, such as open access models, have gone a long way in decreasing barriers
to treatment and improving engagement, but there is still unexplained variability in patient
engagement and therefore an opportunity for improvement.445
Observational and experimental studies have shown that phenomena as diverse as
cooperation, obesity, drug use, smoking, alcohol use may be associated with social
networks.388,446 Thus, it seems highly likely that social support is significant in understanding
patterns of substance use, help-seeking, and adherence. A previous systematic review detailed
psycho-social interventions and medication for opioid use disorder,447 but there is limited
research around the role of social support on medication for opioid use disorder treatment
outcomes.
The study objective was to review existing scientific evidence on the following research
question: For medication for opioid use disorder patients (population), what influence does
social support have on medication for opioid use disorder (intervention) treatment outcomes
(outcome)? This systematic review sought to provide policymakers, administrators,
practitioners, and researchers with a systematic and reproducible strategy to query the literature
around the role of social support on medication for opioid use disorder treatment outcomes.
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With a larger team, I reviewed evidence under two themes, derived from medication for opioid
use disorder outcomes: Treatment retention/Adherence, Drug use/Abstinence. Within these
themes, I divided studies by the following forms of social support: Family, Peer, Combined
family, and peer, General.
Methods
I conformed to frameworks and standard tools of the Preferred Reporting Items for
Systematic Review and Meta-analysis Protocols (PRISMA-P)448,449 and Synthesis without metaanalysis (SWiM) guidelines.450 The protocol was pre-registered on PROSPERO
(CRD42018095645) on May 24, 2018.
Search strategy
I searched online indexes, references in previous reviews/guidelines, and Clinicaltrials.gov.
For more details on search strategy and inclusion/exclusion criteria, see Appendix.
Outcomes
Primary outcomes were 1) medication for opioid use disorder treatment outcomes e.g.
Medication adherence, program retention; 2) opioid use, defined as the percentage of urine
samples negative for opioids or self-reported drug use. Not all the studies included adhered to
these definitions. There were variations and differing definitions for individual studies.
Data extraction, review methods, quality assessments and data synthesis
I utilized a standardized template to extract data from each study. I searched online indexes,
references in previous reviews/guidelines, and Clinicaltrials.gov. In addition, I consulted
content experts. I conducted a systematic review of the literature using the databases of
PubMed, MEDLINE, Embase, PsycINFO and Sociological Abstracts (see Appendix for
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search strategy). I searched literature from inception through Feb 2020. Studies written in
English, conducted in humans, mentioned medication for opioid use disorder in the title or
abstract, included social support were considered for inclusion. Additional studies were
identified by scanning reference lists of previous literature reviews and other studies. To
reduce publication bias, I included a broad range of studies. The ClinicalTrials.gov library was
searched to identify potentially qualifying studies that have not led to published results. I
obtained additional papers through consultation with experts and authors, targeted searches
of thematic journals, technical reports, conference proceedings and national databases.
Specialist journals
Addiction, Addiction Research & Theory, Addictive Behaviors, American Journal of
Addictions, Addiction Science and Clinical Practice, Drug and Alcohol Dependence, Drug
and Alcohol review, Drugs: Education, Prevention and Policy, European Addiction Research,
International Journal of Drug Policy, Journal of Addiction Medicine, Journal of Addiction and
Offender Counselling, Journal of Alcohol and Drug Education, Journal of Drug Issues,
International Journal of Mental Health and Addiction, Addictive Disorders and Their
Treatment, Journal of Substance Abuse, Journal of Substance Abuse and Treatment, Journal
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of Substance Use, Substance Abuse: Research and Treatment, Substance Abuse Treatment,
Prevention and Policy and Substance Use & Misuse.
Inclusion/Exclusion criteria
I included studies that meet the following criteria:
Randomized controlled trials, quasi-experimental studies and observational studies published
in peer-reviewed journals; other scientific publications (e.g. Scientific Monographs); non-peer
reviewed journals and grey literature (technical reports, conference papers).
Participants sought treatment for opioid use or met criteria for opioid abuse, opioid
dependence, or opioid use disorder.
One or more variants of medication for opioid use disorder are offered (e.g. Methadone,
buprenorphine, naltrexone).
The study reported social support (e.g. Family/partner/friend/peer/neighbor support, social
network interventions as interventions or as predictors for the outcome.
The study reported adherence to medication for opioid use disorder as an outcome e.g.
Medication adherence, program retention. There will be no restrictions on study design,
population, or comparator (if included). Studies excluded from review will be case reports,
reviews, systematic literature reviews, qualitative studies, opinion pieces, editorials, comments,
news articles, and letters.
Data extraction
I utilized a standardized template to extract data from each study. I extracted general
information (e.g. Year, setting) and methods (e.g. Design, duration), variant of medication for
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opioid use disorder (e.g. Methadone, buprenorphine, naltrexone), and results specific to each
outcome (e.g. Treatment adherence, self-reported drug use, urine drug screen). Endnote, a
bibliographic software, was used to store, organize and manage all references.451 Covidence
was used to manage the screening phases.452
Review methods, quality assessments and data synthesis
With collaborators, in groups of two, we conducted study selection. A standardized template
was pre-piloted independently, in groups of two, all relevant data was extracted. We resolved
disagreements in study selection and data extraction through discussion. A third author
stepped in when necessary for a final arbitration of any disagreements that occurred. In groups
of two, we independently evaluated quality assessments and outcomes for each study and
reached consensus via discussion. When consensus was not reached, a third reviewer made
final decisions. Quality assessments for experimental studies were conducted using criteria
from the Cochrane Handbook and similarly described the quality of observational studies.449
I assessed possible bias arising from low or differential follow-up rates, as losses to follow-up
may have more negative outcomes than included subjects. I considered potential bias in selfreport data due to social acceptability. For experimental studies, assessment included level of
randomization, rates of attrition in the experimental group, use of intention-to-treat analysis
and how group-level baseline differences were dealt with. For observational studies, bias
assessment centered on group similarity (e.g. Matching), selection-bias and baseline differences
possibly influencing outcomes (e.g. Severity of dependence), and on analyses (e.g. Multivariate
logistic regression) adjusting for pre-study group differences. I assessed risk of bias at the study
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level or specific outcome level. I detailed whether biases were likely to exaggerate or underestimate the reported treatment effect.
In non-randomized studies, systematic bias may occur between different strata of social
support. This was a general problem with observational studies because parsing between causal
relationships around social support and severity of treatment outcomes is complex. Inclusion
of data from unpublished studies may reduce risk of publication bias. I used a structured
narrative format to synthesize the literature, organized by research question and thematic
focus. Within the social support themes, family social support refers to studies that
incorporated patient's partner or other family members. Peer social support connotes studies
that involved peers, friends, or other patients. Combined family and peer social support
indicate studies that involve both family and peer social support. General social support refers
to broad, non-specific social support .
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Results

Figure 1. Preferred Reporting Items for Systematic Review and Meta-Analsys (PRISMA) flow
diagram of study selection
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Figure 2. Evidence for observational studies regarding the role of social support on treatment
outcomes for medication for opioid use disorder. A supermatrix covering all study outcome
categories (columns) and forms of social support (rows) by change in the outcome of interest.
Each study is represented by a stacked bar. The height of each component corresponds to a
quality score representing the suitability of study design with respect to five quality measures:
Description of inclusion/exclusion criteria, clear presentation of main results, explanation of
methodology, presence of descriptive data and definition of variables. Each bar is annotated
with the sample size.
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Figure 3. Evidence for experimental studies regarding the role of social support on treatment
outcomes for medication for opioid use disorder. A supermatrix covering all study outcome
categories (columns) and forms of social support (rows) by change in the outcome of interest.
Each study is represented by a stacked bar. The height of each component corresponds to a
quality score representing the suitability of study design with respect to five quality measures:
Allocation concealment, addressing of incomplete outcome data, intent-to-treat analysis,
addressing of selection bias and adequate sequence generation. Each bar is annotated with the
sample size
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Table 1: Quality of Experimental Studies
Study

Sequence generation Allocation
adequate
concealment

Baseline data/ selection Incomplete outcome Intent-to-treat
bias
data adequately analysis
addressed

Other limitations discussed by authors

Fals-Stewart
Unclear
and O'Farrell,
2003

Unclear

Groups comparable

Yes: Multiple No
imputation

Naltrexone pharmacotherapy intervention not fully
standardized or manually driven.
Complacence measured by self-reports.
Key secondary outcomes (family relationship function and
HIV-risk) behaviors not measured.
Poor generalizability due to study sample characteristics
and low rate of study participation.

Fals-Stewart et Unclear
al., 2001

Unclear

Groups comparable

No:
5 No
participants
who did not
complete
treatment were
excluded

Small sample size.
Recall bias from strategy used for scheduling interviews
with patients.
Underreporting due to stigma and impact of opioid
dependence.
Bias from retrospective data collection, lack of blinding
and the use of proxy informants.

Groups comparable

Unclear:
No
Attrition from
methadone
maintenance
treatment
service
was

Small sample size.
Sample overrepresented males.
Assessment of family interaction processes limited by selfreporting measures.

Gu et al., 2013 Yes:
Block Adequate:
randomization
Central
allocation
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primary
outcome

Kidorf, 2018

Unclear

Rothenberg et No
al., 2002
randomization

Yandoli
al., 2002

et Unclear

Unclear

Groups comparable

Unclear

No

Not indicated

None: No No randomization, No: Participants No
randomizati selection
bias who failed to
on
possible
complete
treatment were
removed from
the trial

Inadequate accounting for potential change in family and
peer relations as a result of treatment participation.

Adequate:
Central
allocation

Temporal ambiguity due to cross-sectional design.
Recall bias and social desirability bias due to self-reporting.
Underreporting of heroin use as the urine morphine test
could only detect use in the past seven days rather than the
30 day period of self-reporting.
Poor generalizability as drug-using patterns and economic
situations differ across other provinces,

Carroll et al., Yes:
Urn Unclear
2001
randomization
program

Groups comparable

Follow-up
Yes
groups
not
comparable:
High attrition at
second follow
up leading to
differences
between
treatment
groups.

Yes: Groups differed Unclear: High Yes
significantly
on attrition after
baseline intensity of detoxification
opioid use

Retrospective study.
Not randomized.
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Catalano et al., Yes:
Block Unclear
1997
randomization

Groups comparable

No:
Missing Yes
data mentioned,
but method of
addressing
omitted

Results produced at post-test only show immediate effects
after intervention, not overall efficacy.
Bias from sole examination of parent differences post-test.
Does not study molecular processes of family change that
produce observed findings.

Catalano et al., Yes:
Block Unclear
1999
randomization

Groups comparable

Unclear

Retrospective study.
Follow-up data unavailable.
Generalizability depends on the skills of NCM caring for
patients.

Day et al., 2018 Yes: Independent None:
randomization
Open trial
algorithm

Groups comparable

Yes:
High Yes
attrition
in
experimental
group addressed
with
high
recruitment in
experimental
group

Organizational barriers.
Discontinuity in staff delivering treatment.
Inadequate recruitment for outcome measurement.

Hojjat et al., Yes:
Unclear
2017
Computerized
random numbers

Groups comparable

Unclear:
missing
reported

No No
data

Patients in cohort experiments other interventions not
captured by study.

None: No Groups comparable
randomizati
on

Unclear

No

Roozen et al., No
2003
randomization

Unclear

Not indicated
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Scherbaum et Yes:
Simple Unclear
al., 2005
randomization via
coin flip

Groups comparable

Yes:
Missing Yes
data addressed
by following the
last observation
carried forward
principle

Recall bias from a longer recall period during nonattendance episode.
Reporting bias from self-reporting.
Underreporting of attendance and non-attendance
episodes due to inclusion of only the most recent pair, and
exclusion of non-attendance duration.
Poor generalizability due to study location limitations.
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Table 2: Quality of Observational Studies
Study

Methodology
explained

Inclusion/exclusion
criteria described

Variables
defined

Number
of Main results clearly Limitations / bias discussed by authors
individuals
at presented
each
state
reported/descripti
ve data

Anton et al., Yes
1981

Yes

Yes

Yes

Yes

Not a randomized study due to unavailability or unwillingness
of patients to participate.
Poor generalizability due to small proportion of addicts with
families willing to participate in therapy sessions.

Cerovecki et Yes
al., 2013

Yes

Yes

Yes

Yes

Sample size of deceased group too small to determine
association between mortality risk and other factors.
Recall bias from interview scheduling.
Underreporting due to the stigma of opioid dependence.
Bias from retrospective data collection, lack of blinding and
the use of proxy informants.

Chaudhry et Yes
al., 2012

Yes

Yes

Yes

Yes

Retrospective study.
Small sample size.

Davila
Yes
Torres, 2011

Yes

Yes

Yes

Yes

Poor generalizability due to old age of study sample.
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Day et al., Yes
2013

Yes

Yes

Yes

Yes

Cross-sectional study design obscures causal inferences
between network support factors and continuing drug use.
Poor generalizability due to the exclusion of social support,
environment, and developmental upbringing.

Feng et al., Yes
2018

Yes

Yes

Yes

Yes

Baseline limited to making causal inferences due to
randomized controlled trial source.
Bias from self-reporting.
Weak measure of family members' support on methadone
maintenance treatment from a single-item question.

Gogineni et Yes
al., 2001

Yes

Yes

Yes

Yes

Not randomized.
Results not confirmed by toxicology
Cross-sectional study design obscures causal inference
between continued injection and social relationships.
Measured of important constructs based on single survey
questions with limited response formats.

Grey et al., Yes
1986

Yes

Yes

Yes

Yes

Small sample size without cross-validation.

Gu et
2014

Yes

Yes

Yes

Yes

Reporting bias from self-reporting.
Failure to study all episodes of attendance and nonattendance.
Inadequate recording of non-attendance period.
Limited generalizability because participants were recruited
from two methadone maintenance treatment clinics from one
city.

al., Yes
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Heinz et al., Yes
2009

Yes

Yes

No

Yes

Reliance on one dichotomous measure as a proxy for
relationship closeness.
Lack of information on partner substance use.
High selective attrition leading to more unhappily married
individuals dropping out of treatment.
Insufficient sample of married individuals for outcome
comparison.
Bias in lack of differentiation between single participants
without a significant other and with a significant other but
without a close and personal relationship.

Hikmayani et Yes
al., 2012

No

No

No

Yes

N/A

Hoang et al., Yes
2015

Yes

Yes

Yes

Yes

Poor generalizability due to selection bias in sample for
wealthier, more motivated individuals with more stable
families.
Sample disproportionately male.
Bias from loss to follow-up.

Hoang et al., Yes
2018

Yes

Yes

Yes

Yes

Unverified information obtained from methadone
maintenance treatment clinical records.
Overestimation of concurrent heroin use due to high level of
missing data.
Biased from loss of patients to follow-up.
Missing data limit analysis on association between psychiatric
comorbidities and concurrent heroin use.
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Lee et al., Yes
2015

Yes

Yes

Yes

Yes

Temporal ambiguity from cross-sectional study design.
Recall bias and social-desirability due to self-reporting.
Inconsistency in drug use assessment tools affected
verification of status. Self-reporting for the past 30 days and
urine test (limited to past 7 days) gave inconsistent
assessments.
Poor generalizability because of specific geographic focus of
study.

Lin et
2011

al., Yes

Yes

Yes

Yes

Yes

Cross-sectional study design limited causal inferences.
Poor generalizability due to modesty of drug use in study
sites.

Lin et
2013

al., Yes

Yes

Yes

No

Yes

Poor generalizability due to specificity of study group.

Lundgren et Yes
al., 2007

Yes

Yes

Yes

Yes

Poor generalizability due to expansive insurance coverage
and treatment programs of study location.

Monico
al., 2015

et Yes

Yes

Yes

Yes

Yes

Poor generalizability due to over-representation of African
Americans with access to BMT clinics.

Mutasa, 2001 Yes

Yes

No

Yes

Yes

Statistical short-fall due to small sample numbers.
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Nguyen
al., 2017

et Yes

Yes

Yes

Yes

Yes

Recall bias due to self-reporting.
Poor generalizability as sampling method was limited to
mountainous settings.
Cross-sectional design obscured causal relations between
methadone maintenance treatment adherence and
determinants.

Sarasvita
al., 2012

et Yes

Yes

Yes

Yes

Yes

Invalid predictors of retention for longer studies due to sixmonth observation period.

Shen et al., Yes
2018

Yes

Yes

Yes

Yes

Cross-sectional study design hinders causal inference.
Social desirability and recall biases due to self-reporting.
Underestimation of heroin use prevalence due to the 7-day
detection limit of urine tests.
Unrobust measure of social network functionality function
due to assessment form a single question.
Poor generalizability of the study due to location.

Smith, 2002 Yes

Yes

Yes

Yes

Yes

Poor generalizability due to homogeneity of sample (same
gender and shared military history).
Fully male sample.
Limited follow-up interviews due to compromised power to
detect significant findings.

Tang, 2016

Yes

Yes

Yes

Yes

Social desirability bias through under-reporting drug use and
availability of comprehensive psychological counseling to
methadone maintenance treatment clients
Poor generalizability due to study location.

Yes
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Torrens
al., 1996

et Yes

Yes

Yes

Yes

Yes

Retention rate in Spain influenced by long-term methadone
policy.
Poor generalizability of study to countries with greater
experience with methadone maintenance.

Tran et al., Yes
2018

Yes

Yes

No

Yes

Cross-sectional design obscured causal associations between
adherence and its determinants.
Recall bias from self-reporting.
Sample size too small due to convenience sampling.
Poor accuracy of medication adherence measurement due to
self-reporting.

Wasserman
et al., 2001

Yes

Yes

Yes

Yes

Yes

Short follow-up period limited detection of independent
effects.
Single instrument used to measure social support.
Undercounting of social network participants due to
restriction to household members only.
Study cannot make causal inferences about social support and
abstinence.

Yang et al., Yes
2013

Yes

Yes

Yes

Yes

Poor generalizability due to limited geographic location of
study participants.

Zhu et al., Yes
2018

Yes

Yes

Yes

Yes

Recall bias due to self-reporting opioid use.
Potential correlates associated with opioid abstinence not
measured.
Statistical significance of difference between abstinent and
non-abstinent groups needs to be further ascertained
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Table 3: Synthesis
Outcome

Significance
outcome

of Study

Form of social medication for opioid use disorder drug Intervention (if any)
support
used

Drug
Positive
Zhu et al., 2018
use/Abstinence outcome at P <
0.05
Shen et al., 2018

Family

Buprenorphine, Methadone

Family

Methadone

Unclear

Kidorf, 2018

Combined Methadone
family and
peer

Unclear

Hoang et al., 2018

Family

Methadone

Feng et al., 2018

Family

Methadone

Monico et al., 2015

Peer

Buprenorphine

Hoang et al., 2015

Family

Methadone

Lin et al., 2011

Family

Methadone

Heinz et al., 2009

Family

Methadone

Scherbaum
2005

et

al., Peer

Methadone

Methadone
treatment
Buprenorphine/Naloxone

Possible impact of bias on
treatment effect, if any
(understate, exaggerate, no
effect, unclear)
vs. Exaggerate

Methadone
treatment
vs. Exaggerate
Psychotherapy + Methadone
treatment
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Roozen et al., 2003

Fals-Stewart
O'Farrell, 2003

No effect

Family

Naltrexone

Community
reinforcement Unclear
approach + Naltrexone therapy

and Family

Naltrexone

Behavioral family counseling + Unclear
Individual naltrexone treatment
vs Individual-based naltrexone
treatment

Family therapy + SCT vs "Low Exaggerate
contact" + SCT vs Standard
clinic treatment (SCT)

Yandoli et al., 2002

Family

Methadone

Mutasa, 2001

Family

Methadone

Fals-Stewart et al., Family
2001

Methadone

Individual
counseling
+ Exaggerate
Methadone
treatment
vs.
Couples therapy + Individual
counseling
+
Methadone
treatment

Catalano et al., 1999 Family

Methadone

Focus on families

Day et al., 2018

Combined Methadone
family and
peer

Unclear

Treatment as usual vs. Social Understate
behavior and network therapy
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Hojjat et al., 2016

Family

Day et al., 2013

Combined Buprenorphine, Methadone
family and
peer

Wasserman
2000

et

al., General

Methadone

Network drug use + General Unclear
support

Methadone

Gogineni et al., 2000 Family

Methadone

Catalano et al., 1997 Family

Methadone

Treatment
Positive
Tran et al., 2018
Retention/Adh outcome at P <
erence
0.05

Group family training + Unclear
Methadone
therapy
vs.
Methadone therapy

Standard methadone treatment Unclear
vs.
Standard
methadone
treatment
+
Supplemental
parenting program

Combined Methadone
family and
peer

Nguyen et al., 2017

Family

Methadone

Tang, 2016

Family

Methadone

Gu et al., 2014

Family

Methadone

Yang et al., 2013

Combined Methadone
family and
peer
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Gu et al., 2013

Family

Methadone

Cerovecki et al., 2013 Family

Methadone

Individual
counseling

+

Family-based Exaggerate

Sarasvita et al., 2012 Combined Methadone
family and
peer
Hikmayani
2012

et

al., Family

Methadone

Lundgren et al., 2007 Family

Methadone

Rothenberg et al., Combined Naltrexone
2002
family and
peer
Lin et al., 2013

Family

Methadone

Lee et al., 2015

Family

Methadone

Davila Torres, 2011

Family

Methadone

Torrens et al., 1996

Combined Methadone
family and
peer

Behavioral naltrexone therapy

Unclear
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No effect

Grey et al., 1986

Family

Naltrexone and Methadone

Anton et al., 1981

Family

Naltrexone

Chaudhry et al., 2011 Family

Naltrexone

Smith, 2002

General

Methadone

Carroll et al., 2000

Family

Naltrexone

Standard naltrexone treatment Unclear
vs. Naltrexone treatment + CM
vs. Naltrexone treatment + CM
+ Significant other involvement
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Included studies
Results from the study selection process are indicated in Figure 1 and general study
characteristics displayed in the Appendix. Systematic searches yielded 4116 papers imported
for screening, with 4087 studies screened for review (29 duplicates, see Figure 1). Screening
yielded 213 articles for full-text review by two independent reviewers. Forty-two studies were
deemed relevant to the review, summarized in Table 1. Thirteen were experimental studies, 29
were observational studies. The United States (18) and China (seven) were the most
represented nations. Treatment and comparison groups were all drawn from opioiddependent populations. Thirty interventions involved maintenance on methadone, six
involved naltrexone, three involved methadone or buprenorphine, one involved methadone
or LAAM (levo-alpha-acetyl-methadol), one involved naltrexone and methadone combination
therapy, and one involved just buprenorphine. Tables 1 and 2 indicate the quality of
experimental and observational studies.
Quality assessments
Tables 1 and 2 indicate the quality of experimental and observational studies. For experimental
studies, allocation concealment was rarely reported and its impact on bias was not clear. The
quality ratings for observational studies were overall high. I indicated relevant evidence for
observational (see Fig 2) and experimental studies (see Fig 3) across treatment
retention/adherence and drug use/abstinence outcomes, for each variety of social support
with a harvest plot.453 Twenty four observational studies met all five criteria.454–476 Four
observational studies met four criteria.466,477–479 Observational studies on treatment
retention/adherence, compared to drug use/abstinence, were more likely to fulfil the criteria
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for quality of execution, with fourteen treatment retention/adherence studies meeting all five
criteria.464–476,480 No experimental studies met all five criteria. Two experimental studies met
four criteria, both of which addressed drug use/abstinence.481,482 The remaining studies in this
review met between zero and three criteria.
Treatment retention/adherence
Twenty studies reported treatment retention/adherence as a medication for opioid use
disorder outcome. Three were experimental483–485 and 17 were observational.464–476,479,480,486,487
Seventeen studies indicated that social support was related with improved medication for
opioid use disorder treatment retention/adherence.464–467,469–475,480,484–487 There was one
randomized controlled trial which improved treatment retention/adherence.484 Most
statistically significant results involved family social support , with a few studies focused on
combined family and peer social support . There was a single study on general social support
with statistically significant results and no studies on peer social support that demonstrated
statistically significant results.
Family social support
Eleven of 14 studies exploring family social support within the treatment retention/adherence
outcome demonstrated significant improvements in treatment retention/adherence467,470–
475,480,484,486,487

and three had no significant change.468,469,483 Improvements in treatment outcome

were found in both experimental467,484 and observational studies.470–475,480,486,487 In one of the
experimental studies, differences between control and treatment groups were large. 484 The
study reported lower estimated probability of attrition at Month 12 [0.35 (control) vs. 0.55
(treatment)], higher median number of days of attendance [Month 6: 147 vs. 91 days; end196

date: 225 vs. 142 days].484 The researchers evaluated the relative efficacy of a combination of
a psycho-social intervention and standard of care medication for opioid use disorder versus
standard of care on methadone attrition and treatment attendance. Family members provided
support (e.g. Recognizing participant improvement in daily life after starting medication for
opioid use disorder) during the family-centric sessions of the interventions. In the other
experimental study,467 some participants received multiple family therapy and the standard
therapy, with the rest only receiving the standard therapy which included counseling,
psychotherapy, and outreach. Multiple family therapy sought to build and strengthen family
ties, support parents and partners in monitoring patient behavior, among other goals. For the
observational studies, living with one's children, good family relationships and higher levels of
perceived family support were associated with improved medication for opioid use disorder
outcomes.473–475 Conversely, absence of family support and living in an unstable relationship
were related to reduced medication for opioid use disorder outcomes.480,486
Combined family and peer social support
All five studies exploring combined family and peer social support within the treatment
retention/adherence outcome indicated significant outcomes.464–466,479,485 Improvements in
treatment outcome were found in one experimental study485 and four observational studies.464–
466,479

The experimental study, applying behavioral naltrexone therapy, reported a positive

correlation between length of time in treatment, and adherence and opiate-free urine
samples.485 Behavioral Naltrexone Therapy was delivered over a six-month period in weekly
and network therapy sessions, comprised of Relapse Prevention, Community Reinforcement
Approach and Network Therapy. For the observational studies, positive family relationships,
197

no communication with former drug-taking peers and disclosing one's health issues to friends
were associated with retention.466,479
General social support
Only one study explored general social support .476 The results were statistically nonsignificant.
Drug use/abstinence
Twenty-two studies reported drug use/abstinence as a medication for opioid use disorder
outcome. Ten were experimental481,482,488–494 and 12 were observational.454–463,477,478 Multiple
studies indicated that social support was related with reduced drug use/abstinence.455,457–
461,463,477,478,481,490–495

Several randomized controlled trials demonstrated the role of social support

in decreasing drug use/abstinence.481,490–493,495 The most detailed variant was family social
support , with a few studies exploring combined family and peer social support , peer social
support and general social support .
Family social support
Thirteen of 16 studies exploring family social support within the drug use/abstinence
outcome demonstrated significant improvements in treatment retention/adherence.455,457–
461,477,478,490,491,493,495,496

Improvements

in

outcome

were

indicated

in

experimental

studies490,491,493,495,496 and observational studies.455,457–461,477,478 Two of the experimental studies
reported large differences between control and treatment groups. The first study493 reported a
higher proportion of drug-free patients six and twelve months in both intervention groups
(22% and 15% for family therapy) compared to the standard treatment group (5% and 0%)
and low contact group (8% at both marks). The researchers evaluated the efficacy of family
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therapy compared to a ``low contact" intervention and standard psychotherapy. All groups
also received medication for opioid use disorder. The family intervention comprised of up to
sixteen sessions and involved the patient's family or partner. Sessions were based on the
discussion of family relationships and medication for opioid use disorder. The low contact
treatment comprised of monthly, standardized 30-minute interviews for up to 12 months.
Standard treatment involved supportive counselling and the delivery of information related to
managing drug use. In the other experimental study,495 patients were assigned to a
supplemented medication for opioid use disorder treatment with 33 sessions of family training
and 9 months of home-based case management, or the control group with standard
medication for opioid use disorder. Family training focused on relapse prevention and coping,
anger management and child development. For the observational studies, increased social
support461 and having a spouse or child in one's social network460,497 were associated with
reduced drug use and abstinence. Conversely, factors such as family conflict,478 interactions
with drug-using friends455,478 and low family support487 were associated with poorer treatment
outcomes.
Peer social support
There were two studies, both significant, which explored peer social support within the drug
use/abstinence outcome.463,481 In the experimental study based in Germany, participants were
assigned to medication for opioid use disorder or medication for opioid use disorder and
group psychotherapy. Patients in the psychotherapy group demonstrated less drug use than
control subjects.481 Psychotherapy centered on the patient’s understanding of situations
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predisposing drug use. In the observational study, narcotics anonymous meeting attendance
in the past six months was associated with drug abstinence.463
General social support
A single study explored general social support within the drug use/abstinence outcome.462
Results were non-significant.
Combined family and peer social support
Only one study that explored combined family and peer social support within the druguse/abstinence outcome had results that were statistically significant.498 The remaining two did
not demonstrate significant results.454,482 In the significant experimental study,498 individuals
who inject drugs were recruited from a community needle exchange group and a medication
for opioid use disorder program. Patients attended a weekly community support group with a
drug-free family or friend and participated in weekly community activities to expand drug-free
social support. Results indicated reductions in heroin use (27 vs. 17 days/month), intravenous
drug use (27 days vs. 20 days/month) and number of injections (123 vs. 48 injections/month).
Synthesis
Table 3 synthesizes the 42 studies per theme and outcome indicating positive treatment effects
or no effect. Table 3 also indicates whether biases may have understated or over-reported
treatment effects. Figure 4 displays the studies by social support variant and statistical
significance. Evidence is not consistent for either outcome, although studies mostly support
the conclusion that social support improves medication for opioid use disorder treatment
outcomes. Table 3 also summarizes whether biases might understate or exaggerate treatment
effects, if any. This information is derived from Table 1. For experimental studies, bias was
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considered likely to understate positive outcomes in one study, to exaggerate in four and
unclear in the remaining eight studies. The most common source of bias for experimental
studies was the lack of intent-to-treat analysis and recall bias and reporting bias may also play
a role.
Discussion
In this systematic review, I present a current and comprehensive synthesis of the published
literature on the role of social support on medication for opioid use disorder treatment
outcomes. I examined the effect of social support on two medication for opioid use disorder
treatment outcomes: Treatment retention/adherence; Drug use/abstinence. I detailed several
observational and experimental studies over a range of social support variants. Overall, social
support is significantly associated with improved medication for opioid use disorder treatment
outcomes. Quality of observational studies was overall high, but quality of experimental
studies was much lower. A previous review explored psycho-social interventions and
medication for opioid use disorder,447 but there is limited work around social support on
medication for opioid use disorder outcomes. I thus extend the literature by detailing the role
of social support on medication for opioid use disorder outcomes, broadening the scope of
social networks on health outcomes.
While studies indicated that social support was associated with improved treatment outcomes,
there

were

several

studies

(21%)

which

did

not

indicate

a

significant

relationship.454,456,462,468,476,482,483,488,489 Given the large proportion of non-significant findings,
more research is necessary to establish the relationship between social support and medication
for opioid use disorder treatment outcomes. Comparing treatment outcomes, six out of 22
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(28%) studies were not significant for drug use/abstinence vs three out of 20 (15%) for
treatment retention/adherence. I was unable to conduct a meta-analysis due to variations
within outcomes. Family social support was the most common variant of social support
detailed across both outcomes. It is not clear why other forms of social support were not
similarly studied, despite their likely importance. Compared to the control arms, the treatment
arms for studies focused on family social support network tended to have large improvements
in treatment outcome. Given the role of families in substance use outcomes,499 further research
can detail family social support on treatment outcomes.
Treatment retention/adherence
Several studies indicated that social support was associated with augmented medication for
opioid use disorder treatment retention/adherence.464–467,469–475,479,480,484–487 There was only a
single randomized controlled trial which improved treatment retention/adherence.484 Most
studies with statistically significant results involved family social support , with a few studies
centered on combined family and peer social support . There was a single study on general
social support with statistically significant results and no studies on peer social support with
statistically significant results. Given the relationship between families and medication for
opioid use disorder treatment outcomes,498,500 the focus on family social support and treatment
outcomes is understandable. However, the number of studies detailing family social support
and medication for opioid use disorder treatment retention is still scarce. Despite the
substantial scholarship on peer effects and substance use,501,502 there are no studies exploring
peer social support on its own, and treatment retention/adherence. Thus, it is not clear if
certain forms of social support are more effective at improving treatment retention/adherence
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or there is reporting bias, or some other effect involved. Future studies can explore if certain
variants of social support are more effective than others at improving medication for opioid
use disorder treatment retention/adherence. Overall, social networks are associated with
treatment retention/adherence.464,503 Thus, social support interventions are a critical research
gap that may improve treatment retention/adherence.
Some studies suggest that family social support is related to improved medication for opioid
use disorder treatment retention/adherence.467,484,486,487 The randomized controlled trial
conducted by Gu et al. (2013) in China provides strong evidence in this regard.484 However,
there are only two experimental studies detailing family social support

and treatment

retention/adherence.467,484 Evidence is clearly lacking around family social support
interventions around treatment retention/adherence. As family-related factors are related to
substance use outcomes,499 studies on family social support and medication for opioid use
disorder outcomes are a clear gap in the scholarship. A few studies suggest that combined
family and peer social support were associated with improved medication for opioid use
disorder treatment retention/adherence.464–466,479,485 However, there was only one experimental
study in this area485 and a total of five studies. The United States-based experimental study
detailed the use of significant other and peer support to improve naltrexone adherence. 485 As
with family social support , research around the combined role of family and peer social
support is limited within medication for opioid use disorder treatment retention/adherence.
As a mix of family and peer social support are critical to medication for opioid use disorder
treatment outcomes,465 scholarship in this area is important. However, it is not clear if social
support interventions that centers on either the family or peers are more effective than
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interventions which have some combination of both. A single study detailed general social
support on medication for opioid use disorder treatment retention/adherence.476 This United
States-based study detailed that the perception of or orientation toward non-specific social
support did not contribute significantly to the predicted length of time in treatment. It is not
clear if general social support affects medication for opioid use disorder treatment
retention/adherence as evidence is lacking in this area. Most research on social networks and
substance use tend to center on specific alters such as family members and peers,456,504 but it
may be possible that generalized social support has an effect on treatment outcomes. Future
research can detail if general or more specific forms of social support make a greater difference
to treatment retention/adherence.
Drug use/abstinence
There is evidence that social support was associated with drug use/abstinence as a medication
for opioid use disorder outcome.455,457–461,463,477,478,481,490–495 Several randomized controlled trials
demonstrated the role of social support in increasing drug use/abstinence as a medication for
opioid use disorder outcome.481,490,491,493,495,496 The bulk of studies detailed family social support
, with a few studies exploring combined family and peer social support , peer social support
and general social support . Like the relationship between treatment retention/adherence and
social support, I expected several studies focusing on family social support but noted the lack
of studies on peer social support. Overall, the number of studies per variant of social support
was limited, indicating a clear research gap.
Several studies indicated that family social support contributed to improved medication for
opioid use disorder treatment outcomes around drug use/abstinence.456,488,495 An randomized
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controlled trial conducted in the Netherlands provides strong evidence in this regard.496
However, there were only seven experimental studies in this area455,457–461,477,478,496 and of these,
two did not demonstrate significant results.456,488 Evidence is limited and somewhat mixed
around family social support and drug use/abstinence-related treatment outcomes, and there
is a stark gap in the scholarship. Given the relationship between family social support and
medication for opioid use disorder outcomes,480,486 future research can detail if family social
support consistently improves outcomes around drug use/abstinence. There were two
observational studies which indicated that peer social support related to improved treatment
outcomes around drug use/abstinence.463,481 While there is some evidence around peer social
support and treatment outcomes surrounding drug use/abstinence, literature is still scarce,
indicative of a literature gap. The lack of research is surprising, given the broader literature on
peer effects and substance use.505,506 Three studies indicated that combined family and peer
social support

were associated with augmented treatment outcomes around drug

use/abstinence.454,482,494 Of these three, only one (an observational study) indicated significant
results. As with treatment retention/adherence, it is not clear if combined family and peer
social support is more effective at improving treatment outcomes, compared to interventions
focused on peer or family social support. As peer and family social support , acting individually,
have effects on treatment outcomes,463,496 interventions combining peer and family social
support may be more effective. There is a clear literature gap, with more studies, especially
experimental research, needed in this area. There was a single, non-significant, observational
study detailing general social support and treatment outcomes around drug use/abstinence.462
While there is some research on more specific forms of social support on medication for
opioid use disorder outcomes,460,461,493 generic social support seems understudied. As with
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treatment retention/adherence, it was not clear if general vs specific social support is more
effective at improving treatment outcomes. There is an evident lack of research on general
social support in this area.
Limitations
Most of the studies had key methodological concerns. I emphasized more robust study designs
and assessed the probable impact of bias to compensate for methodological weaknesses.
Possible sources of bias are: Group baseline differences; selection bias; attrition bias;
differential rates of follow-up. Selection bias may exaggerate or under-report treatment effects.
If rates of attrition are relatively high or greater in untreated groups, there may be a possibility
that treatment effects are overestimated if participants lost to follow-up have greater negative
outcomes. A few studies in this review conducted analysis to control for bias through
multivariate analysis and/or comparison of losses to follow-up with those followed-up.
Attempts to account for biases may not always be successful and I thus assessed the risk of
biases (see Table 3), providing an assessment of probable impact of bias on various outcomes.
Limitations also arose from differences in methods of reviewed studies, making it more
complex to assess or synthesize all studies under the same rubric. The details provided on
methods and analysis was highly varied, possibly leading to fluctuations in the confidence level
of results.
While evidence was generally scarce within both outcomes and within individual variants of
social support, some themes were severely understudied. For example, there was only a single
(non-significant) study exploring general social support within drug use/abstinence treatment
outcomes.462 Thus, while I indicated that social support was associated with improved
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medication for opioid use disorder treatment outcomes, I cannot say whether specific variants
of social support were related to treatment outcomes. Moreover, there were no studies which
detailed forms of social support apart from family, peer, combined family and peer, and
general social support. For example, there seemed to be no research on social support from
authority figures. The role of employer social support may be important to treatment
outcomes given the role of workplace authority figures in the lives of medication for opioid
use disorder patients.507
Conclusion
The main strength of the study is the quality assessment of the content and provision of broad
summaries of the literature. I detailed the population, intervention and outcomes included,
along with data extraction methods and search strategy. I also centered on the specific variants
of social support on medication for opioid use disorder treatment outcomes. Although
evidence is limited, social support likely improves a range of medication for opioid use disorder
treatment outcomes. Interventions around social support could potentially augment
medication for opioid use disorder treatment outcomes, possibly playing a role in mitigating
the opioid epidemic. Some kinds of social support may be more efficacious than others in
improving treatment outcomes, e.g. Family social support vs peer social support . Despite the
variety of outcomes and social support, I suggest the key role of social support on broad
medication for opioid use disorder outcomes.
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Conclusion: Chapter Three
I indicated the results of a systematic review on the influence of social network interactions
on medication for opioid use disorder treatment outcomes. I detailed literature on the role of
family, peer, and general social support on medication for opioid use disorder treatment
outcomes. Most studies, many of which were randomized controlled trials, indicated that social
support may improve medication for opioid use disorder treatment outcomes. Given that
evidence is still limited on the role of social support on medication for opioid use disorder
treatment outcomes, I suggest future research centering on social support and integration of
social support interventions into medication for opioid use disorder treatment programs to
improve treatment outcomes.
Medication for opioid use disorder and opioid use disorder are heavily stigmatized, often
reducing likelihood of seeking treatment.136,508 Socioeconomic marginalization is associated
with opioid use disorder,509 with factors such as union decline associated with overdose
rates.510,511 Even with the marginalization and stigma associated with opioid use disorder,
medication for opioid use disorder patients still seek treatment. This reclamation of agency
draws parallels with previous chapters, where marginalized men who have sex with men seek
testing at risk to themselves. However, even though medication for opioid use disorder
patients overcome significant hurdles in seeking treatment, medication for opioid use disorder
treatment outcomes can still be improved. While patients can overcome some aspects of
marginalization and retain agency to enter treatment, the effects of disadvantage persist and
affect treatment outcomes. Thus, echoing previous chapters, mitigating stigma and
marginalization could facilitate improved wellbeing of opioid use disorder patients.
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Conclusion
In the first chapter, I detailed a range of cannabis-centric studies. First, I detailed cannabis
usage preferences among United States cannabis users. I put forth that frequent cannabis use
may increase risk of health harms and highlighted the need to minimize problematic use. I also
detailed if sociodemographic indicators were associated with increased likelihood for cannabisrelated emergency department admissions in New York City. Results may suggest that
cannabis use further burdens marginalized groups. I then investigated large cannabis firms’
motivations for participating in the cannabis space. I suggested that policymakers be aware
that non-profits and for-profits both seek to expand cannabis access and consider the groups
as a unified whole.
With increasing proliferation of cannabis use, marginalized communities are likely to bear a
greater burden of poor health outcomes. Some communities face a lack of agency through the
processes of marginalization but still attempt to retain some level of agency by engaging in risk
reduction practices, drawing parallels to the broad chapters of my thesis. Some large firms in
the cannabis space are likely contributing to increases in cannabis use. However, all firms are
not solely focused on increasing cannabis consumption. Some firms are cognizant about the
demographic groups disproportionately affected by drug use and seek to use the cannabis
industry to reduce risk and enhance agency for marginalized communities. Such firms are
usually founded by individuals from marginalized communities.512
By virtue of retailing a stigmatized and federally illegal product, cannabis firms are marginalized
from the broader firm space. Cannabis firms incur a range of costs due to federal illegality,
such as increased banking fees and greater premiums from service providers. Firms attempting
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to recoup these costs may provide poor occupational environments and employment benefits
for their employees, worsening marginalization of entry-level workers.513,514 Thus,
marginalization on the firm level may be transferred to marginalization faced by employees,
possibly resulting in reduced health outcomes. My results suggest that some firms are aware
of the negative effects the cannabis industry can have and thus strive toward equitable working
conditions and health outcomes. Workers in the cannabis space have also attempted to
organize for improved conditions, augmenting health outcomes and mitigating risk.515 In line
with the broader themes of this document, workers are marginalized in the cannabis space,
but seek agency by organizing and reducing marginalization and health risks.
In the second chapter I explored sexually transmitted infection testing in the Chinese men
who have sex with men environment. I first detailed factors associated with sexually
transmitted infection testing. Expressions of altruism may promote contributions toward
public health initiatives in marginalized communities. In the same vein, I detailed the
association between men who have sex with men community-centric behaviors and
contributions toward others’ sexually transmitted infection testing. I proposed that
community-oriented behaviors may be related with a reduction in testing service costs. I also
evaluated whether men who have sex with men selected a sexually transmitted infection test
appropriate for their sexual behavior. I suggested that disclosing sexual identity to treatment
providers can improve men who have sex with men sexually transmitted infection prevalence
estimates. I also detailed the correlates of antisocial behavior on the world's largest gay dating
app among Chinese men who have sex with men. I suggested that age, condom use, and
number of social ties may be associated with antisocial behavior, with implications for the
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design of online sexual health interventions. Finally, I assessed if same-sex sexual behavior
disclosure of Chinese men who have sex with men was related to number of HIV self-testing
kits requested, and number of test results successfully uploaded by alters in a network-based
HIV self-testing intervention. Findings had implications for the development of networkbased interventions for key populations.
China has the world’s largest men who have sex with men population. Despite repeals against
legal persecution, discrimination against the broader lesbian, gay, bisexual, and transgender
population still exists.57 Lesbian, gay, bisexual, and transgender discrimination is a barrier to
preventing sexually transmitted infections, such as HIV.58 A recent survey led by the UN
Development Program and the Beijing lesbian, gay, bisexual, and transgender Center indicated
that 11% of heterosexual participants were unable to accept lesbian, gay, bisexual, and
transgender family members and more than 10% of respondents did not believe that lesbian,
gay, bisexual, and transgender individuals should be allowed to raise children.56 Such
sentiments and the associated legislation results in marginalization and stigma, wresting agency
from the lesbian, gay, bisexual, and transgender community. Even within such sites of limited
agency, several Chinese organizations have campaigned for lesbian, gay, bisexual, and
transgender rights, increasing the social visibility of the community, and reducing
discrimination. For example, in 2018, a group of Chinese artists protested against sexual
orientation conversion efforts.60,516 Several lesbian, gay, bisexual, and transgender groups in
major Chinese cities launched a campaign to support Li Yinhe, a sociologist pushing for a
same-sex marriage law in China.517,518 In 2008 and 2009, a group of Beijing lesbian, gay,
bisexual, and transgender activists had a Valentine’s Day same-sex marriage event.517 More
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recently in 2013, some Chinese lesbian, gay, bisexual, and transgender began seeking out
lawyers and legal professionals who would be willing to represent clients in China’s first series
of lesbian, gay, bisexual, and transgender rights litigation.519 Similarly, my results suggest that
while men who have sex with men are marginalized in China, men who have sex with men
still seek sexually transmitted infection testing and are willing to contribute anonymously to
other men who have sex with men. Although men who have sex with men often face
marginalization and incur poorer health outcomes, many men who have sex with men work
with their communities to improve overall wellbeing and reduce health risks.
In the final chapter I detailed those various forms of social support may influence medication
for opioid use disorder treatment outcomes. Failure to implement successful social support
programs within medication for opioid use disorder treatment settings may represent an
important missed opportunity to engage patients at risk of treatment failure.
Illicit opioid use and poor medication for opioid use disorder treatment outcomes may be
related to marginalization and loss of agency.508,510,511 While opioid use disorder can affect
anyone, the opioid crisis has predominantly affected those from the most marginalized areas
of the United States.520 Opioid use disorder rates among people who earn less than $20000 a
year are three times higher than those who make more than $50000.521 In 2016, individuals
under the poverty line were more likely to have misused opioids and have an opioid use
disorder in the past year compared to individuals above the poverty level.522 Increases in county
unemployment rates predicted increases in opioid death rates.523 Per-capita opioid-related
hospital stays and emergency department visits are higher and have increased at higher rates
in low-income communities compared to high-income communities.524 Opioid prescriptions
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are also negatively correlated with labor force participation.525 In addition, there is a negative
relationship between prescriptions and economic opportunity, where counties with worse
economic prospects having a greater prevalence of substance use and opioid prescriptions. 522
Those on Medicaid are more likely to be prescribed opioids, at higher doses and longer
durations, possibly resulting in greater risk of dependence.526–528 Those with mental illness and
childhood trauma are overrepresented among people prescribed opioids and overdoses.529–532
Medicaid recipients are also less likely to have access to medication for opioid use disorder.
There are a range of barriers that further marginalize medication for opioid use disorder
patients. Some communities oppose medication for opioid use disorder treatment in their
neighborhoods and officials have attempted to make medication for opioid use disorder sites
illegal in some areas.533
The increased overdose mortality among middle-aged white Americans may be due to
increasing economic challenges and psychological stresses.534 Environmental and social
stresses likely contribute to opioid use disorder. Solitary animals demonstrate greater opioid
self-administration compared to animals housed together.535,536 Socially dominant male
monkeys demonstrate less cocaine self-administration compared to their lower-ranked or
solitary counterparts.537 In addition, compared to rodents housed in environments with
multiple opportunities for play, exploration and exercise, rodents housed in environments with
fewer opportunities for play, exploration and exercise are more sensitive to the reward effects
of heroin.538 While animal models may be highly simplified, they may indicate that
marginalization and loss of agency within human environments may increase risk for substance
use.520
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Various forms of marginalization appear related to opioid use disorder and further impact
opioid use disorder treatment outcomes. Marginalization increases the health risks of opioid
use disorder patients and repudiates agency. However, even within this sphere of limited
agency, individuals with opioid use disorder and the broader people who use drugs community
engage in various activities to reduce risk and retain some agency. Through needle exchanges
and similar environments, some opioid use disorder patients build a sense of community.539
Such community-based initiatives have resulted in people who use drugs unions that seek to
alleviate stigma around people who use drugs and opioid use disorder.539 Even within sites of
marginalization and health risks, marginalized individuals still seek to reduce risk and preserve
some agency. On a broader scale, there are governmental initiatives that seek to mediate risk
and marginalization for medication for opioid use disorder patients. Significant federal funds
have been allocated to improving access to medication for opioid use disorder in rural and
underserved areas.522 Similarly, grants have been allocated to identify child welfare practices
which may mitigate the impact of parental substance use, and interventions are ongoing to
increase economic self-sufficiency of opioid use disorder patients eligible for the Temporary
Assistance for Needy Families program.522 My findings in the opioid space indicate that social
support provided by family and peers can improve upon treatment outcomes and that
medication for opioid use disorder patients from marginalized communities face lowered
levels of social support . Despite the stigma against medication for opioid use disorder and
opioid use disorder, patients seek to reduce risk and retain agency, drawing parallels to the
broad themes of my thesis.
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In previous chapters, I indicated that marginalization could worsen health outcomes in the
Chinese men who have sex with men community. Similarly, compared to heterosexual
communities, United States lesbian, gay, bisexual, and transgender communities were more
likely to have misused prescription opioids and have opioid use disorder.529 Lesbian, gay,
bisexual, and transgender communities live with high levels of discrimination and stigma,
which can disrupt one’s psychological processes. Such stigma can become internalized and
some may turn to opioids to cope.540,541 Lesbian, gay, bisexual, and transgender individuals may
also be exposed to opioids in medical settings at disproportionate rates, compared to
heterosexuals.542 For example, opioid therapy is often prescribed to transgender people postsurgery, who also report increased prevalence of chronic pain.543,544 Opioid use may also have
deleterious effects in a sexual context. Non-medical opioid use among men who have sex with
men is associated with condomless sexual intercourse and other possibly less safe sexual
behaviors.545,546 Medication for opioid use disorder may have unwanted interactions with
antiretroviral therapy taken by those living with HIV.547 Fear of unwanted side effects may
deter lesbian, gay, bisexual, and transgender individuals from engaging in medication for
opioid use disorder. Opioid use disorder can also co-occur with posttraumatic stress
disorder.548 Post-traumatic stress disorder in lesbian, gay, bisexual, and transgender
populations can arise from sexual violence and hate crimes. The themes I have indicated thus
do not exist mutually exclusive of each other but overlap to possibly worsen marginalization.
A men who have sex with men identity can worsen marginalization and as indicated, opioid
use disorder can intersect with marginalized sexual identities to widen inequality. While
marginalization strips agency from men who have sex with men medication for opioid use
disorder patients, such individuals still manage to retain some level of agency. Men who have
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sex with men have organized their own Narcotics Anonymous groups to mitigate the effects
of opioid use disorder.549,550 Thus, even with the twin effects of marginalization around opioid
use disorder and a men who have sex with men identity, patients still seek to reduce risk around
their health behaviors.
I indicated how marginalized communities improve their health outcomes and retain agency
through mechanisms such as solidarity and social support. I detail a set of specific cases where
marginalized communities can benefit from a sense of togetherness, viewed as positive by
broader society. When this argument is extended to other marginalized communities, not all
cases result in positive outcomes. There are many marginalized communities where increases
in solidarity and agency are a concern. For example, white nationalist groups consider
themselves marginalized551 and solidarity in such groups often troubles law enforcement
agencies. Some white Americans feel victimized and stigmatized because of their ethnicity.
They perceive traditionally marginalized ethnic groups as being the oppressors.551 Another
example is the pro-ana (pro-anorexia) community. Anorexia is an eating disorder and patients
may benefit from social support .552 However, some online communities of anorexia patients
reinforce social dynamics that encourage anorexia instead of promoting recovery.553 Pro-ana
communities exchange tips on how to maintain potentially harmful behaviors.554,555 Patients
engaging in such communities face reduced self-esteem and increased negative affect in the
short and long term.556,557 In opposition to the pro-ana community, there exists the Fat
Acceptance Movement. The movement challenges claims about the relationship between body
weight and health, and promotes respect for those who are overweight.558 Women in this
community gain self-acceptance and emancipation from dieting, among other benefits.558–560
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However, the fat acceptance movement has been accused of promoting obesity and weight
gain.561,562 Gang Stalking is another example parallel to the pro-ana community. Gang Stalking
is a perceived form of systematic intimidation perpetuated by an individual or organization,
usually identified as the government or a large corporation.563 Individuals who believe they are
gang stalked call themselves Targeted Individuals or TIs. Such individuals who set out to find out
more about Gang Stalking on the internet are informed that they are neither crazy nor
delusional.563,564 Those who deny Gang Stalking as a real phenomenon are labelled closeminded or naïve, creating a closed echo chamber.565 Much like the pro-ana community,
increased participation in Gang Stalking communities may result in reduced treatment seeking
for a medical condition, in this case Delusional Disorder.563,566
Given the amorphous nature of marginalization, not all marginalized communities are
constant and stable. For example, as United States HIV rates of new infections decrease,567
communities of individuals with HIV will similarly decrease. Existing communities of those
with HIV may thus face reduced levels of social support which could further exacerbate
marginalization. Similarly, as smoking cessation behaviors spread through a social network,
smokers become increasingly forced to the peripheries of the network.384 Thus, medical
advances and similar phenomena can possibly increase marginalization in communities
exemplifying strong solidarity.
Unlike the above example in the smoking case, marginalized behavior may not always be at
the peripheries of a network. For example, risk of current smoking was greater among popular
students in schools with high smoking prevalence than among popular students in schools
with low smoking prevalence.568,569 Smoking also enhanced popularity in adolescent social
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networks.570 Similarly, perceived popularity in adolescent peer groups predicted bullying571 and
powerful bullies were perceived to be more popular and better liked.572 In line with the
perceived social status of marginalized behaviors, lower status individuals may seek to engage
in such behaviors. In the smoking case, there may be an ebb and flow around marginalization.
Marginalized youth may pick up smoking to attain status in a social network, but later be
marginalized when members of their social network give up smoking.
Apart from seeking social status, there are other reasons why individuals would engage in
marginalized behaviors. Given the sense of support and belonging found within certain
marginalized communities, it is possible that non-marginalized individuals may seek to
somehow marginalize themselves to attain some sense of community. Bug chasing, where
physiologically healthy, HIV-negative men who have sex with men seek seroconversion by
engaging in unprotected anal intercourse with HIV-positive men who have sex with men fits
this description.573 Bug chasers report gaining a HIV infection as a rite of passage and initiation
into a community from which one can never be exiled.574 Some HIV negative men who have
sex with men feel they have been cast aside as potential sexual partners and seek a newly
renewed sense of community.575–577 For bug chasers, the HIV-positive men who have sex with
men population may appear to have significantly stronger bonds of community and
cohesiveness compared to the broader men who have sex with men population.578 Some HIVpositive men will refuse to have unprotected intercourse with bug chasers and only seek out
other HIV-positive men who have sex with men.574 This may create a closed community of
HIV-positive men who have sex with men, who share a sense of camaraderie and kinship,
further creating a sense of alienation among bug chasers.
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As with the above cases, how does one decide when to encourage agency within marginalized
communities? Perhaps we can foster agency in communities that face poor health outcomes.
Such definitions would include communities described in the empirical sections of this thesis,
but also include pro-ana communities. Refining the argument further, we can facilitate agency
in communities where improvement in agency would result in improved health outcomes. If
we enhance togetherness in HIV-positive men who have sex with men communities, would it
further alienate bug chasers and increase their numbers? There are likely no clear demarcations
or indicators when we should tackle health concerns in marginalized communities. This
dissertation favors marginalized communities that broader academia has agreed upon as
needing improvements in health outcomes. However, men who have sex with men and
individuals with substance use disorders were not always viewed as deserving of medical
treatment by the medical establishment. While we currently malign pro-ana and Gang Stalking
communities, academic opinion toward them could change in the future. Such questions are
pertinent when designing policy solutions for health outcomes within marginalized
communities. I suggest carefully considering when to foster agency in marginalized
communities, for even in scorned communities such as white nationalists, there may be higher
rates of opioid use disorder579,580 that require addressing.
While the topics covered in this thesis are broad, they share a thematic arc. Low sexually
transmitted infection testing uptake, opioid use disorder and cannabis use are issues often
disproportionately faced by marginalized communities. Establishing marginalization as the
causal factor behind these concerns is often complex, but there is significant work indicating
that problematic patterns of drug use and poor sexual health outcomes are engendered by
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marginalization. Drawing together research from several arenas, I establish a clear strand of
reasoning. Marginalization is associated with conditions inimical to health and well-being,
creating a host of health risks. Such marginalization limits the agency of affected communities.
However, even within these sites of marginalization, men who have sex with men seek testing
and opioid use disorder patients seek medication, mitigating health risks borne from
marginalization. I advance that marginalized communities are not completely helpless
considering reduced health outcomes, indicating how some communities reclaim agency.
Finally, I indicated other cases where fostering agency in marginalized communities needs to
be carefully considered.
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Appendix
Chapter 1: Cannabis Use Patterns at the Dawn of United States Cannabis Reform
Regarding mixing cannabis with tobacco, participants were asked whether they used tobacco
mixed with cannabis in the last 12 months, with Never and Yes provided as response options.
Concerning how soon after the participant woke up and had their first joint on the day they
used cannabis, the selections of Immediately within 5 minutes, Within less than an hour,
Within 1-4 hours, Within 5-12 hours and After more than 12 hours were provided. For normal
daily cannabis use, participants were asked to select the weight, from a dropdown list of 29
weights, starting at 50mg and gradually increasing to the final selection of >20g. Regarding the
number of hours spent stoned in a session, participants were asked to select from a dropdown
list of 24 options, increasing in one-hour increments to the last option of 24 Hours. For the
number of days cannabis was used in the last 12 months, participants keyed in their answer in
a box provided. Participants were asked how long before bed they had their last joint, with the
following options: Last thing before bed, 1-2 hours before bed, 3-4 hours before bed and
More than 4 hours before bed. Concerning the most common way participants used cannabis,
the following options were provided: Smoked in a joint (rolled cannabis cigarette) with
tobacco, Smoked in a joint without tobacco, Smoked in a blunt (cigar that has been hollowed
out and filled with cannabis) with tobacco, Smoked in a blunt without tobacco, Smoked in a
pipe with tobacco, Smoked in a pipe without tobacco, Smoked in a bong/water pipe with
tobacco, Smoked in a bong/water pipe (filtration device generally used for smoking cannabis)
without tobacco, Bucket bong (method of consuming smokable substances such as cannabis,
using two containers), Hot knife (method of smoking cannabis with two knife blades),
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Vaporizer (device used to vaporize cannabis for inhalation), Eaten in food, Tincture/drank as
tea, and Medical spray. For the preferred preparation of cannabis in the last year, participants
could select the following: High potency herbal cannabis, Resin/hash (drug made from the
resin of the cannabis plant), Normal weed/bush/pressed, Edibles (food product that contains
cannabinoids), Kief (resinous trichomes of cannabis that may accumulate in containers), Oil,
and Butane Hash Oil (oil extracted from cannabis using butane as a solvent). Prior to analysis,
the variable regarding the time of first joint in a day was categorized into >60mins and
<60mins of waking, to model time to first cigarette. The variable regarding the grams of
cannabis used per session was recoded into a continuous variable, and the >20g value was
recoded as 21 grams. On average, there are about 0.32 grams of cannabis in a joint 172. For
ease of interpretation, the age variable was recoded into a categorical variable with intervals of
ten years each, and consecutive age groups representing less than 5% of the sample were
subsumed into a larger group (41-79 years) for clearer interpretation.
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Chapter 1: Correlates of Cannabis-related emergency department Visits in New York
City
An unintentional emergency department visit were those where I excluded International
Classification of Diseases for self-inflicted injury, injury purposely inflicted by other persons,
injury undetermined whether accidentally or purposely inflicted, poisoning by adverse effects,
poisoning by underdosing, and International Classification of Diseases codes for substance
abuse detoxification and additional codes which conveyed services and procedures billed for
outpatient visits rather than emergency department visits described using revenue codes for
drug and alcohol rehabilitation and procedure codes. International Classification of Diseases
codes refer to the 10th revision of the International Statistical Classification of Diseases and
Related Health Problems, a medical classification list by the World Health Organization. The
International Classification of Diseases contains codes for diseases, symptoms, abnormal
findings, complaints, social circumstances and external causes of injury or diseases (see
www.icd10data.com for more information).
Based on the presence of cannabis and other drugs, I divided the data into two categories
using the relevant International Classification of Diseases codes: 1) cannabis-related (cannabis
was identified, possibly with one or more other psychoactive drugs); 2) non-cannabis related,
where no cannabis was involved. A cannabis-related diagnosis was assigned with the following
codes: F12 and T407. International Classification of Diseases codes with two integers
represent a range of codes. For example, F12 represents codes like F12.1, F12.12 and F12.15.
Codes with three digits, like T407, represent specific diagnoses, such as cannabis poisoning.
Other

psychoactive

drugs

included

alcohol,

cocaine,

heroin,

stimulants
223

(methamphetamine/amphetamine), hallucinogens (3,4-methylenedioxymethamphetamine,
phencyclidine, d-lysergic acid diethylamide and miscellaneous hallucinogens), opiates/opioids
and sedatives/benzodiazepines.
The alcohol, opioid, cocaine, anxiety disorder, mood disorder and schizophrenia and other
psychotic disorders variables were assigned using the relevant International Classification of
Diseases codes. I assigned an alcohol-related diagnosis using the following International
Classification of Diseases codes: F10, K70, E52, Y90, G621, I426, K292, E244, E512, G721,
K852, K860, G312, R780, T510, T519, O354 and O993. For an alcohol-related diagnosis,
conditions arising from overconsumption of alcohol were included, like alcoholic liver disease
(K70). Opioid-related International Classification of Diseases codes were as follows: F11,
T400, T401, T402, T403, T404 and T406. Cocaine-related International Classification of
Diseases codes were the following: F14 and T405. The Substance Abuse and Mental Health
Services Administration Mental Health Client Level Data report581 was used to assign the
anxiety disorder, mood disorder and schizophrenia and other psychotic disorders variables.
Demographic characteristics of patients in the Statewide Planning and Research Cooperative
System dataset included age (13-17, 18-24, 25-34, 35-44, 45-54, 55-64, 65-84), sex (male,
female), ethnicity (White non-Hispanic, Black non-Hispanic, Hispanic, Other) and zip code. I
used zip code to assign participants to neighborhood poverty levels, measuring neighborhood
socioeconomic status. The following neighborhood poverty levels were assigned, based on
percent residents living below the federal poverty line: <5%, 5% to <10%, 10% to <20%,
20% to <30%, 30 to <40% and ≥40%.582 The 2012-2016 American Community Survey
definitions were used to define poverty levels. Examples of admission case types based on
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International Classification of Diseases codes include substance related disorders
(intoxication, dependence, abuse), limb fractures and other admission types.
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Chapter 2: Community-centric Behaviors and Chinese Men who have Sex with Men
A. Sociodemographics
The next set of questions will ask you to provide some information about yourself.
A1. Age: ____ years old
A2. Nationality
1.

Han Chinese

2. Other _________

A3. Current marital status:
1.
2.
3.
4.

Never married
Engaged or Married
Separated or divorced
Widowed

A4. Highest level of completed education:
1.
2.
3.
4.
5.

Elementary
Middle school
High school or vocational school
Bachelor or associate degree
Above bachelor’s degree

A5. What is your occupation?
o
Student
o
Civil servant
o
Farmer
o
Labor worker (blue collar)
o
Office worker (white collar)
o
Seller/service staff
o
Technician
o
Unemployed
o
Other______
A6. What is your total individual monthly income from all sources?
1.
2.
3.
4.
5.

<1500 RMB/month
1500-3000 RMB/month
3001-5000 RMB/month
5001-8000 RMB/month
>8000 RMB/month

A7. What is your gender identity?
1. Male
2. Female
3. Transgender
4. Unsure/Other
A8. What is your sexual orientation?
1.
2.
3.
4.

Homosexual
Bisexual
Heterosexual
Unsure/Other

B. Sexual behaviors
The next set of questions will ask you about your sexual behaviors with other men.
B1. What is your role during anal sex?
1. Mostly receptive (bottom)
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2.
3.

Mostly insertive (top)
Half and half (versatile)

B2. In the past 3 months, how many sex partners have you had? (Number)
____
partners
B3. In the past 3 months, have you had anal sex?
1. Yes
2. No (Skip to B5)
B4. In the past 3 months, when you had anal sex, how frequently did you use condoms?
1.
2.
3.
4.

0% condom use
Less than 50% condom use
More than 50% condom use
100% condom use

B5. In the past 3 months, have you had condomless vaginal sex?
1. Yes
2. No
B6. In the past 3 months, have you had condomless oral sex?
1. Yes
2. No
B7. In the past, have you told anyone about your sexuality or sexual history with men? (Select all that apply)
1. Yes, my long-term female partner/wife
2. Yes, my family members
3. Yes, my friends
4. Yes, my healthcare providers
5. Yes, others:_________
6. No one
C. Clinical Information
C1. Do you have any symptoms that you are worried may be due to a sexually transmitted infection?
1. Yes. Symptoms: _____________
2. No
C2. Have you ever tested for HIV in the past?
1. Yes
2. No (Skip to C5)
C3. When was the last time you tested for HIV? (If cannot recall exactly, please estimate)
Year:________Month:______Day:________
C4. In the last two years, how frequently did you get tested for HIV?
1. Less than once every two years
2. Once a year
3. Once every six months
4. Once every three months
5. Monthly
C5. Today, did you agree to get tested for gonorrhea and chlamydia?
1. Yes (Go to C6)
2. No (Go to C7)
C6 (Pay-it-forward arm). If you agreed to testing for gonorrhea and chlamydia today, what is the MAIN reason? (Choose
ONE)
1. “Pay It Forward” allowed for discounted testing
2. “Pay It Forward” allowed paying kindness forward to community members
3. Recent symptoms
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4.
5.
6.
7.

Recent high-risk sexual behavior
Testing site’s staff told me to get tested
A friend told me to get tested
Other ____________________

C6 (Pay-what-you-want arm). If you agreed to testing for gonorrhea and chlamydia today, what is the MAIN reason?
(Choose ONE)
1. “Pay What You Want” allowed for discounted testing
2. Recent symptoms
3. Recent high-risk sexual behavior
4. Testing site’s staff told me to get tested
5. A friend told me to get tested
Other ____________________
C6 (Standard of care arm). If you agreed to testing for gonorrhea and chlamydia today, what is the MAIN reason?
(Choose ONE)
1.
2.
3.
4.
5.

Because the research staff introduced gonorrhea and chlamydia testing
Recent symptoms
Recent high-risk sexual behavior
Testing site’s staff told me to get tested
Other ____________________

C7. If you did NOT agree to testing for gonorrhea and chlamydia today, why NOT? (select all that apply)
1. I don’t know anything about gonorrhea or chlamydia
2. I don’t want to know if I have gonorrhea or chlamydia
3. I don’t need to get tested
4. Too much of a hassle
5. Too expensive
6. I am worried about confidentiality
7. I am afraid of pain/ discomfort
8. I don’t want to leave sample today
9. I am embarrassed to get tested in front of my friend/partner
10. I am afraid that my results will be positive
11. Other ____________________
D. Community Engagement
The next set of questions asks about your experiences with men who have sex with men-related causes, events and
organizations in your community.
D1. Have you ever participated in online forums or discussions on social media (ie. Weixin, Weibo, Twitter, or other online communities) about issues related to the men who have sex with men community?
o
Yes
o
No
D2. Are you aware of any ongoing men who have sex with men-related community events?
o
Yes
o
No
D3. Have you ever encouraged someone to use men who have sex with men-related community resources, such as free
HIV and syphilis testing services?
o
Yes
o
No
D4. Have you ever attended men who have sex with men-related community events?
o
Yes
o
No
D5. Have you ever donated to men who have sex with men-related causes, events, or organizations? (other than today)
o
Yes
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o

No

D6. Have you ever volunteered for men who have sex with men-related causes, events, or organizations?
o
Yes
o
No
E. Community Connectedness
The following set of questions asks about your feelings toward the men who have sex with men. Here, “men who have
sex with men community” broadly refers to the collective of individuals and community organizations that have an
interest in men who have sex with men-related issues.
E1. You feel that you are a part of the men who have sex with men community.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
E2. Participating in the men who have sex with men community is a positive thing for you.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
E3. You are proud of the men who have sex with men community.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
E4. It is important for you to be an advocate for the men who have sex with men community.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
E5. If you and your peers work together, the problems in the men who have sex with men community can be solved.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
E6. You really feel that any problems faced by the men who have sex with men community are also your own problems.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
E7. The diagram below is designed to represent your relationship (“Self”) with lesbian, gay, bisexual, and transgender as
a group ("lesbian, gay, bisexual, and transgender"). Please indicate your relationship by selecting the option that best
captures your relationship with this lesbian, gay, bisexual, and transgender as a group.

F. Social Cohesion
F1. You can count on other men who have sex with men in your group of friends if you need to borrow money.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
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F2. You can count on other men who have sex with men in your group of friends if you need to talk about your problems.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
F3. You can count on other men who have sex with men in your group of friends if you need somewhere to stay.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
F4. The group of men who have sex with men with whom you socialize with is an integrated group.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
F5. You can trust the majority of the men who have sex with men you know.
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
F6. In general, men who have sex with men in your group of friends in the area where you live only worry about
themselves
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
F7. In general the men who have sex with men you socialize with are always arguing amongst each other
o
Strongly Agree
o
Agree
o
Disagree
o
Strongly Disagree
G. Pay-It-Forward Participation (Pay-it-forward arm only)
G1. Today, you came to testing:
1. By yourself (Skip to G3)
2. Accompanied by someone else
G2. How would you describe your relationship to the person accompanying you?
1. Sex partner
2. Men who have sex with men peer
3. Non-men who have sex with men peer
4. Family
5. Other, specify:____
G3. Did you choose to contribute any amount of money?
1. Yes
2. No
G4. What determined your contribution amount?
1. One’s own financial situation
2. Normal price of testing
3. Quality of testing service
4. Estimate of how much others contributed
5. Feel bad if not pay anything
6. Other, specify:______
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G5. What do you believe are the main benefits to participating in the pay-it-forward program? (select all that apply)
1. I can receive discounted GC/CT test
2. I can experience warm glow through receiving donated testing
3. It reduces my sexually transmitted infection risk by making my community healthier
4. It can help more men who have sex with men get tested
5. It allows someone to help me, and then I can help someone else
6. Other ____________________

G. Pay-What-You-Want Participation
(Pay-what-you-want arm only)
G1. Today, you came to testing:
1. By yourself (Skip to G3)
2. Accompanied by someone else
G2. How would you describe your relationship to the person accompanying you?
1. Sex partner
2. Men who have sex with men peer
3. Non-men who have sex with men peer
4. Family
5. Other:____
G3. Did you choose to contribute any amount of money?
1.
2.

Yes
No

G4. What determined your contribution amount?
1. One’s own financial situation
2. Normal price of testing
3. Quality of testing service
4. Estimate of how much others contributed
5. Feel bad if not pay anything
6. Other:_______
G5. What do you believe are the main benefits to participating in the pay-it-forward program? (select all that apply)
1. I can receive discounted GC/CT test
2. I can experience warm glow through receiving discounted testing
3. It reduces my sexually transmitted infection risk by making my community healthier
4. It can help more men who have sex with men get tested
5. It allows men who have sex with men to have more control over testing price
6. Other ____________________
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Chapter 2: Lack of Sexual Behavior Disclosure May Distort sexually transmitted
infection Testing Outcomes

Study design
The randomized controlled trial was designed to evaluate the comparative effectiveness of
Pay-it-Forward and Pay-what-you-Want against the standard of care for increasing
gonorrhea/chlamydia test uptake in men who have sex with men. Pay-it-forward consists of
telling participants that their test was paid for by another men who have sex with men and
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asking the participant how much they would like to contribute to the next participant. 321 Paywhat-you-Want is a pricing strategy where consumers select a desired amount for a particular
product or service.583 In a solely monetary sense, pay-as-you-what is similar to pay-it-forward
pricing where consumers select the price for a good or service.
However, pay-as-you-what and pay-it-forward vary socially. In pay-as-you-what, the consumer
pays for themselves, while in pay-it-forward, the consumer pays for someone else. Comparing
pay-as-you-what and pay-it-forward can provide insight on whether participants are engaging
in testing solely because it is free or if there are community-based effects of altruism involved.
Participants were randomly assigned into clusters within the study arms. A cluster is a group
of ten eligible men who arrived one after another at the study sites and decided to participate.
Cluster randomization was utilized to minimize intervention contamination to account for
men who have sex with men who turned up in pairs and to simplify processes undertaken by
site staff. Men who have sex with men in the same cluster were collectively assigned to the
same study arm. Similarly, those who arrived with partners were placed in the same study arm.
Randomized controlled trial randomization sequence was designed through STATA 15.331 For
the pay-it-forward arm, participants were told the experiment was for promoting
gonorrhea/chlamydia test uptake and that the standard price of a gonorrhea/chlamydia test
was 150RMB (USD22). They were offered a free test and told it was paid for by another men
who have sex with men. In the pay-as-you-what introduction, men who have sex with men
were told the standard gonorrhea/chlamydia test price was 150RMB (USD22). Men who have
sex with men were told that they could first receive a free gonorrhea/chlamydia test and then
decide the amount to pay. Participants were told that payment and receiving a
gonorrhea/chlamydia test was voluntary and the payment amount was up to the participant.
233

Men who have sex with men assigned to the SOC arm received the same gonorrhea/chlamydia
test information through a pamphlet and no further details. Those in the SOC arm were told
that the standard price of the gonorrhea/chlamydia test was 150RMB (USD22). 101 were
allocated to the pay-it-forward arm, 100 to the pay-as-you-what arm and 100 to the SOC arm
across the three testing sites. Within the randomized controlled trial, gonorrhea/chlamydia
test uptake was 56%, 46%, and 18% respectively.
Model specification
I analyzed the data using probit models with sample selection. Test uptake (selection stage)
was operationalized as a dichotomous variable indicating whether men had selected the
gonorrhea/chlamydia test. In the outcome stage, the variable of interest was choice of rectal
gonorrhea/chlamydia test. Standard errors were calculated with a jackknife estimator, using
30 jackknife samples that accounted for the study design. Statistical analyses were conducted
using Stata version 15.0.38. P<.05 was considered statistically significant. The first-stage model
applies a probit model to represent a measure of the propensity of a participant to choose a
gonorrhea/chlamydia test on the basis of factors believed to be related to the decision to test.
The first model’s assessment of the probability of the gonorrhea/chlamydia test choice is then
applied in the second stage to adjust the estimates produced from a probit model to account
for the effect of selection bias. To effectively use this approach, I had to develop an
understanding not only of factors that influenced selection of the rectal gonorrhea/chlamydia
test but also of factors that affected the decision to engage in the gonorrhea/chlamydia
test/test uptake. Formally, I can write the two models as follows:
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where Y1* represents the decision to test and Y2* represents the decision to select the rectal
gonorrhea/chlamydia test as unobserved latent variables. Z is the set of instruments used to
adjust for selection, W is the set of variables of interest for which I wish to infer the effect on
the outcome Y2, and X is the set of controls for the outcome model. Z were included in the
selection stage but not the outcome stage: Whether participant had experienced sexually
transmitted infection symptoms prior to the gonorrhea/chlamydia test, Previous HIV test,
HIV test frequency, Site, Arm. These variables likely influenced test uptake but not
gonorrhea/chlamydia test choice and were generally not associated with gonorrhea/chlamydia
test choice. W: Top, Bottom, Versatile, Out to anyone, Out to health provider. Inclusion of
W was dependent on the hypothesis of interest. X: Age, Income, Number of male partners in
last three months, Frequency of condomless anal intercourse.
Given the relatively small number of participants both versatile and out, I was limited in the
number of controls to include. I thus did not include controls co-linear with reported variables
(e.g. Marital status, education). Regarding the sexually transmitted infection symptoms
variables, participants were not asked where on the body symptoms were observed, just
whether they had symptoms. Thus, the symptoms variable may affect test uptake but not rectal
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gonorrhea/chlamydia test choice, perhaps indicative of a strong instrument. The Arm variable
varies the attractiveness of testing but does not affect rectal gonorrhea/chlamydia test choice,
perhaps indicating its strength as an instrument.
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Chapter 3: The Role of Social Support on Treatment Outcomes regarding
Medication for Opioid Use Disorder: A Systematic Review
The following is an example of the PubMed search strategy:
(("buprenorphine, naloxone drug combination"[MeSH Terms] OR "naltrexone"[MeSH
Terms] OR "methadone"[MeSH Terms] OR "opiate substitution treatment"[MeSH Terms]
OR "opioid-related disorders"[MeSH Terms] OR "medication assisted therapy"[tw] OR
"medication assisted therapies"[tw] OR Naltrexone[tw] OR Methadone[tw] OR Celupan[tw]
OR Trexan[tw] OR ReVia[tw] OR Nemexin[tw] OR Nalorex[tw] OR Antaxone[tw] OR "EN
1639A"[tw] OR Vivitrol[tw] OR Suboxone[tw] OR "Buprenorphine Naloxone"[tw] OR
Methadone[tw] OR Dolophine[tw] OR Metadol[tw] OR Symoron[tw] OR Methadose[tw] OR
Phenadone[tw] OR Physeptone[tw] OR Phymet[tw] OR Amidone[tw] OR Methaddict[tw]
OR "Methadone Maintenance Treatment"[tw] OR "Opiate Substitution Treatments"[tw] OR
"Opioid Substitution Treatment"[tw] OR "Opioid Substitution Treatments"[tw] OR "Opioid
Substitution Therapy"[tw] OR "Opioid Substitution Therapies"[tw] OR "Opiate Replacement
Therapy"[tw] OR "Opiate Replacement Therapies"[tw] OR "Opioid Replacement
Therapy"[tw] OR "Opioid Replacement Therapies"[tw]) AND ("social support"[MeSH
Terms] OR "community health services"[MeSH Terms] OR "community networks"[MeSH
Terms] OR "spouses"[MeSH Terms] OR "friends"[MeSH Terms] OR "family"[MeSH Terms]
OR "societies"[MeSH Terms] OR "residence characteristics"[MeSH Terms] OR "social
support"[tw] OR "social supports"[tw] OR "social network"[tw] OR "social networks"[tw] OR
"support system"[tw] OR "support systems"[tw] OR Spouse[tw] OR Spouses[tw] OR
Partner[tw] OR Partners[tw] OR Friend[tw] OR Friends[tw] OR Society[tw] OR
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Community[tw] OR Communities[tw] OR Peer[tw] OR Peers[tw] OR Family[tw] OR
Families[tw] OR Husband[tw] OR Husbands[tw] OR Wife[tw] OR Wives[tw] OR coworker[tw] OR co-workers[tw] OR coworker[tw] OR coworkers[tw] OR neighbor[tw] OR
neighbors[tw] OR Neighborhood[tw] OR Neighborhoods[tw] OR Neighbourhood[tw] OR
neighbourhoods[tw])) NOT (("buprenorphine, naloxone drug combination"[MeSH Terms]
OR "naltrexone"[MeSH Terms] OR "methadone"[MeSH Terms] OR "opiate substitution
treatment"[MeSH Terms] OR "medication assisted therapy"[tw] OR "medication assisted
therapies"[tw] OR Naltrexone[tw] OR Methadone[tw] OR Celupan[tw] OR Trexan[tw] OR
ReVia[tw] OR Nemexin[tw] OR Nalorex[tw] OR Antaxone[tw] OR "EN 1639A"[tw] OR
Vivitrol[tw] OR Suboxone[tw] OR "Buprenorphine Naloxone"[tw] OR Methadone[tw] OR
Dolophine[tw] OR Metadol[tw] OR Symoron[tw] OR Methadose[tw] OR Phenadone[tw] OR
Physeptone[tw] OR Phymet[tw] OR Amidone[tw] OR Methaddict[tw] OR "Methadone
Maintenance Treatment"[tw] OR "Opiate Substitution Treatments"[tw] OR "Opioid
Substitution Treatment"[tw] OR "Opioid Substitution Treatments"[tw] OR "Opioid
Substitution Therapy"[tw] OR "Opioid Substitution Therapies"[tw] OR "Opiate Replacement
Therapy"[tw] OR "Opiate Replacement Therapies"[tw] OR "Opioid Replacement
Therapy"[tw] OR "Opioid Replacement Therapies"[tw]) AND ("social support"[MeSH
Terms] OR "community health services"[MeSH Terms] OR "community networks"[MeSH
Terms] OR "spouses"[MeSH Terms] OR "friends"[MeSH Terms] OR "family"[MeSH Terms]
OR "societies"[MeSH Terms] OR "residence characteristics"[MeSH Terms] OR "social
support"[tw] OR "social supports"[tw] OR "social network"[tw] OR "social networks"[tw] OR
"support system"[tw] OR "support systems"[tw] OR Spouse[tw] OR Spouses[tw] OR
Partner[tw] OR Partners[tw] OR Friend[tw] OR Friends[tw] OR Society[tw] OR
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Community[tw] OR Communities[tw] OR Peer[tw] OR Peers[tw] OR Family[tw] OR
Families[tw] OR Husband[tw] OR Husbands[tw] OR Wife[tw] OR Wives[tw] OR coworker[tw] OR co-workers[tw] OR coworker[tw] OR coworkers[tw] OR neighbor[tw] OR
neighbors[tw] OR Neighborhood[tw] OR Neighborhoods[tw] OR Neighbourhood[tw] OR
neighbourhoods[tw]))
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Study characteristics related to design of study, medication for opioid use disorder drug used, target population, outcome, number of participants, follow-up, and
conclusions
Author, date

Ref

Anton et al., [38]
1981

Location

Study medication Population
Design for opioid use
disorder drug
used

Outcomes

United
States

Observ Naltrexon
ational, e
retrosp
ective
study

Naltrexone Total N: 65
Family
maintenance Naltrexone + HIP
for
three N: 40
months
or % male: 85
more
Mean age: 26.9
Ethnicity: 42.5% White;
57.5% Black

Opioid
dependent
self-referred
patients

Sample characteristics (N, % Form of
male, age, ethnicity)
support

social Follow-up

Conclusions

1 year

Higher retention rate for patients
treated with multiple family therapy
(MFT) than those who did not receive
MFT.

unclear

Patients who attended at least 1 family
counselling session had better results
for those under the significant other
(SO) than those in the contingency
management (CM) group with regards
to retention, compliance, and drug use
outcomes.

Naltrexone + HIP +
MFT
N: 25
% male: 96
Mean age: 24.8
Ethnicity: 72% White;
28% Black
Carroll et al., [30]
2001

United
States

random Naltrexon
ized
e
controll
ed trial

Opioid
Compliance
dependent with
patients who naltrexone
had
treatment
completed
outpatient
detoxification

N: 127
% male: 76
Mean age: 32
Ethnicity: 77% White

Family

240

Catalano et al., [51]
1997

United
States

random Methadon
ized
e
controll
ed trial

Opioid
Parent self- N: 35
Family
dependent reported
% male: 25
parents who drug-use
Mean age: 35.36
had been in
Ethnicity: 77% White;
methadone
18%
Black;
treatment for
Mixed/Other: 5%
a minimum
of 90 days
and have one
or
more
children
between the
ages of 3 and
14 years old
living
with
them at least
50% of the
week

3 years

Parents in the experimental group
(Standard methadone treatment +
supplemental parenting program) who
had lower levels of opiate use than
subject in standard methadone
treatment group.

Catalano et al., [52]
1999

United
States

random Methadon
ized
e
controll
ed trial

Opioid
Self-reported N: 178
dependent frequency of % male: 26.7
parents who use
of Mean age: 35.4
had been in marijuana, Ethnicity: 77% White
methadone cocaine,
treatment for opiates and
a minimum drug use in
of 90 days previous
and have one month
or
more
children
between the
ages of 3 and
14 years old
living
with
them at least

3 years

Parents in experimental group who
did a parent skills training and homebased case management to reduce
parents' risk for relapse had lower
levels of opiate use than control
subjects.

Family
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50% of the
week

Cerovecki et al., [43]
2013

Croatia

Observ Methadon
ational, e
prospe
ctive
study

Opioid
Fatal
N: 287
dependent outcome risk % male: NA
patients
factors like Mean age: NA
treated
in quality
or Ethnicity: NA
family
relationships
medicine
and
settings
continuation
of drug use
during
previous
therapeutic
attempts

Family

12 years

Increased fatal outcome for patients
with more unstable relationships and
loss of continuity of care

Chaudhry et al., [48]
2012

UK

Observ Naltrexon
ational, e
retrosp
ective
study

Opioid
Treatment
dependent retention
patients who
had
successfully
completed
detoxification

N: 142
Family
% male: 93.7
Mean age: NA
Ethnicity: 25.4% White;
70.4% Asian; 4.2% Other

10 years

Parental supervision of naltrexone
administration was a predictor of longterm retention in treatment.
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Davila Torres, [47]
2011

United
States

Observ Methadon Latino opioid Retention
ational, e
dependent and
retrosp
patients
treatment
ective
program
study
completion

Day et al., 2013 [71]

UK

Cross- Buprenorp Opioid
section hine,
dependents
al
Methadon
analysis e

Day et al., 2018 [58]

UK

random Methadon
ized
e
controll
ed trial

N: 291
% male: 66.7
Mean age: NA
Ethnicity: NA

Family

1 year

Heroin use in N: 118
Combined family 6 months
the previous % male: 79
and peer
month
Mean age: 35.5
Ethnicity: 73% White;
14% South Asian; 4%
Black, 8% Mixed

Opioid
Number of N: 83
Combined family 1 year
dependent days
of % male: 79
and peer
individuals heroin use in Mean age: 35.5
who had been the
past Ethnicity: 73% White;
prescribed month
14% South Asian; 4%
methadone or
Black; 8% Mixed
buprenorphin
e for the past
12 months
and
had
reported
heroin use on
one or more
days 28 days
prior
to
beginning of
the study

Successful treatment completion
associated with living in stable housing
and higher perceived physician/nurse
support.
Substance use involvement of heroin
using social network was higher
amongst patients who had used heroin
in the past month.

No significant differences were found
between the 3 intervention arms in
primary or secondary outcome
measures: Treatment as usual (TAU,
Brief Social Behavior and Network
Therapy (BSBNT) ± TAU or Personal
Goal Setting (PGS) ± TAU)
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Fals-Stewart [53]
and O'Farrell,
2003

United
States

random Naltrexon
ized
e
controll
ed trial

Opioid
Percentage of N: 124
Family
dependent opioid-free % male: 100
individuals urines
Mean age: 32.9
living with at
Ethnicity: 66% White;
least
one
26% Black; 3% Hispanic;
parent/spous
5% Other
e/intimate
partner/famil
y
member
willing
to
participate
and did not
have a current
substance use
disorder or
meet
Diagnostic
and Statistical
Manual
of
Mental
DisordersIII-R criteria
for
schizophrenia
,
bipolar
disorder, or
psychosis

4 years

Male opioid-dependents living with a
family member with a family-based
naltrexone
compliance
contract
produced better outcomes during
treatment.
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Fals-Stewart et [54]
al., 2001

United
States

random Methodon
ized
e
controll
ed trial

Opioid
Urine tests
dependent
male partners
who had been
married for at
least 1 year or
in a stable
common-law
relationship
for at least 2
years
who
had to refrain
from seeking
additional
substance
abuse
treatment
except
for
self-help
meetings like
Alcoholics
Anonymous

Feng
2018

China

Observ Methadon
ational, e
retrosp
ective
study

Opioid
Self-reported N: 2446
dependent heroin use or % male: 79.2
patients
a
positive Mean age: NA
enrolled in urine
Ethnicity: NA
methadone morphine
clinic
test result

et

al., [61]

N: 36
Family
% male: 100
Mean age: 38.1
Ethnicity: 18% White;
15% Black; 3% Hispanic

Family

4 years

Patients who received BCT reported
greater reductions in drug use severity
and family and social problems from
baseline to post treatment than
patients receiving standard MM
treatment.

1 year

Higher heroin use concurrent with
treatment for patients with family
members with history of heroin use.
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Gogineni et al., [60]
2001

United
States

Observ Methadon
ational, e
prospe
ctive
study

Grey
1986

United
States

China

et

al., [36]

Gu et al., 2013 [31]

Opioid
Continued
dependent opioid use
patients
enrolled in
methadone
maintenance
treatment
clinic

N: 252
Family
% male: 56
Mean age: 40.3
Ethnicity: 64% White;
22%
Black;
9%
Latino/Hispanic;
2%
Native American; 3%
Other

None

Patients with substance-using live-in
partners or drug-using
social
relationships had higher drug use.

Observ Naltrexon Opioid
Retention
N: 60
Family
ational, e
and dependent (number of % male: 73.3
prospe Methadon patients who required
Ethnicity: 58.3% White;
ctive e
had
been clinic
11.7% Black; 30.0%
study
opiate-free appointment Hispanic
for 7 days s kept)
prior
to
treatment (for
naltrexone)
and
opiate
dependents
for at least 1
year
for
methadone
maintenance
treatment

3 months

Drug
abuse
was
correlated
significantly with perceived family
support.

random Methadon
ized
e
controll
ed trial

1 year

Patients who received a combination
of psycho-social intervention with the
standard of-care (SOC) methadone
maintenance treatment service as
compared to that of the SOC
methadone maintenance treatment
service alone showed lower likelihood
of attrition.

Heroin
Attrition
N: 288
dependent from
the % male: 92
patients
methadone Mean age: NA
recently
maintenance Ethnicity: 98.9% Han
admitted to treatment
the
three service,
participating which
was
methadone defined as a
maintenance failure to visit

Family
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treatment
clinics

Gu et al., 2014 [41]

China

Case- Methadon Opioid
crossov e
dependent
er
patients
design

Heinz
2009

United
States

Observ Methadon
ational, e
retrosp
ective
study

et

al., [62]

Hikmayani
al., 2012

et [42]

the
methadone
maintenance
treatment
clinic
consecutively
for at least 1
month
immediately
prior to the
study’s
completion
date
Methadone N: 131
maintenance % male: 88
clinic
Mean age: NA
nonattendanc Ethnicity: NA
e

Family

Opioid
Positive
N: 635
Family
dependent urinalysis
% male: 54.1
patients with tests
for Mean age: 39.2
a history of cocaine and Ethnicity: 39.5% White;
cocaine use opiates
59% Black; Other: 1.5%

Indonesia Observ Methadon Heroin
ational, e
dependent
prospe
patients
ctive
study

Retention
N: 98
rate
in % male: NA
methadone Mean age: 31.6
management Ethnicity: NA
treatment
clinics

Family

1 month

Increased
nonattendance
at
methadone maintenance treatment
clinics for patients with interpersonal
conflicts with family, financial
difficulty and with worry about police
arrest.

6 years

Reduced cocaine and heroin use for
married participants who reported a
close relationship with one's partner.

1 year
months

6 Low retention significantly associated
with absence of family support.
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Hoang et al., [63]
2015

Vietnam Observ Methadon Opioid
ational, e
dependent
prospe
patients
ctive
study

Concurrent N: 965
heroin
use % male: 98.1
after
Mean age: 34.4
methadone Ethnicity: NA
treatment
initiation

Family

10 months Increased continued use of heroin
after
methadone
maintenance
treatment with likelihood of family
conflict.

Hoang et al., [64]
2018

Vietnam Observ Methadon Opioid
ational, e
dependent
retrosp
patients
ective
study

Concurrent N: 500
heroin
use % male: 96.8
after
Mean age: NA
methadone Ethnicity: NA
treatment
initiation

Family

5 years

Hojjat et al., [50]
2017

Iran

Family

1 year two Harm reduction education in families
months
of patients undergoing methadone
maintenance treatment can be
effective on their marital satisfaction
and treatment retention.

Kidorf, 2018

[59]

random Methadon
ized
e
controll
ed trial

Unclear random Methodon
ized
e
controll
ed trial
and
Single
group
design

Individuals Relapse rate
with
a
substance
dependent
husband with
no history of
drug
dependence

Total N: 50
Control
% male: NA
Mean age: 32.7
Ethnicity: NA

Increased odds of concurrent heroin
use during treatment for patients with
no emotional support from family or
financial stability.

Experimental
% male: NA
Mean age: 30.2
Ethnicity: NA

Opioid
Rate
of N: 18
dependent alcohol and % male: NA
individuals other drug Mean age: NA
recruited
use
Ethnicity: NA
from
a
community
syringe
exchange or
from
a
methadone

Combined family unclear
and peer

Patients with drug-free community
support benefited from it clinically.
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maintenance
program

Lee et al., 2015 [46]

Taiwan

Observ Methadon
ational, e
prospe
ctive
study

Lin et al., 2011 [65]

China

Lin et al., 2013 [45]

Taiwan

Heroin
Treatment
dependent retention
patients
enrolled in
methadone
maintenance
treatment
clinic

N: 177
% male: 76.9
Mean age: 37.15
Ethnicity: NA

Family

unclear

Increased expressed emotion between
family members and patients is linked
to retention.

Cross- Methadon Opioid
Self-reported N: 560
section e
dependent drug use and % male: 84.1
al study
patients
urine tests Mean age: 33
enrolled in
Ethnicity: NA
methadone
maintenance
treatment
clinic

Family

7 months

Perceived family support associated
with improved health and negatively
correlated with concurrent substance
abuse

Observ Methadon
ational, e
prospe
ctive
study

Family

1 year

Perceived higher family support
predicted a lower risk of methadone
maintenance treatment dropout

Opioid
Retention
N: 368
dependent rate
in % male: 86.4
patients
methadone Mean age: 37.2
enrolled in maintenance Ethnicity: NA
methadone treatment
maintenance clinics
treatment
clinic
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Lundgren et al., [39]
2007

United
States

Observ Methadon
ational, e
prospe
ctive
study

Monico et al., [70]
2015

United
States

Observ Buprenorp African
ational, hine
American
prospe
opioid
ctive
dependent
study
patients

Mutasa, 2001

UK

Observ Methadon
ational, e
prospe
ctive
study

[66]

Nguyen et al., [44]
2017

Vietnam Observ Methadon
ational, e
prospe
ctive
study

Opioid
Longest
N: 8258
Family
dependent consecutive % male: 65.7
patients
stay
in Mean age: 36.5
enrolled in methadone Ethnicity: 68.6% White;
methadone maintenance 25.9% Latino; 5.5%
maintenance treatment
Black
treatment
clinic
clinic

6 years

Patients who resided with children,
were younger and had no public health
insurance were more likely to stay in
methadone maintenance treatment for
6 months or less.

3
&
months

6 12-step meeting during the first 6
months of methadone maintenance
treatment associated with superior
abstinence outcomes.

Opioid
MST
N: 45
Family
dependent noncomplian % male: 66.7
individuals ce
(misuse Mean age: NA
living within drugs)
Ethnicity: 88.89% White;
catchment
6.67% South Asian;
area
4.44% Black

unclear

Medication
noncompliance
was
associated with social company
availability, family-related conflicts
and peer association.

Opioid
Treatment
dependent adherence
patients
enrolled in
methadone
maintenance
treatment
clinic

4 months

Patients who were reminded by family
members by mobile phone to adhere
to treatment were more likely to do so.

Treatment N: 300
retention and % male: 60
long-term
Mean age: 46.2
abstinence Ethnicity: 100% Black

N: 241
% male: NA
Mean age: NA
Ethnicity: NA

Peer

Family
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Roozen et al., [55]
2003

Netherla random Naltrexon Opioid
nds
ized
e
dependent
controll
patients
ed trial

Abstinence Naltrexone
for a 6- N: 24
month
% male: 87
treatment
Mean age: 30.5
period
Ethnicity: NA

Family

3 years

Patients who received a combination
of naltrexone and CRA (community
reinforced approach) had better
outcomes than those with traditional
treatment.

Prospe Naltrexon Opioid
Retention in N: 82
Combined family unclear
ctive e
dependent treatment
% male: 77
and peer
study
individuals
Mean age: 33.6
with
a
Ethnicity: 64% White;
significant
25% Hispanic; 11%
other
who
Black
could commit
to
participating
in treatment

Poorer outcomes for patients who
used methadone regularly at baseline
than heroin only.

Methadone
N: 20
% male: 82
Mean age: 29.9
Ethnicity: NA
Rothenberg et [32]
al., 2002

United
States

Sarasvita et al., [40]
2012

Indonesia Observ Methadon
ational, e
prospe
ctive
study

Opioid
Duration of N: 178
dependent treatment in % male: 90
patients
days
Mean age: 27.2
enrolled in
Ethnicity:
methadone
Javanese;
maintenance
Sudanese;
treatment
Bataknese
clinic

Combined family 1 year
and peer
months
32.6%
16.3%
4.5%

6 Patients with family support and with
less peer support were less likely to
drop out.
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Scherbaum
al., 2005

Shen
2018

et

Smith, 2002

et [57]

al., [67]

[49]

Germany random Methadon Opioid
ized
e
dependent
controll
patients
ed trial

Drug use

N: 73
% male: 73
Mean age: 30
Ethnicity: NA

Peer

2 1/2 years A reduction in drug use was observed
in the intervention (psychotherapy)
group and but this was only observed
at the 6-month follow up but not by
the end of the study.

Family

1 year

Patients with a spouse, child or who
had a close family member were less
likely to have positive urine tests for
heroin.

12 weeks

Retention as measured by length of
time in treatment

China

Observ Methadon
ational, e
prospe
ctive
study

Opioid
Positive
N: 324
dependent urinalysis
% male: 76.9
patients
tests
for Mean age: 45.2
enrolled in heroin use Ethnicity: 83% Han
methadone
maintenance
treatment
clinic

United
States

Observ Methadon
ational, e
prospe
ctive
study

Male veteran Length
of N: 80
General
literate opioid time
in % male: 60
dependents treatment
Ethnicity: 60% Black;
individuals was
not 38.8% White; 1.2%
predicted by Latino
social
support, buut
interaction of
perceived
social
support and
orientation
towards
social
support
predict
therapeutic
alliance
(adherence)
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Tang, 2016

[37]

China

Observ Methadon
ational, e
prospe
ctive
study

Torrens et al., [33]
1996

Spain

Observ Methadon Opioid
ational, e
dependent
prospe
patients
ctive
study

Tran et al., 2018 [34]

Vietnam Observ Methadon
ational, e
prospe
ctive
study

Opioid
Self-reported
dependent medication
patients
adherence
enrolled in
methadone
maintenance
treatment
clinic

Wasserman et [69]
al., 2001

United
States

Opioid
Biochemciall N: 128
dependent y confirmed % male: 55
patients with opiate
and Mean age: 45
at least 1 cocaine
Ethnicity: 50% White
month
abstinence
enrollment in
methadone or
LAAM
maintenance

Observ Methadon
ational, e
prospe
ctive
study

Opioid
Treatment
dependent adherence
patients with
a history of
quitting
attempts
Retention
rate

N: 523
% male: 75.9
Mean age: 38.5
Ethnicity: NA

Family

9 months

N: 370
% male: 66
Mean age: 29.6
Ethnicity: NA

Combined family 2 years 10 Patients living with family or stable
and peer
months
partners had higher rates of retention.

N: 510
% male: 98.4
Mean age: 36.6
Ethnicity: NA

Combined family 5 months
and peer

Low rate of methadone maintenance
treatment non-adherence associated
with job stability, engagement in selfcare, and active participation of
partners, family, and friends in the
treatment process.

General

Having social networks with less drug
users (abstinence specific structural
support) correlated with reduced drug
use and demoralization for cocaine
abstinence but not opiate abstinence.
There was no effect for general
support.

unclear

Patients are more likely to engage in
sexual activity, have stronger family
relationships,
and
experience
improved
health status
posttreatment.
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Yandoli et al., [56]
2002

UK

random Methadon
ized
e
controll
ed trial

Patients with Frequency of N: 119
at least six opiate
use % male: 63
months'
(allocated as Mean age: 28.2
duration of opiate free, Ethnicity: NA
opioid
occasional
dependence users, regular
who agreed users)
to be seen
with
their
partner/famil
y
during
treatment if
required

Family

Yang
2013

China

Observ Methadon
ational, e
retrosp
ective
study

Opioid
Retention
N: 2728
dependent rate
in % male: 72.8
patients
methadone Mean age: 36.4
enrolled in maintenance Ethnicity: NA
methadone treatment
maintenance clinic
treatment
clinic

Combined family 4 years 9 Protective factors for methadone
and peer
months
maintenance treatment retention were:
Strong relationships with family, living
on support of family or friends and
not communicating with former drug
taking peers in the past month.

United
States

Observ Buprenorp Opioid
ational, hine,
dependent
retrosp Methadon patients
ective e
study

et

al., [35]

Zhu et al., 2018 [68]

Long-term N: 699
opioid
% male: 65.2
abstinence (at Mean age: 37.4
least 5 years) Ethnicity: NA

Family

14 months Family therapy produced significantly
more drug-free
subjects than standard treatment at six
months and at twelve months.

3 years

Long-term abstinence was positively
associated with greater social support.
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